Details of the Researcher

PHOTO

Taku Fujimura
Section
Graduate School of Medicine
Job title
Associate Professor
Degree

  • 博士（医学）（東北大学）

Research History 7

  • 2023/04 - Present
    Tohoku University　Department of Dermatology　Associate professor

  • 2017/09 - 2023/03
    東北大学病院　皮膚科　講師

  • 2010/08 - 2017/08
    東北大学医学系研究科皮膚科学分野　助教

  • 2007/07 - 2010/07
    Department of Dermatology, University of Heidelberg　Research Fellow

  • 2004/04 - 2007/06
    東北大学医学部付属病院　病院助手 助手

  • 2002/10 - 2003/12
    東北大学医学部免疫学教室　大学院生 大学院生

  • 2000/07 - 2002/06
    北海道大学遺伝子制御研究所免疫制御分野　大学院生 大学院生

Show all Show first 5

Education 2

  • Tohoku University　Graduate School, Division of Medicine

    - 2004/03/31

  • Tohoku University　Faculty of Medicine

    - 1998/03/31

Committee Memberships 2

  • 日本皮膚科学会　皮膚リンパ腫治療安全検討ワーキンググループ

    2018/09 - Present

  • 日本皮膚科学会　皮膚悪性腫瘍ガイドライン委員

    2017/04 - Present

Professional Memberships 6

  • 日本皮膚悪性腫瘍学会

  • Society of Investigative Dermatology(2006/05-2019/10)

  • 日本研究皮膚科学会(2004/03-2019/10)

  • 日本免疫学会(2000/11-2019/10)

  • 日本癌学会(2000/09-2006/09)

  • 日本皮膚科学会(1998/07-2019/10)

︎Show all ︎Show first 5

Research Interests 3

  • melanoma

  • Oncoimmunology

  • Dermatology

Research Areas 1

  • Life sciences / Dermatology /

Awards 4

  1. ポスター賞

    2018/04　日本臨床皮膚科学会　銀賞

  2. Japan Skin Cancer Society Award

    2016/05　Japan Skin Cancer Society　Immunomodulatory effect of peritumoral administration of interferon-beta on melanoma through tumor-associated macrophages.

  3. 22nd WCD2011, ILDS Scholarship

    2011/05/24　国際皮膚科学会

  4. 第105回日本皮膚科学会総会優秀ポスター賞

    2006/06/03　日本皮膚科学会

Papers 289

  1. Melanoma skin cancer statistics derived from 7442 Japanese patients: Japanese melanoma study.

    Yasuhiro Fujisawa, Shusuke Yoshikawa, Tatsuya Takenouchi, Shoichiro Mori, Jun Asai, Hisashi Uhara, Yuki Ichigosaki, Taku Fujimura, Yoshiyuki Nakamura, Yasuhiro Nakamura, Fumitaka Ohno, Takeshi Fukumoto, Toshiyuki Ozawa, Kenjiro Namikawa, Satoru Sugihara, Toshihiko Hoashi, Takatoshi Shimauchi, Yu Sawada, Hiroaki Iwata, Taku Maeda, Takuya Miyagawa, Yoshitsugu Shibayama, Naohito Hatta, Akiko Kishi, Masashi Ishikawa, Hisao Kawahira, Norito Katoh, Ryuhei Okuyama

    International journal of clinical oncology　2025/04/07

    DOI： 10.1007/s10147-025-02747-9 　

    More details Close

    BACKGROUND: Malignant melanoma (MM) is a rare but aggressive cutaneous cancer, accounting for only 2% of skin cancers in Japan but nearly half of skin cancer-related deaths. While the global incidence of MM is rising, its epidemiology varies significantly by ethnicity and geographic region. In Japan, melanoma incidence remains lower than in Western countries, with acral lentiginous melanoma (ALM) being the most prevalent subtype. However, comprehensive epidemiological and clinical data remain limited. METHODS: We analyzed data from 7442 Japanese melanoma patients collected between 2005 and 2022 through the Japanese Melanoma Study (JMS). Demographic, clinical, and survival data were evaluated, including subtype distribution, TNM staging, and treatment outcomes. RESULTS: ALM was the most common subtype (40.8%), followed by superficial spreading melanoma (20.2%). Lymph node metastasis was observed in 28.6% of cases, and distant metastasis in 10.9%. The BRAF mutation rate was 27.2%, with significantly lower frequencies in ALM (8.5%) and mucosal melanoma (4.8%). Among Stage IV patients, those treated with both immune checkpoint inhibitors (ICIs) and BRAF(+ MEK) inhibitors demonstrated significantly improved survival compared to chemotherapy alone (P < 0.05). Adjuvant BRAF(+ MEK) inhibitor therapy also resulted in superior relapse-free survival compared to those who did not receive adjuvant therapy (P < 0.005). CONCLUSION: This study provides the largest dataset of Japanese melanoma patients to date, highlighting distinct epidemiological and clinical characteristics. Given their lower BRAF mutation rates and the limited efficacy of current ICI treatments, these findings emphasize the urgent need for optimize immunotherapy strategies in Japanese melanoma patients.

  2. Decreased serum levels of IL-4 correlate with the efficacy of the PAI-1 inhibitor TM5614 in patients with malignant melanoma refractory to anti-PD-1 antibodies: post hoc study of TM5614-MM trial. International-journal

    Emi Yamazaki, Taku Fujimura, Manami Takahashi-Watanabe, Satsuki Tada, Chisako Kitayama, Ryo Amagai, Yumi Kambayashi, Masahiro Watanabe, Masamitsu Maekawa, Nariyasu Mano, Yoshihide Asano

    The British journal of dermatology　2024/08/31

    DOI： 10.1093/bjd/ljae343 　

  3. Three-Year Analysis of Adjuvant Therapy in Postoperative Melanoma including Acral and Mucosal Subtypes. International-journal

    Yusuke Muto, Yumi Kambayashi, Hiroshi Kato, Satoru Mizuhashi, Takamichi Ito, Takeo Maekawa, Shoichiro Ishizuki, Hiroshi Uchi, Shigeto Matsushita, Yuki Yamamoto, Koji Yoshino, Yasuhiro Fujisawa, Ryo Amagai, Kentaro Ohuchi, Akira Hashimoto, Satoshi Fukushima, Yoshihide Asano, Taku Fujimura

    Cancers　16　(15)　2024/08/02

    DOI： 10.3390/cancers16152755 　

    More details Close

    BACKGROUND: Adjuvant therapy has improved the clinical prognosis for postoperative melanoma patients. However, the long-term efficacy of this therapy on the melanoma acral and mucosal subtypes has not been fully evaluated in previous trials. This study assessed the 3-year recurrence-free survival and overall survival of patients with melanoma, including the acral and mucosal subtypes, treated with anti-PD-1 antibody (Ab) or with the combination of the BRAF and MEK inhibitors dabrafenib and trametinib. METHODS: We retrospectively analyzed both the 3-year time to relapse (TTR) and overall survival (OS) of 120 patients treated with anti-PD-1 antibody (Ab), or with the combination of dabrafenib and trametinib. RESULTS: The overall median TTR was 18.4 months, with a range of 0.69 to 36 months. The 3-year TTR of the acral and mucosal types was 28.1% and 38.5%, respectively. Baseline tumor thickness (TT) and acral type were associated with the TTR in subgroup analysis. Moreover, we classified 104 acral and non-acral cutaneous patients into the anti-PD-1 Abs or dabrafenib plus trametinib combined therapies cohort in multiple analyses. The acral subtype and TT were detected as important prognostic factors. In the 3-year OS, only tumor ulceration was associated with the OS in both univariate and multiple analyses. There was no significant difference in baseline or treatment-related factors of the mucosal type (p > 0.05). CONCLUSION: This study suggests that adjuvant therapy is more effective with non-acral cutaneous melanoma than either the acral or mucosal types at the 3-year TTR endpoint.

  4. Phase I/II clinical trial of brentuximab vedotin for pretreated Japanese patients with CD30-positive cutaneous T-cell lymphoma. International-journal

    Yoji Hirai, Jun Sakurai, Shiho Yoshida, Takashi Kikuchi, Toshiharu Mitsuhashi, Tomoko Miyake, Taku Fujimura, Riichiro Abe, Hiroki Fujikawa, Hikari Boki, Hiraku Suga, Sayaka Shibata, Tomomitsu Miyagaki, Takatoshi Shimauchi, Eiji Kiyohara, Yoshio Kawakami, Shin Morizane

    The Journal of dermatology　2024/06/14

    DOI： 10.1111/1346-8138.17324 　

    More details Close

    Brentuximab vedotin (BV), a conjugate of anti-CD30 antibody and monomethyl auristatin E, has emerged as a promising treatment option for refractory CD30+ mycosis fungoides (MF) and primary cutaneous anaplastic large-cell lymphoma (pcALCL). BV has been shown to be safe and effective in treating Hodgkin's lymphoma and peripheral T-cell lymphoma. This multicenter, prospective, single-arm phase I/II study evaluated the efficacy of BV in Japanese patients with CD30+ cutaneous lymphomas, namely CD30+ cutaneous T-cell lymphoma. Participants were divided into two groups: those with CD30+ MF or pcALCL (cohort 1, n = 13) and those with CD30+ lymphoproliferative disorders other than those in cohort 1 (cohort 2, n = 3). The studied population included the full analysis set (FAS), modified FAS (mFAS), and safety analysis set (SAF). These sets were identified in cohorts 1 and 1 + 2 and labeled FAS1 and FAS2, mFAS1 and mFAS2, and SAF1 and SAF2, respectively. Each treatment cycle lasted 3 weeks, and BV was continued for up to 16 cycles after the third cycle based on treatment response. The primary endpoint was the 4-month objective response rate (ORR4) determined by the Independent Review Forum (IRF). ORR4 was 69.2% for FAS1 and 62.5% for FAS2 (P < 0.0001). Secondary endpoints of ORR, assessed using the global response score (53.8% in FAS1) and modified severity-weighted assessment tool (62.5% in FAS1), using the IRF, provided results comparable to the primary findings. The incidence of ≥grade 3 adverse events (≥15%) in SAF1 was peripheral neuropathy in three patients (23%) and fever and eosinophilia in two patients (15%). In conclusion, BV showed favorable efficacy, tolerability, and safety profile in Japanese patients with relapsed or refractory CD30+ primary cutaneous T-cell lymphoma. The trial was registered with University Hospital Medical Information Network Clinical Trials Registry, Japan (protocol ID: UMIN000034205).

  5. Bexarotene-induced hypothyroidism and dyslipidemia; a nation-wide study.

    Katsunori Manaka, Junichiro Sato, Yusuke Hikima, Hirofumi Horikoshi, Maho Taguchi, Akimichi Morita, Hiraku Suga, Hikari Boki, Taku Fujimura, Yoji Hirai, Takatoshi Shimauchi, Chiharu Tateishi, Eiji Kiyohara, Ikko Muto, Hideki Nakajima, Riichiro Abe, Kazuyasu Fujii, Chikako Nishigori, Eiji Nakano, Kentaro Yonekura, Takeru Funakoshi, Masahiro Amano, Tomomitsu Miyagaki, Reiko Yamashita, Makoto Sugaya, Toshihisa Hamada, Masaomi Nangaku, Taroh Iiri, Noriko Makita

    Endocrine journal　2024/06/05

    DOI： 10.1507/endocrj.EJ23-0699 　

    More details Close

    Central hypothyroidism and dyslipidemia are well-known adverse events (AEs) of bexarotene therapy. Although hypothyroidism is known to cause dyslipidemia, no study has examined the association between hypothyroidism and dyslipidemia in patients undergoing bexarotene therapy. The aim of this study is to examine this association. A retrospective observational study was performed among 294 patients who initiated bexarotene therapy in Japan (nation-wide postmarketing complete surveillance). Jonckheere-Terpstra (one sided) test was performed to evaluate the effect of the bexarotene dose on lipid metabolisms, and regression analyses were performed to evaluate associations of bexarotene dose, free thyroxine (FT4), body mass index (BMI), and lipid metabolisms. Most patients developed hypothyroidism. Two-third of patients showed FT4 values below the lower limit at 1 week. Triglycerides (TG) increased in a bexarotene dose-dependent manner, and grade ≥3 AEs on hypertriglyceridemia was observed in 39% of the patients. Additionally, one-third of grade ≥3 AEs on hypertriglyceridemia occurred within 1 week. The delta_FT4 (difference in FT4 from baseline) negatively correlated with TG increase at 1 week (p = 0.012) but not with low density lipoprotein cholesterol (LDL-C) increase at any week. Bexarotene-induced hypothyroidism is almost inevitable and occurred quickly. Bexarotene-induced hypertriglyceridemia showed positive bexarotene dose dependency and negative delta_FT4 dependency. Prophylactic and appropriate thyroid hormone compensation therapy and starting bexarotene at low doses with subsequent titration while managing dyslipidemia may have a beneficial effect for the successful continuation of bexarotene therapy without severe endocrine and metabolic AEs.

  6. Phase II, multicenter study of plasminogen activator inhibitor-1 inhibitor (TM5614) plus nivolumab for treating anti-PD-1 antibody-refractory malignant melanoma: TM5614-MM trial. International-journal

    Taku Fujimura, Koji Yoshino, Hiroshi Kato, Satoshi Fukushima, Shoichiro Ishizuki, Atsushi Otsuka, Shigeto Matsushita, Ryo Amagai, Yusuke Muto, Emi Yamazaki, Yumi Kambayashi, Takashi Yahata, Toshio Miyata, Yasuhiro Fujisawa, Yoshihide Asano

    The British journal of dermatology　2024/06/04

    DOI： 10.1093/bjd/ljae231 　

    More details Close

    BACKGROUND: Anti-programmed cell death 1 antibodies (anti-PD-1 Abs) are widely used for advanced melanoma, but the efficacy of an anti-PD-1 Abs is limited in the Asian population. There remains an unmet need to improve the therapeutic effects of anti-PD-1 Abs treatment, particularly in melanoma patients who are refractory to anti-PD-1 Abs. The aim was to evaluate anti-PD-1 Abs treatment in combination with TM5614 (plasminogen activator inhibitor-1: PAI-1 inhibitor) in patients with unresectable melanoma. METHODS: The TM5614-MM study was a multicentre, open-label, single-arm, phase 2 clinical trial to evaluate the efficacy and safety of nivolumab in combination with TM5614 in patients with advanced, unresectable malignant melanoma recruited at 7 Japanese institutes between 13 September 2021 and 31 March 2023. Patients with metastatic or unresectable melanoma previously treated with anti-PD-1 Abs were enrolled. Nivolumab 480 mg was administered intravenously every 4 weeks for 8 weeks, while TM5614 was administered orally at a dose of 120 mg (0-4 weeks) and 180 mg once daily (5-8 weeks). The primary endpoint was the overall response rate after 8 weeks of concomitant use of TM5614. RESULTS: Thirty nine patients were enrolled, and 34 patients in the anti-PD-1 Abs-refractory cohort. The overall response rate at 8 weeks was 25.9% (95% CI: 12.9-44.9%; P = .027) in 27 anti-PD-1-Abs refractory patients by investigator assessment in the protocol per set cohort. Seven patients discontinued treatment due to progressive disease or adverse events. Treatment-related grade 3 or higher adverse events occurred in 3 of 39 patients (7.7%) in the intention-to-treat cohort. CONCLUSIONS: TM5614 in combination with nivolumab is well-tolerated and effective in anti-PD-1 Abs-refractory, unresectable melanoma. TRIAL REGISTRATION: This trial was registered with Clinical Trial gov, jRCT2021210029.

  7. Efficacy and safety of TM5614 in combination with paclitaxel in the treatment of paclitaxel-resistant cutaneous angiosarcoma: Phase II study protocol. International-journal

    Taku Fujimura, Koji Yoshino, Motoki Nakamura, Hiroshi Kato, Takamichi Ito, Takeo Maekawa, Yasuhiro Fujisawa, Shigeto Matsushita, Ryo Amagai, Emi Yamazaki, Manami Takahashi, Erika Tamabuchi, Akira Hashimoto, Yumi Kambayashi, Naoya Yamazaki, Toshio Miyata, Yoshihide Asano

    Experimental dermatology　2023/11/09

    DOI： 10.1111/exd.14976 　

    More details Close

    Cutaneous angiosarcoma (CAS) is an endothelial cell-derived, highly aggressive type of vascular tumour. Although chemoradiotherapy with paclitaxel (PTX) is recognized as a first-line therapy for CAS, second-line therapy for CAS remains controversial, and there is no standard therapy for taxane-resistant CAS. Plasminogen activator inhibitor-1 (PAI-1) is associated with poor clinical outcomes, and elevated levels of PAI-1 in both tissue and serum are correlated with poor response to therapy in various cancers, including skin cancers. Since PAI-1 protects endothelial cells from Fas ligand-mediated apoptosis, PAI-1 inhibition might induce apoptosis of endothelial cell-derived tumours such as CAS. This is a single-arm, open-label, multi-institutional, Phase 2 clinical trial to assess the efficacy and safety of PTX in combination with TM5614 (PAI-1 inhibitor) in patients with PTX-resistant CAS. PTX will be administered for 28 weeks, with oral administration of TM5614. The primary endpoint of this study will be the overall response rate (ORR) at 28 weeks after starting treatment (central image evaluation). The secondary endpoint will include the ORR at 28 weeks after starting treatment (investigator evaluation), ORR at 8 weeks and 16 weeks after initiation of treatment (central and investigator evaluation), progression-free survival, overall survival, disease control rate and safety profiles. Assuming the null hypothesis of a response rate of 13.6% and an alternative hypothesis of 45%, a minimum of 15 patients are required to achieve a two-sided, Type I error of 5% and power of 70% based on the exact binomial distribution. Data quality control will be conducted by a combination of centralized (remote) and on-site monitoring. This study will contribute to the development of novel combination therapy for PTX-resistant CAS patients, which remains an unmet clinical need.

  8. Adverse events associated with postoperative outcomes of adjuvant anti-PD-1 antibody therapy in both acral and non-acral cutaneous melanomas: A multicenter, observational, post hoc analysis study. International-journal

    Yusuke Muto, Yumi Kambayashi, Hiroshi Kato, Satoshi Fukushima, Takamichi Ito, Takeo Maekawa, Yasuhiro Fujisawa, Koji Yoshino, Hiroshi Uchi, Shigeto Matsushita, Yuki Yamamoto, Ryo Amagai, Kentaro Ohuchi, Akira Hashimoto, Yoshihide Asano, Taku Fujimura

    The Journal of dermatology　2023/07/30

    DOI： 10.1111/1346-8138.16912 　

    More details Close

    Since anti-PD-1 Abs can cause irreversible immune-related adverse events (irAEs), the associations between their efficacies and the incidence of irAEs are important to evaluate the use of anti-PD-1Abs for the treatment of melanoma, especially in the adjuvant setting. The purpose of this post hoc analysis study was to retrospectively analyze the associations between recurrence-free survival (RFS) at 12 months and the onset of any irAEs in 31 non-acral cutaneous and 30 acral melanoma cases treated with anti-PD-1 Abs therapy at the adjuvant setting in Asians. There were 20 cases with greater than grade 1 AEs in both the acral and non-acral cutaneous groups. Of the acral melanoma, 10 cases were nails or toes, and 20 cases were soles and heels. The log-rank test showed that RFS was better in cases with AEs than in cases without AEs. The present study suggested that the different profiles of irAEs between non-acral cutaneous and acral melanoma might correlate with the different response to anti-PD1 Abs of melanoma in the adjuvant setting.

  9. Postoperative adjuvant therapy for120 melanoma patients, including acral and mucosal subtypes: A multicenter, observational study of two-year follow-up results. International-journal

    Yusuke Muto, Yumi Kambayashi, Hiroshi Kato, Satoshi Fukushima, Takamichi Ito, Takeo Maekawa, Ishizuki Shoichiro, Hiroshi Uchi, Shigeto Matsushita, Yuki Yamamoto, Koji Yoshino, Yasuhiro Fujisawa, Ryo Amagai, Kentaro Ohuchi, Akira Hashimoto, Yoshihide Asano, Taku Fujimura

    The British journal of dermatology　2023/05/27

    DOI： 10.1093/bjd/ljad183 　

  10. Treatment for taxane-resistant cutaneous angiosarcoma: A multicenter study of 50 Japanese cases. International-journal

    Taku Fujimura, Takeo Maekawa, Hiroshi Kato, Takamichi Ito, Shigeto Matsushita, Koji Yoshino, Yasuhiro Fujisawa, Shoichiro Ishizuki, Kojiro Segawa, Jun Yamamoto, Akira Hashimoto, Yumi Kambayashi, Yoshihide Asano

    The Journal of dermatology　2023/03/20

    DOI： 10.1111/1346-8138.16786 　

    More details Close

    Cutaneous angiosarcoma (CAS) is a rare and highly aggressive type of vascular tumor. Although chemoradiotherapy with taxanes is recognized as a first-line therapy for CAS, second-line therapy for CAS remains controversial. From the above findings, the efficacy and safety profiles of taxane-switch (change paclitaxel to docetaxel or vise), eribulin methylate, and pazopanib regimens in second-line chemotherapy were evaluated retrospectively in 50 Japanese taxane-resistant CAS patients. Although there was no significant difference in progression-free survival (P = 0.3528) among the regimens, the incidence of all adverse events (AEs) (P = 0.0386), as well as severe G3 or more AEs (P = 0.0477) was significantly higher in the eribulin methylate group and pazopanib group than in the taxane-switch group. The present data suggest that switching to another taxane should be considered for the treatment of taxane-resistant CAS in second-line therapy based on the safety profiles.

  11. The Antimicrobial Peptide Cathelicidin Exerts Immunomodulatory Effects via Scavenger Receptors. International-journal

    Ryo Amagai, Toshiya Takahashi, Hitoshi Terui, Taku Fujimura, Kenshi Yamasaki, Setsuya Aiba, Yoshihide Asano

    International journal of molecular sciences　24　(1)　2023/01/03

    DOI： 10.3390/ijms24010875 　

    More details Close

    An active form of cathelicidin antimicrobial peptide, LL-37, has immunomodulatory and stimulatory effects, though the specific pathways are not clear. The purpose of this study was to identify the cellular pathways by which LL-37 amplifies the inflammation induced by damage-associated molecular patterns (DAMPs). We performed DNA microarray, reverse transcription polymerase chain reaction, immunoblotting, and proximity ligation assays using cultured keratinocytes treated with LL-37 and/or the DAMP poly(I:C), a synthetic double-stranded RNA. In contrast to the combination of LL-37 and poly(I:C), LL-37 alone induced genes related to biological metabolic processes such as VEGFA and PTGS2 (COX-2). Inhibition of FPR2, a known receptor for cathelicidin, partially suppressed the induction of VEGFA and PTGS2. Importantly, VEGFA and PTGS2 induced by LL-37 alone were diminished by the knockdown of scavenger receptors including SCARB1 (SR-B1), OLR1 (SR-E1), and AGER (SR-J1). Moreover, LL-37 alone, as well as the combination of LL-37 and poly(I:C), showed proximity to the scavenger receptors, indicating that LL-37 acts via scavenger receptors and intermediates between them and poly(I:C). These results showed that the broad function of cathelicidin is generally dependent on scavenger receptors. Therefore, inhibitors of scavenger receptors or non-functional mock cathelicidin peptides may serve as new anti-inflammatory and immunosuppressive agents.

  12. Adjuvant Anti-PD-1 Antibody Therapy for Advanced Melanoma: A Multicentre Study of 78 Japanese Cases. International-journal

    Yusuke Muto, Yumi Kambayashi, Hiroshi Kato, Satoshi Fukushima, Takamichi Ito, Takeo Maekawa, Yasuhiro Fujisawa, Koji Yoshino, Hiroshi Uchi, Shigeto Matsushita, Yuki Yamamoto, Ryo Amagai, Kentaro Ohuchi, Akira Hashimoto, Taku Fujimura

    Acta dermato-venereologica　102　adv00756　2022/08/11

    DOI： 10.2340/actadv.v102.678 　

    More details Close

    Anti-PD-1 antibodies (Abs) are among the optimal adjuvant therapies for melanoma at high risk of recurrence, especially BRAF wild-type melanoma, but the anti-tumour effects of anti-PD-1 Abs in the adjuvant setting for acral melanoma have not been evaluated previously. The aim of this study was to analyse the efficacy and safety profiles of anti-PD-1 Ab monotherapy in the adjuvant setting in an Asian population including a high ratio of acral melanoma. The efficacy and safety profiles of anti-PD-1 Ab monotherapy in the adjuvant setting were retrospectively analysed in 78 Japanese patients with advanced melanoma, including 31 cases (40%) of acral melanoma. Overall relapse-free survival was 60.3% (47 of 78 cases, 95% confidence interval (CI) 49.2-70.4%), and 39.7% of patients (31 of 78 patients, 95% CI 29.6-50.8%) relapsed during the adjuvant PD-1 Ab treatment. Six cases (7.9%) discontinued the protocol due to serious adverse events. One case (1.3%) discontinued the protocol due to trauma. The relapse-free survival of acral melanoma was 25.8%, whereas that of high cumulative sun damage was 60.0%, and that of low cumulative sun damage was 57.1%. The acral type had a significantly lower 12-month relapse-free survival than other cutaneous types (p = 0.029). The acral type appeared to be an independent prognostic factor on multivariate analysis (p = 0.015). Adverse events due to anti-PD-1 antibody were observed in 37.1% overall. The results of this study suggest that anti-PD-1 Ab therapy in the adjuvant setting is less effective for acral melanoma than for other cutaneous types.

  13. Successful treatment of metastatic fibrosarcomatous dermatofibrosarcoma protuberans with imatinib mesylate. International-journal

    Yumi Kambayashi, Yuki Kasahara, Kentaro Ohuchi, Ryo Amagai, Akira Hashimoto, Yoshihide Asano, Taku Fujimura

    Dermatologic therapy　35　(10)　e15736　2022/07/27

    DOI： 10.1111/dth.15736 　

    More details Close

    Dermatofibrosarcoma protuberans (DFSP) is a fibrohistiocytic tumor characterized by a high risk of local recurrence but a low risk of metastasis. A small subpopulation of DFSP undergoes fibrosarcomatous (FS) change, and approximately 15%-57% of cases of DFSP with FS change metastasizes, leading to a poor prognosis. In this report, a case of metastatic FS-DFSP that was successfully treated with imatinib mesylate in which the IHC staining pattern of recurrent DFSP was quantitatively analyzed in primary and metastatic DFSP areas, is described. Importantly, the recurrent area was composed of two IHC staining patterns (CD34low PD-L1high Ki67high , and CD34high PD-L1low Ki67low pattern), while the metastatic area showed a clonal pattern (CD34high PD-L1low Ki67intermediate ) in the present case. In this report, we described a case of metastatic fibrosarcomatous DFSP successfully treated with imatinib mesylate. This case suggests a subpopulation of DFSP with a favorable metastatic pattern.

  14. 悪性黒色腫の診療ガイドライン

    中村 泰大, 浅井 純, 井垣 浩, 猪爪 隆史, 並川 健二郎, 林 礼人, 福島 聡, 藤村 卓, 伊東 孝通, 今福 惠輔, 田中 亮多, 寺本 由紀子, 皆川 茜, 宮川 卓也, 宮下 梓, 和田 誠

    皮膚科　2　(1)　134-142　2022/07

    Publisher: (有)科学評論社

    ISSN： 2436-570X

  15. A pediatric case of corticosteroid-resistant erosive pustular dermatosis of scalp-like alopecia treated successfully with oral indomethacin, doxycycline, and topical tacrolimus. International-journal

    Rui Sasaki, Yoshihide Asano, Taku Fujimura

    The Journal of dermatology　2022/05/10

    DOI： 10.1111/1346-8138.16425 　

  16. 抗PD-1抗体によるメラノーマ術後補助療法の有効性・安全性の検証 多施設共同研究

    武藤 雄介, 加藤 裕史, 福島 聡, 伊東 孝通, 前川 武雄, 藤澤 康弘, 吉野 公二, 内 博史, 松下 茂人, 藤村 卓

    日本皮膚科学会雑誌　132　(5)　1362-1362　2022/05

    Publisher: (公社)日本皮膚科学会

    ISSN： 0021-499X

    eISSN： 1346-8146

  17. 進行期メラノーマに対するニボルマブ・PAI-1阻害薬併用療法の安全性・有効性の検討

    藤村 卓, 吉野 公二, 加藤 裕史, 福島 聡, 大塚 篤司, 松下 茂人, 神林 由美, 橋本 彰, 藤澤 康弘

    日本皮膚科学会雑誌　132　(5)　1314-1314　2022/05

    Publisher: (公社)日本皮膚科学会

    ISSN： 0021-499X

    eISSN： 1346-8146

  18. 抗PD-1抗体によるメラノーマ術後補助療法の有効性・安全性の検証 多施設共同研究

    武藤 雄介, 加藤 裕史, 福島 聡, 伊東 孝通, 前川 武雄, 藤澤 康弘, 吉野 公二, 内 博史, 松下 茂人, 藤村 卓

    日本皮膚科学会雑誌　132　(5)　1362-1362　2022/05

    Publisher: (公社)日本皮膚科学会

    ISSN： 0021-499X

    eISSN： 1346-8146

  19. Fulminant type 1 diabetes mellitus triggered by coronavirus disease 2019 vaccination in an advanced melanoma patient given adjuvant nivolumab therapy. International-journal

    Kentaro Ohuchi, Ryo Amagai, Erika Tamabuchi, Yumi Kambayashi, Taku Fujimura

    The Journal of dermatology　49　(5)　e167-e168　2022/05

    DOI： 10.1111/1346-8138.16304 　

  20. Stromal Factors as a Target for Immunotherapy in Melanoma and Non-Melanoma Skin Cancers. International-journal

    Taku Fujimura

    International journal of molecular sciences　23　(7)　2022/04/06

    DOI： 10.3390/ijms23074044 　

    More details Close

    Immune checkpoint inhibitors (ICIs), such as anti-programmed cell death 1 (PD1) antibodies (Abs) and anti-cytotoxic T-lymphocyte associated protein 4 (CTLA4) Abs, have been widely administered for not only advanced melanoma, but also various non-melanoma skin cancers. Since profiles of tumor-infiltrating leukocytes (TILs) play important roles in immunotherapy using ICIs, it is important to evaluate cancer stromal cells such as tumor-associated macrophages (TAMs) and cancer-associated fibroblasts (CAFs), as well as stromal extracellular matrix protein, to predict the efficacy of ICIs. This review article focuses particularly on TAMs and related factors. Among TILs, TAMs and their related factors could be the optimal biomarkers for immunotherapy such as anti-PD1 Ab therapy. According to the studies presented, TAM-targeting therapies for advanced melanoma and non-melanoma skin cancer will develop in the future.

  21. Nodal anaplastic large cell lymphoma with lymphomatoid papulosis following treatment of initially presumed atopic dermatitis with dupilumab: A case report. International-journal

    Mayuko Amagai, Maki Ozawa, Ryo Amagai, Kentaro Ohuchi, Yusuke Muto, Yumi Kambayashi, Setsuya Aiba, Taku Fujimura

    Dermatologic therapy　35　(3)　e15290　2022/03

    DOI： 10.1111/dth.15290 　

  22. Safety and efficacy of bexarotene for Japanese patients with cutaneous T-cell lymphoma: Real-world experience from post-marketing surveillance. International-journal

    Toshihisa Hamada, Akimichi Morita, Hiraku Suga, Hikari Boki, Taku Fujimura, Yoji Hirai, Takatoshi Shimauchi, Chiharu Tateishi, Eiji Kiyohara, Ikko Muto, Hideki Nakajima, Riichiro Abe, Kazuyasu Fujii, Chikako Nishigori, Eiji Nakano, Kentaro Yonekura, Takeru Funakoshi, Masahiro Amano, Tomomitsu Miyagaki, Noriko Makita, Katsunori Manaka, Yoshihito Shimoyama, Makoto Sugaya

    The Journal of dermatology　49　(2)　253-262　2022/02

    DOI： 10.1111/1346-8138.16201 　

    More details Close

    To establish real-world evidence about the safety and efficacy of bexarotene for Japanese patients with cutaneous T-cell lymphoma, we conducted a nationwide cohort study using data from post-marketing surveillance for bexarotene treatment. In total, 294 patients with cutaneous T-cell lymphoma were identified between June 2016 and June 2018. Of these, 267 patients were included as the safety analysis set. Of the 267 patients, 175 were included in the efficacy analysis set. Of these, 139 patients had mycosis fungoides, including 46 with early stage disease and 93 with advanced stage disease. Among the 139 patients with mycosis fungoides, the objective response rate was 46.8%. A significant difference in objective response rate was detected between patients who started with bexarotene at 300 mg/m2 (61.6%) and patients who started with bexarotene at less than 300 mg/m2 (22.6%, p < 0.001). Of the 139 patients with mycosis fungoides, 92 were treated with a combination of bexarotene plus photo(chemo)therapy. A significant difference in objective response rate was seen between bexarotene with a combination of photo(chemo)therapy (57.6%) and bexarotene without a combination of photo(chemo)therapy (25.5%, p < 0.001). Starting bexarotene at 300 mg/m2 and combination with photo(chemo)therapy were detected as independent factors influencing response. Common treatment-related adverse events included hypothyroidism (85.8%), hypertriglyceridemia (68.5%), hypercholesterolemia (43.8%), and neutropenia (21.3%). Hypertriglyceridemia, hypercholesterolemia, and neutropenia occurred more frequently in patients who started with bexarotene at 300 mg/m2 than patients who started with bexarotene at less than 300 mg/m2 (hypertriglyceridemia, 76.4% vs. 57.0%, p = 0.001; hypercholesterolemia, 49.0% vs. 36.4%, p = 0.045; neutropenia, 28.0% vs. 12.1%, p = 0.002; respectively). The present study indicates that starting bexarotene at 300 mg/m2 and combination of photo(chemo)therapy offer a promising efficacy for the treatment of patients with mycosis fungoides. Efficacy of low-dose bexarotene plus photo(chemo)therapy should be evaluated in future.

  23. Cutaneous angiosarcoma treated with taxane-based chemoradiotherapy: A multicenter study of 90 Japanese cases

    Taku Fujimura, Sadanori Furudate, Takeo Maekawa, Hiroshi Kato, Takamichi Ito, Shigeto Matsushita, Koji Yoshino, Akira Hashimoto, Yusuke Muto, Kentaro Ohuchi, Ryo Amagai, Yumi Kambayashi, Yasuhiro Fujisawa

    Skin Health and Disease　2022

    DOI： 10.1002/ski2.180 　

    eISSN： 2690-442X

  24. 進行期悪性黒色腫に対するダブラフェニブ・トラメチニブ術後補助療法 多施設共同後ろ向き研究

    藤村 卓, 武藤 雄介, 神林 由美, 加藤 裕史, 松下 茂人, 前川 武雄, 福島 聡, 吉野 公二, 内 博史, 藤澤 康弘

    日本皮膚科学会雑誌　132　(1)　86-86　2022/01

    Publisher: (公社)日本皮膚科学会

    ISSN： 0021-499X

    eISSN： 1346-8146

  25. Retrospective analysis of adjuvant therapy using dabrafenib plus trametinib in Japanese patients with advanced melanoma: analysis of 36 cases. International-journal

    Ryo Amagai, Yusuke Muto, Hiroshi Kato, Shigeto Matsushita, Takeo Maekawa, Satoshi Fukushima, Koji Yoshino, Hiroshi Uchi, Yasuhiro Fujisawa, Yuki Yamamoto, Kentaro Ohuchi, Yumi Kambayashi, Taku Fujimura

    Melanoma research　31　(6)　575-578　2021/12/01

    DOI： 10.1097/CMR.0000000000000770 　

    More details Close

    Patients with resected stage IIIB, IIIC and IIID melanomas have a high risk of recurrence. Therefore, an appropriate protocol for stage III melanoma is needed. Since adjuvant dabrafenib plus trametinib (D+T) combined therapy and anti-PD1 antibody (Ab) therapy reduce the risk of recurrence in patients with resected stage III BRAF-mutated melanoma, selecting the adjuvant therapy for BRAF-mutated melanoma is controversial. The efficacy and safety profiles of D+T combined therapy in the adjuvant setting were retrospectively analyzed in 36 Japanese. BRAF-mutated advanced melanoma patients. The relapse-free rate (RFR) at 12 months was 82.1% (95% confidential interval (CI), 63.9-92.6%). In the 21 patients who completed the protocol, the RFR at 12 months was 85.7% (95% CI, 64.5-95.9%). In the seven patients whose protocol was interrupted by adverse events, the RFR was 71.4% (95% CI, 35.2-92.4%). The incidence rate of any AEs for all patients was 69.7% (95% CI, 52.5-82.8%), including 13 cases of pyrexia, five cases of skin rash and four cases of liver dysfunction. The present study suggested that D+T therapy in the adjuvant setting is a useful and very tolerable protocol for BRAF-mutated melanoma in the Japanese population.

  26. Successful treatment of BRAF/MEK inhibitor-resistant advanced cutaneous melanoma with nivolumab plus ipilimumab combination therapy followed by intensity-modulated radiotherapy. International-journal

    Takami Okuma, Sadanori Furudate, Yumi Kambayashi, Akira Hashimoto, Setsuya Aiba, Taku Fujimura

    The Journal of dermatology　48　(9)　1419-1422　2021/05/18

    DOI： 10.1111/1346-8138.15962 　

    More details Close

    BRAF kinase inhibitors in combination with MEK kinase inhibitors are among the most promising chemotherapeutic regimens for the treatment of advanced BRAF-mutant melanoma. Although the NCCN guideline for cutaneous melanoma recommended BRAF/MEK inhibitors as first-line therapies for unresectable BRAF-mutated melanoma, resistance to these drugs should be taken into account in real-world practice. Therefore, development of a protocol for BRAF/MEK inhibitor-resistant advanced melanoma is needed. In this report, a case of BRAF/MEK inhibitor-resistant advanced cutaneous melanoma that was successfully treated with nivolumab plus ipilimumab combination therapy followed by intensity-modulated radiotherapy (IMRT) is reported. In the present case, not only the locally irradiated lesion, but remote metastases including inguinal lymph nodes decreased after ipilimumab plus nivolumab followed by IMRT treatment leading to complete remission, suggesting that IMRT triggered an abscopal response. Moreover, immunohistochemical analysis showed increased CD3+ , CD4+ , and CD8+ T cells after radio-immunotherapy (RIT). This case suggests that RIT might break the tolerance in the tumor microenvironment and induce a systemic anti-melanoma immune response.

  27. 進行期黒色腫に対するエンコラフェニブ,ビニメチニブ併用療法 22例の多施設共同後ろ向き解析

    大内 謙太郎, 吉野 公二, 加藤 裕史, 藤澤 康弘, 山本 有紀, 伊東 孝通, 松下 茂人, 前川 武雄, 相場 節也, 藤村 卓

    日本皮膚科学会雑誌　131　(5)　1416-1416　2021/05

    Publisher: (公社)日本皮膚科学会

    ISSN： 0021-499X

    eISSN： 1346-8146

  28. 当科におけるメラノーマに対する術後補助療法の後方視的検討

    武藤 雄介, 藤村 卓, 神林 由美, 古舘 禎騎, 大内 謙太郎, 天貝 諒, 千葉 広夢, 大熊 崇生, 相場 節也

    日本皮膚科学会雑誌　131　(5)　1416-1416　2021/05

    Publisher: (公社)日本皮膚科学会

    ISSN： 0021-499X

    eISSN： 1346-8146

  29. RB1 gene mutations are a distinct predictive factor in Merkel cell carcinoma. International-journal

    Yusuke Muto, Eijitsu Ryo, Kenjiro Namikawa, Akira Takahashi, Dai Ogata, Taku Fujimura, Yasushi Yatabe, Setsuya Aiba, Naoya Yamazaki, Taisuke Mori

    Pathology international　71　(5)　337-347　2021/05

    DOI： 10.1111/pin.13090 　

    More details Close

    Merkel cell carcinoma (MCC) is a rare cutaneous neuroendocrine carcinoma that tends to show local recurrence and metastasis. Typically, MCC is polyomavirus (MCPyV)-associated and cytokeratin 20 (CK20) positive. However, little is known about this tumor and its origins. Here, we aimed to determine the developmental origins of MCC and to identify prognostic clinicopathologic factors. Initial examinations revealed that CK20 and MCPyV expression (CK20+, MCPyV+ (60%); CK20+, MCPyV- (10%); CK20-, and MCPyV- (30%)) did not affect overall survival. With RB1 gene sequencing of FFPE specimens, which covered an entire exon, all RB1 mutation-positive cases showed positive regional lymph node and/or distant metastases (8/8 cases, 100%), whereas the frequency of the metastasis was statistically significantly lower in RB1 mutation-negative cases, (10/16 cases, 62%, P = 0.033). The results were also confirmed with immunohistochemistry, and either RB1 alterations, entire exon sequencing, or immunohistochemistry was associated with the metastasis (P = 0.007). RB1 alterations may be used to access the aggressive clinical course of MCC.

  30. Phosphor-signal transducers and activator of transcription 1 signaling in mucosal lichen planus developing from metastatic bladder cancer treated with pembrolizumab. International-journal

    Erika Tamabuchi, Taku Fujimura, Chunbing Lyu, Setsuya Aiba

    Dermatologic therapy　34　(4)　e14961　2021/04/28

    DOI： 10.1111/dth.14961 　

  31. Unbiased Detection of Driver Mutations in Extramammary Paget Disease. International-journal

    Yoshihiro Ishida, Nobuyuki Kakiuchi, Kenichi Yoshida, Yoshikage Inoue, Hiroyuki Irie, Tatsuki R Kataoka, Masahiro Hirata, Takeru Funakoshi, Shigeto Matsushita, Hiroo Hata, Hiroshi Uchi, Yuki Yamamoto, Yasuhiro Fujisawa, Taku Fujimura, Ryunosuke Saiki, Kengo Takeuchi, Yuichi Shiraishi, Kenichi Chiba, Hiroko Tanaka, Atsushi Otsuka, Satoru Miyano, Kenji Kabashima, Seishi Ogawa

    Clinical cancer research : an official journal of the American Association for Cancer Research　27　(6)　1756-1765　2021/03/15

    DOI： 10.1158/1078-0432.CCR-20-3205 　

    More details Close

    PURPOSE: Extramammary Paget disease (EMPD) is an uncommon skin malignancy whose genetic alterations are poorly characterized. Previous reports identified mutations in chromatin remodeling genes and PIK3CA. In order to unambiguously determine driver mutations in EMPD, we analyzed 87 EMPD samples using exome sequencing in combination with targeted sequencing. EXPERIMENTAL DESIGN: First, we analyzed 37 EMPD samples that were surgically resected using whole-exome sequencing. Based on several in silico analysis, we built a custom capture panel of putative driver genes and analyzed 50 additional formalin-fixed, paraffin-embedded samples using target sequencing. ERBB2 expression was evaluated by HER2 immunohisotochemistry. Select samples were further analyzed by fluorescence in situ hybridization. RESULTS: A median of 92 mutations/sample was identified in exome analysis. A union of driver detection algorithms identified ERBB2, ERBB3, KMT2C, TP53, PIK3CA, NUP93, AFDN, and CUX1 as likely driver mutations. Copy-number alteration analysis showed regions spanning CDKN2A as recurrently deleted, and ERBB2 as recurrently amplified. ERBB2, ERBB3, and FGFR1 amplification/mutation showed tendency toward mutual exclusivity. Copy-number alteration load was associated with likelihood to recur. Mutational signatures were dominated by aging and APOBEC activation and lacked evidence of ultraviolet radiation. HER2 IHC/fluorescence in situ analysis validated ERBB2 amplification but was underpowered to detect mutations. Tumor heterogeneity in terms of ERBB2 amplification status was observed in some cases. CONCLUSIONS: Our comprehensive, unbiased analysis shows EMPD is characterized by alterations involving the PI3K-AKT pathway. EMPD is distinct from other skin cancers in both molecular pathways altered and etiology behind mutagenesis.

  32. Outcome of combination therapy using BRAF and MEK inhibitors among Asian patients with advanced melanoma: An analysis of 112 cases. International-journal

    Yasuhiro Fujisawa, Takamichi Ito, Hiroshi Kato, Hiroyuki Irie, Tatsuya Kaji, Takeo Maekawa, Jun Asai, Yuki Yamamoto, Taku Fujimura, Yasuo Nakai, Masahito Yasuda, Kanako Matsuyama, Ikko Muto, Shigeto Matsushita, Hiroshi Uchi, Yoshiyuki Nakamura, Jiro Uehara, Koji Yoshino

    European journal of cancer (Oxford, England : 1990)　145　210-220　2021/03

    DOI： 10.1016/j.ejca.2020.12.021 　

    More details Close

    BACKGROUND: As most clinical trials evaluating BRAF and MEK inhibitor combination therapy (B + Minh) have been conducted in Western countries, little is known about the effect of B + Minh among East Asian populations. MATERIAL AND METHODS: Data from patients with advanced melanoma treated using B + Minh (either dabrafenib + trametinib or encorafenib + binimetinib) were retrospectively collected from 16 institutes in Japan. Response rates, adverse events, patterns of failure and survival were analysed. RESULTS: We analysed 112 of 144 collected patient records and, of these, 14 had acral/mucosal melanoma. The response rate for the entire cohort was 75.0%. There were no statistical differences in response rates between acral/mucosal and cutaneous melanomas (64.3% versus 76.5%), whereas previous treatment using immune checkpoint inhibitors (ICIs) did not affect response (72.7% versus 73.9%) to B + Minh, response to ICI after B + Minh was only 20%. Patients who achieved complete response had the best overall survival rates at 24 months (94.7%). Elevated serum lactate dehydrogenase levels and 3 or more metastatic sites were independently associated with survival. The most common relapse site was the brain (17.9%). More than half of the patients (58.8%) experienced grade III/IV pyrexia. CONCLUSION: B + Minh was effective among Japanese patients with melanoma, including those with acral/mucosal melanoma. Factors associated with survival were similar to previous Western studies. B + Minh response was not affected by the previous use of ICI; however, vigilance against brain metastasis during B + Minh therapy is required as the brain was our most commonly encountered relapse site.

  33. Case series of BRAF-mutated advanced melanoma treated with encorafenib plus binimetinib combination therapy. International-journal

    Taku Fujimura, Koji Yoshino, Hiroshi Kato, Yasuhiro Fujisawa, Yoshiyuki Nakamura, Yuki Yamamoto, Kayo Kunimoto, Takamichi Ito, Shigeto Matsushita, Takeo Maekawa, Kentaro Ohuchi, Ryo Amagai, Yusuke Muto, Sadanori Furudate, Yumi Kambayashi, Akira Hashimoto, Setsuya Aiba

    The Journal of dermatology　48　(3)　397-400　2021/03

    DOI： 10.1111/1346-8138.15688 　

    More details Close

    The efficacy of encorafenib plus binimetinib (E + B) combination therapy for BRAF-mutated advanced melanoma as second-line therapy and beyond is still unknown. In this report, we investigated 22 cases of BRAF-mutated advanced melanoma treated with E + B combination therapy. The objective response rate (ORR) for the total cohort was 68.4%. Notably, the ORR for the second-line and beyond cohort was 73.3%, suggesting that the therapeutic effect of E + B combination therapy is comparable with that of first-line targeted therapy. In contrast, overall survival and progress-free survival in our present cohort was worse than that in a previous clinical trial. Notably, although the incidence rate of severe adverse events was higher than that in a previous report, our present study suggested that E + B combination therapy is a well-tolerated antimelanoma regimen. Our present study suggested that the efficacy and safety profile of E + B combination therapy as a second-line therapy and beyond is comparable with that of first-line targeted therapy.

  34. Possible roles of CXCL13/CXCR5 axis in the development of bullous pemphigoid. International-journal

    Kentaro Ohuchi, Taku Fujimura, Chunbing Lyu, Ryo Amagai, Yusuke Muto, Setsuya Aiba

    The Journal of dermatology　48　(3)　353-359　2021/03

    DOI： 10.1111/1346-8138.15713 　

    More details Close

    CXCL13 recruits CXCR5+ follicular helper T (Tfh) cells in inflammatory lesions to develop secondary lymphoid organs. Tfh cells activate B cells to produce antibodies during humoral immune responses. Indeed, as previous reports suggested, CXCR5+ cell numbers were increased in the peripheral blood of bullous pemphigoid (BP) patients when compared with healthy donors, and the ratio of CXCR5+ cells was positively correlated with the anti-BP180-NC16A titers. From the above findings, in this report, we hypothesized that a chemokine related to CXCR5+ cells, namely CXCL13, may play a role in the development of BP. We performed immunohistochemical staining of CXCR5, CXCL13, LL37, CXCL10 and CCL20 for 10 cases of BP and 10 cases of pemphigus vulgaris (PV), and quantitatively analyzed the staining by digital microscopy. Moreover, we investigated the CXCL10 and CXCL13 production in BP and PV patients by enzyme-linked immunosorbent assay. The immunomodulatory effects of LL37 on the production of T-helper 17-related chemokines were evaluated using monocyte-derived M2 macrophages. Immunohistochemical staining and digital microscopic analysis showed that the ratios of CXCR5+ , CXCL13+ and LL37+ cells in the dermis were significantly higher in BP patients than in PV patients. Notably, the ratio of CXCL13+ cells was positively correlated with the anti-BP180-NC16A titers. Moreover, the serum levels of CXCL13 were positively correlated with the anti-BP180-NC16A titers. Furthermore, CD163+ M2 macrophages stimulated by LL37 in vitro produced CXCL10 and CCL20. In the lesional skin of BP, CD163+ macrophages CXCL10 and CCL20 were produced. The serum levels of CXCL10 were negatively correlated with the anti-BP180-NC16A titers. The present study results indicate that the mechanism of the development of BP may involve the CXCL13/CXCR5-mediated migration of Tfh cells.

  35. Dabrafenib plus trametinib combination therapy triggered onset of pustulosis palmaris et plantaris in a patient with advanced cutaneous melanoma. International-journal

    Yusuke Muto, Taku Fujimura, Yumi Kambayashi, Kentaro Ohuchi, Ryo Amagai, Takami Okuma, Sadanori Furudate, Akira Hashimoto, Setsuya Aiba

    The Journal of dermatology　48　(3)　e135-e136　2021/03

    DOI： 10.1111/1346-8138.15747 　

  36. Topical and Systemic Formulation Options for Cutaneous T Cell Lymphomas. International-journal

    Taku Fujimura, Ryo Amagai, Yumi Kambayashi, Setsuya Aiba

    Pharmaceutics　13　(2)　2021/02/02

    DOI： 10.3390/pharmaceutics13020200 　

    More details Close

    Although various anti-cutaneous T-cell lymphoma (CTCL) therapies are available for clinical use, appropriate chemotherapy lines for the treatment of CTCLs have yet to be established. Therefore, to date, various clinical trials for the treatment of advanced CTCLs are ongoing. In this review, we evaluate the therapeutic options that are available in clinical practice for treatment of early- and advanced-stage CTCLs (targeted therapies, histone deacetylase (HDAC) inhibitors, retinoids, interferons, cytotoxic drugs, etc.). We also examine clinical trials of novel regimens for the treatment of CTCLs.

  37. Plasminogen Activating Inhibitor-1 Might Predict the Efficacy of Anti-PD1 Antibody in Advanced Melanoma Patients. International-journal

    Kentaro Ohuchi, Yumi Kambayashi, Takanori Hidaka, Taku Fujimura

    Frontiers in oncology　11　798385-798385　2021

    DOI： 10.3389/fonc.2021.798385 　

    More details Close

    Plasminogen activating inhibitor-1 (PAI-1) plays crucial roles in the development of various cancers, including melanomas. Indeed, various pro-tumorigenic functions of PAI-1 in cancer progression and metastasis have been widely reported. Among them, PAI-1 is also reported as a key regulator of PD-L1 expression on melanoma cells through endocytosis, leading to abrogating the efficacy of anti-PD1 antibodies (Abs). These findings suggested that PAI-1 expression might predict the efficacy of anti-PD1 Abs. In this report, the expression and production of PAI-1 in melanoma patients were evaluated, and the immunomodulatory effects of PAI-1 on tumor-associated macrophages were investigated in vitro. Immunohistochemical staining of PAI-1 showed that PAI-1 expression on melanoma cells was significantly decreased in responders compared to non-responders. Moreover, baseline serum levels of PAI-1 were significantly decreased in responders compared to non-responders. Notably, PAI-1 decreased the production of various chemokines from monocyte-derived M2 macrophages in vitro, suggesting that PAI-1 might decrease tumor-infiltrating lymphocytes to hamper the anti-tumor effects of anti-PD1 Abs. These results suggest that baseline serum levels of PAI-1 may be useful as a biomarker for identifying patients with advanced cutaneous melanoma most likely to benefit from anti-melanoma immunotherapy.

  38. Serum soluble CD163 and proinflammatory chemokines may be biomarkers of the onset of adverse events in dabrafenib plus trametinib combination therapy for advanced melanoma. International-journal

    Ryo Amagai, Taku Fujimura, Yusuke Muto, Yumi Kambayashi, Sadanori Furudate, Kentaro Ohuchi, Takami Okuma, Akira Hashimoto, Setsuya Aiba

    Dermatologic therapy　34　(1)　e14544　2021/01

    DOI： 10.1111/dth.14544 　

    More details Close

    Various adverse events (AEs) have been reported to occur at a high rate in patients treated with dabrafenib plus trametinib (D + T) combination therapy. Among such AEs, the incidence of pyrexia was highest among the series of AEs in patients treated with D + T combination therapy. Although little is known about the mechanisms of pyrexia caused by D + T combination therapy, a recent report suggested that sCD163, as well as interferon-inducible chemokines (CXCL9, CXCL10, CXCL11), might correlate with pyrexia caused by encorafenib plus binimetinib combination therapy. In addition to these soluble factors, CXCL5 is a biomarker for predicting immune-related AEs in melanoma patients treated with nivolumab. From the above findings, we hypothesized that these soluble factors might also correlate with the onset of AEs in D + T combination therapy. The serum levels of sCD163 were increased in patients with pyrexia in parallel with their severity, whereas the serum levels of CXCL5 were increased in patients without pyrexia. Moreover, increased levels of CXCL9, CXCL10, and CXCL11 were prominent in patients with AEs over G2 levels. As these chemokines recruit Th1, Th17, and activated CD8+ T cells, increased serum levels of these chemokines might correlate with the positive feedback of inflammatory reactions related to AEs.

  39. 本邦メラノーマにおけるBRAF/MEK阻害剤併用療法の効果についての多施設共同研究:102例の解析

    藤澤 康弘, 伊東 孝通, 加藤 裕史, 入江 浩之, 加持 達弥, 前川 武雄, 浅井 純, 山本 有紀, 藤村 卓, 吉野 公二

    日本皮膚悪性腫瘍学会学術大会プログラム・抄録集　36回　136-136　2020/12

    Publisher: (一社)日本皮膚悪性腫瘍学会

  40. Increased serum CCL26 level is a potential biomarker for the effectiveness of anti-PD1 antibodies in patients with advanced melanoma. International-journal

    Taku Fujimura, Kayo Tanita, Kentaro Ohuchi, Yota Sato, Chunbing Lyu, Yumi Kambayashi, Yasuhiro Fujisawa, Ryota Tanaka, Akira Hashimoto, Setsuya Aiba

    Melanoma research　30　(6)　613-618　2020/12

    DOI： 10.1097/CMR.0000000000000685 　

    More details Close

    Nivolumab plus ipilimumab combined therapy is among the most effective therapies for advanced melanoma. However, this therapy is also associated with a high frequency of immune-related adverse events (irAEs). To avoid such severe irAEs caused by additional administration of anti-CTLA4 antibodies, biomarkers to distinguish responders from non-responders among patients treated with anti-PD1 antibodies are important. The purpose of this study is to evaluate the increased serum levels of CCL11, CCL24, and CCL26 as a predictive biomarker for the efficacy of anti-PD1 antibodies in advanced cutaneous melanoma patients. This study analyzed increased serum levels of CCL11, CCL24, and CCL26 in 46 cases of advanced cutaneous melanoma treated with anti-PD1 antibodies. Serum levels on day 42 were compared to baseline (day 0) and analyzed statistically. Receiver operating characteristic curves were established to evaluate the correlation between serum levels of CCL11, CCL24, and CCL26 and efficacy of anti-PD1 antibodies. Increased serum levels of CCL26 correlated significantly with the efficacy of anti-PD1 antibodies. In contrast, no significant correlations were seen between increased serum levels of CCL11 and CCL24 and efficacy of anti-PD1 antibodies. Increased serum levels of CCL26 may be a useful biomarker for identifying those patients with advanced cutaneous melanoma most likely to benefit from anti-melanoma immunotherapy.

  41. Severe eczematoid and lichenoid eruption with full-thickness epidermal necrosis developing from metastatic urothelial cancer treated with enfortumab vedotin. International-journal

    Rui Sasaki, Taku Fujimura, Chunbing Lyu, Setsuya Aiba

    The Journal of dermatology　47　(12)　1436-1438　2020/12

    DOI： 10.1111/1346-8138.15577 　

    More details Close

    Enfortumab vedotin (EV) is a novel, fully humanized monoclonal antibody-drug conjugate composed of an anti-Nectin-4 antibody joined to monomethyl auristatin E. In this report, we described a case of a severe eczematoid and lichenoid eruption with full-thickness epidermal necrosis developing in patients with metastatic urothelial cancer treated with EV. Because phase II and phase III clinical studies are ongoing, in the future, substantial amounts of EV are expected to be used for the treatment of metastatic urothelial cancer. Therefore, understanding the mechanisms of drug eruption caused by EV is important for oncologists as well as dermatologists.

  42. Serum CCL22 levels decreased in parallel with disease activity in CCR4-positive mycosis fungoides treated with mogamulizumab. International-journal

    Kentaro Ohuchi, Taku Fujimura, Chunbing Lyu, Ryo Amagai, Yusuke Muto, Setsuya Aiba

    Dermatologic therapy　33　(6)　e14099　2020/11

    DOI： 10.1111/dth.14099 　

    More details Close

    Mogamulizumab is a humanized anti-C-C chemokine receptor type (CCR)4 antibody that shows cytotoxicity against CCR4+ lymphoma cells via antibody-dependent cell-mediated cytotoxicity in advanced cutaneous T cell lymphoma (CTCL) patients. The production levels of ligands for CCR4, that is, Chemokine (C-C motif) ligand (CCL)17 and CCL22, are important for the assessment of the disease activity in CTCL patients. We evaluated the serum levels of CCL17, CCL19, CCL22, C-X-C motif chemokine ligand (CXCL)10, and CXCL13, which are ligands for CCR4, CCR7, CCR4, C-X-C Motif Chemokine Receptor (CXCR)3, and CXCR5, respectively, at baseline and 4 weeks after the administration of mogamulizumab in five patients with mycosis fungoides. The serum levels of CCL22 were significantly decreased in patients who responded to mogamulizumab, but no differences were identified in the serum levels of CCL17, CCL19, CXCL10, or CXCL13. Immunofluorescence staining revealed that the majority of CCL22-producing cells were cluster of differentiation (CD)163+ tumor-associated macrophages, and they were surrounded by CCR4+ CTCL cells. Our present data suggested that the serum CCL22 level may be a predictive marker of the efficacy of mogamulizumab for the treatment of CCR4+ CTCL.

  43. Multiple angiolymphoid hyperplasia with eosinophilia on the right arm showing unusual presentation. International-journal

    Erika Tamabuchi, Taku Fujimura, Chinbing Lyu, Setsuya Aiba

    Dermatologic therapy　33　(6)　e14314　2020/11

    DOI： 10.1111/dth.14314 　

  44. Erythema nodosum developed in a patient with advanced cutaneous melanoma treated with dabrafenib plus trametinib combination therapy. International-journal

    Yusuke Muto, Taku Fujimura, Yumi Kambayashi, Kentaro Ohuchi, Ryo Amagai, Takami Okuma, Sadanori Furudate, Akira Hashimoto, Setsuya Aiba

    Dermatologic therapy　33　(6)　e14430　2020/11

    DOI： 10.1111/dth.14430 　

  45. Anti-PD-1 antibody therapy for epithelial skin malignancies: An investigator-initiated, open-label, single-arm, multicenter, phase II clinical trial (NMSC-PD1 Study). International-journal

    Maki Ishii, Ikuko Hirai, Keiji Tanese, Takayuki Fusumae, Yoshio Nakamura, Keitaro Fukuda, Hiroshi Uchi, Kenji Kabashima, Atsushi Otsuka, Kenji Yokota, Naoya Yamazaki, Kenjiro Namikawa, Taku Fujimura, Tatsuya Takenouchi, Yuki Yamamoto, Mana Nishiguchi, Yasunori Sato, Masayuki Amagai, Takeru Funakoshi

    Medicine　99　(44)　e22913　2020/10/30

    DOI： 10.1097/MD.0000000000022913 　

    More details Close

    INTRODUCTION: Malignant cutaneous epithelial tumors comprise various skin malignancies originating from the cutaneous epithelium, including cutaneous squamous cell carcinoma, basal cell carcinoma, and malignant cutaneous adnexal tumors. Treatment options are limited, as the rarity of these tumors, especially among Asians, renders well-controlled clinical trials extremely challenging to conduct. Thus, we designed a clinical trial to evaluate the efficacy and safety of the anti-programmed cell death-1 (PD-1) monoclonal antibody nivolumab in patients with metastatic cutaneous squamous cell carcinomas and other rare metastatic cutaneous epithelial tumors. METHODS AND ANALYSIS: This is an open-label, single-arm, multicenter, phase 2 clinical trial involving patients with metastatic malignant cutaneous epithelial tumors. Nivolumab (480 mg) will be administered intravenously every 4 weeks for a maximum of 26 doses. The primary outcome of the study will be the response rate based on response evaluation criteria in solid tumors, version 1.1. Assuming a null hypothesis of a response rate ≤5% and an alternative hypothesis of a 25% response rate, a minimum of 26 patients are required to achieve a 5% two-sided type I error and 80% power based on the exact binomial distribution. Finally, a target cohort size of 30 patients was determined as some patient dropout will be expected. DISCUSSION: This is the first phase 2 clinical trial evaluating the efficacy and safety of the PD-1 inhibitor nivolumab in Asian patients with metastatic malignant cutaneous epithelial tumors. The findings of the study will contribute to the development of novel treatment approaches for patients with rare cutaneous malignancies, which remains an unmet clinical need. TRIAL REGISTRATION: Registry number: jRCT 2031190048.

  46. Treatment of Advanced Melanoma: Past, Present and Future. International-journal

    Taku Fujimura, Yumi Kambayashi, Kentaro Ohuchi, Yusuke Muto, Setsuya Aiba

    Life (Basel, Switzerland)　10　(9)　2020/09/16

    DOI： 10.3390/life10090208 　

    More details Close

    Therapeutic options for treating advanced melanoma are progressing rapidly. Until six years ago, the regimen for treating advanced melanoma mainly comprised cytotoxic agents such as dacarbazine, and type I interferons. Since 2014, anti-programmed cell death 1 (PD1) antibodies have become recognized as anchor drugs for treating advanced melanoma with or without additional combination drugs such as ipilimumab. In addition, v-Raf murine sarcoma viral oncogene homolog B1 (BRAF) kinase inhibitors in combination with mitogen-activated protein kinase kinase (MEK) inhibitors are among the most promising chemotherapeutic regimens for treating advanced BRAF-mutant melanoma, especially in patients with low tumor burden. Since anti-PD1 antibodies are widely applicable for the treatment of both BRAF wild-type and mutated advanced melanomas, several clinical trials for drugs in combination with anti-PD1 antibodies are ongoing. This review focuses on the development of the anti-melanoma therapies available today, and discusses the clinical trials of novel regimens for the treatment of advanced melanoma.

  47. Demographic and clinical characteristics of extramammary Paget's disease patients in Japan from 2000 to 2019 Peer-reviewed

    F.M. Ghazawi, N. Iga, R. Tanaka, Y. Fujisawa, K. Yoshino, C. Yamashita, Y. Yamamoto, T. Fujimura, T. Yanagi, H. Hata, S. Matsushita, M. Le, S.F. Roy, F. Lagacé, Y. Ishida, K. Kabashima, A. Otsuka

    Journal of the European Academy of Dermatology and Venereology　2020/09/10

    Publisher: Wiley

    DOI： 10.1111/jdv.16868 　

  48. 本邦メラノーマにおけるBRAF/MEK阻害剤併用の効果についての多施設共同研究

    藤澤 康弘, 吉野 公二, 加藤 裕史, 入江 浩之, 加持 達弥, 前川 武雄, 浅井 純, 山本 有紀, 藤村 卓, 安田 正人, 松山 かなこ, 武藤 一考, 松下 茂人, 内 博史, 伊東 孝通

    日本皮膚科学会雑誌　130　(9)　2085-2085　2020/08

    Publisher: (公社)日本皮膚科学会

    ISSN： 0021-499X

    eISSN： 1346-8146

  49. Significance of Immunosuppressive Cells as a Target for Immunotherapies in Melanoma and Non-Melanoma Skin Cancers. International-journal

    Taku Fujimura, Setsuya Aiba

    Biomolecules　10　(8)　2020/07/22

    DOI： 10.3390/biom10081087 　

    More details Close

    Tumor-associated macrophages (TAMs) have been detected in most skin cancers. TAMs produce various chemokines and angiogenic factors that promote tumor development, along with other immunosuppressive cells such as myeloid-derived suppressor cells (MDSCs), regulatory T cells (Tregs) and tumor-associated neutrophils. TAMs generated from monocytes develop into functional, fully activated macrophages, and TAMs obtain various immunosuppressive functions to maintain the tumor microenvironment. Since TAMs express PD1 to maintain the immunosuppressive M2 phenotype by PD1/PD-L1 signaling from tumor cells, and the blockade of PD1/PD-L1 signaling by anti-PD1 antibodies (Abs) activate and re-polarize TAMs into immunoreactive M1 phenotypes, TAMs represent a potential target for anti-PD1 Abs. The main population of TAMs comprises CD163+ M2 macrophages, and CD163+ TAMs release soluble (s)CD163 and several proinflammatory chemokines (CXCL5, CXCL10, CCL19, etc.) as a result of TAM activation to induce an immunosuppressive tumor microenvironment together with other immunosuppressive cells. Since direct blockade of PD1/PD-L1 signaling between tumor cells and tumor-infiltrating T cells (both effector T cells and Tregs) is mandatory for inducing an anti-immune response by anti-PD1 Abs, anti-PD1 Abs need to reach the tumor microenvironment to induce anti-immune responses in the tumor-bearing host. Taken together, TAM-related factors could offer a biomarker for anti-PD1 Ab-based immunotherapy. Understanding the crosstalk between TAMs and immunosuppressive cells is important for optimizing PD1 Ab-based immunotherapy.

  50. Concordance and Discordance Rates of V-Raf Murine Sarcoma Viral Oncogene Homolog B1 (BRAF)V600E Status in Metastatic against Primary Lesion of Melanoma: A Meta-analysis.

    Hiroshi Yokomichi, Takashi Inozume, Makoto Wada, Jun Asai, Hiroshi Igaki, Kenjiro Namikawa, Ayato Hayashi, Satoshi Fukushima, Taku Fujimura, Hiroshi Koga, Yasuhiro Nakamura, Mie Mochizuki, Zentaro Yamagata

    JMA journal　3　(3)　274-279　2020/07/15

    DOI： 10.31662/jmaj.2020-0016 　

  51. Successful treatment of mogamulizumab-resistant mycosis fungoides with mogamulizumab plus etoposide combined therapy: Investigation of the immunomodulatory effects of etoposide on the tumor microenvironment. International-journal

    Kentaro Ohuchi, Taku Fujimura, Yumi Kambayashi, Ryo Amagai, Chunbing Lyu, Kayo Tanita, Yota Sato, Setsuya Aiba

    Dermatologic therapy　33　(4)　e13487　2020/07

    DOI： 10.1111/dth.13487 　

    More details Close

    Mogamulizumab shows cytotoxicity against CCR4+ lymphoma cells by antibody-dependent cell-mediated cytotoxicity (ADCC) in advanced cutaneous T-cell lymphoma (CTCL) patients. Although mogamulizumab is used as one of the anchor drugs for the treatment of advanced CTCL, its efficacy is unsatisfactory, especially in mycosis fungoides (MF). Therefore, additional drugs to enhance the antitumor effects of mogamulizumab are needed to further optimize its use for the treatment of MF. In this report, two cases of mogamulizumab-resistant MF successfully treated with additional administration of etoposide are presented. Moreover, the possible mechanisms of mogamulizumab-etoposide combined therapy for the treatment of MF were investigated based on the modulation of chemokine profiles in vivo using an EL-4 mouse T-cell lymphoma model. Intraperitoneal administration of etoposide significantly increased the mRNA expressions of CCL17, CXCL5, and CXCL10, suggesting that CCR4+ CTCL cells gather around the tumor-associated macrophagess. Furthermore, the immunomodulatory effects of etoposide on the mRNA expressions of these chemokines were validated using monocyte-derived M2 macrophages in vitro. Since mogamulizumab shows cytotoxicity against CCR4+ lymphoma cells by ADCC that depends on the contact between the lymphoma cells and the effector cells, these chemokines could enhance the therapeutic effect of mogamulizumab.

  52. Successful treatment of unresectable recurrent cutaneous squamous cell carcinoma of the scalp with meningeal invasion with nivolumab monotherapy. International-journal

    Taku Fujimura, Yumi Kambayashi, Hisayuki Tono, Chinbing Lyu, Kentaro Ohuchi, Akira Hashimoto, Setsuya Aiba

    Dermatologic therapy　33　(4)　e13672　2020/07

    DOI： 10.1111/dth.13672 　

    More details Close

    Although the number of cutaneous squamous cell carcinoma (cSCC) cases is increasing, the effectiveness of systemic therapy for the treatment of advanced cSCC is limited. Since cSCC possesses a high tumor mutation burden (TMB) compared to other cancer species, and since high TMB correlated with increased neoantigens and the efficacy of anti-PD1 antibodies (Abs) in various cancers, cSCC could be a target for anti-PD1 Abs monotherapy. In this report, we describe a case of unresectable recurrent cSCC of the scalp with meningeal invasion, but highly expressed programmed death-ligand 1 (PD-L1), treated with nivolumab monotherapy.

  53. Successful treatment of CCR4+ mycosis fungoides palmaris et plantaris with mogamulizumab monotherapy. International-journal

    Taku Fujimura, Yumi Kambayashi, Kentaro Ohuchi, Ryo Amagai, Yusuke Muto, Setsuya Aiba

    Dermatologic therapy　33　(4)　e13731　2020/07

    DOI： 10.1111/dth.13731 　

  54. Increased expression of dermal LL37 may trigger migration of CCR7+ regulatory T cells in extramammary Paget's disease. International-journal

    Chunbing Lyu, Taku Fujimura, Ryo Amagai, Kentaro Ohuchi, Yota Sato, Kayo Tanita, Shigeto Matsushita, Yasuhiro Fujisawa, Atsushi Otsuka, Yuki Yamamoto, Toshiya Takahashi, Setsuya Aiba

    Journal of dermatological science　99　(1)　65-68　2020/07

    DOI： 10.1016/j.jdermsci.2020.05.003 　

  55. Severe pyrexia from nivolumab-resistant advanced melanoma after successful combined therapy with encorafenib plus binimetinib. International-journal

    Ryo Amagai, Taku Fujimura, Yumi Kambayashi, Yota Sato, Kayo Tanita, Kentaro Ohuchi, Akira Hashimoto, Setsuya Aiba

    The Journal of dermatology　47　(6)　654-657　2020/06

    DOI： 10.1111/1346-8138.15346 　

    More details Close

    Various serious adverse events (AE) have been reported to occur at a high rate in patients treated with BRAF plus mitogen-activated protein kinase kinase (MEK) inhibitor combination therapy, but their subtypes differ among the BRAF/MEK inhibitors. Pyrexia or a spike of fever are well-known AE of BRAF inhibitors, with or without MEK inhibitors, and have been reported to have a high incidence after dabrafenib/trametinib, but not after encorafenib/binimetinib. In this report, we describe three cases of severe pyrexia in nivolumab-resistant advanced melanoma after successful combined therapy with encorafenib plus binimetinib. Interestingly, in all cases, the serum levels of soluble CD163 C-X-C motif chemokine (CXCL)9, CXCL10 and CXCL11, which are known biomarkers for adult-onset Still's disease (AOSD), increased in parallel with the development of pyrexia. Our present cases suggest that pyrexia caused by BRAF/MEK inhibitors may possess a similar pathophysiology as that of AOSD.

  56. Severe Demyelinating Neuropathy in an Advanced Melanoma Patient Treated with Nivolumab plus Ipilimumab Combined Therapy

    Yumi Kambayashi, Taku Fujimura, Hiroshi Kuroda, Atsushi Otsuka, Hiroyuki Irie, Setsuya Aiba

    Case Reports in Oncology　13　(1)　474-477　2020/04/30

    Publisher: S. Karger AG

    DOI： 10.1159/000506976 　

    eISSN： 1662-6575

  57. Case series of cutaneous T-cell lymphomas treated with bexarotene-based therapy. International-journal Peer-reviewed

    Taku Fujimura, Yota Sato, Kayo Tanita, Ryo Amagai, Takatoshi Shimauchi, Dai Ogata, Satoshi Fukushima, Azusa Miyashita, Yasuhiro Fujisawa, Yumi Kambayashi, Setsuya Aiba

    The Journal of dermatology　2020/03/24

    DOI： 10.1111/1346-8138.15322 　

    More details Close

    Bexarotene is useful for both early and advanced cutaneous T-cell lymphoma (CTCL), and is sometimes applied to ultraviolet-tolerant early CTCL patients as one of the first-line therapies in the real world. However, continuous administration of bexarotene is sometimes difficult because of its adverse events (AE). Development of an appropriate protocol for bexarotene that can induce a consistent response for CTCL without severe AE (SAE) is needed. We retrospectively investigated 29 Japanese cases of CTCL and evaluated the efficacy of treatment and incident ratios of all AE and SAE. Objective response rate (ORR) for the overall cohort was 65.5%. ORR of the 300 mg/m2 cohort (conventional dose) was 76.2%, while that of the 150-300 mg/body (low dose) with narrowband ultraviolet B light (NBUVB) cohort was 37.5%. Mean event-free survival was 10.0 months for all patients, 6.7 months for the bexarotene conventional-dose cohort and 19.1 months for the low-dose with NBUVB cohort. The incident ratio of total SAE for all patients was 20.7%. The incident ratio of total SAE was 23.8% for the conventional-dose cohort and 12.5% for the low-dose with NBUVB cohort. Our present study suggests that low-dose bexarotene plus NBUVB therapy is well-tolerated and could be one of the optimal therapies for advanced CTCL.

  58. Systemic treatment of patients with advanced cutaneous squamous cell carcinoma: response rates and outcomes of the regimes used. International-journal Peer-reviewed

    Dai Ogata, Kenjiro Namikawa, Masaki Otsuka, Jun Asai, Hisoshi Kato, Masahito Yasuda, Takeo Maekawa, Taku Fujimura, Junji Kato, Tatsuya Takenouchi, Kotaro Nagase, Masakazu Kawaguchi, Tatsuya Kaji, Yutaka Kuwatsuka, Yoshitsugu Shibayama, Toshihiro Takai, Mao Okumura, Yumi Kambayashi, Syusuke Yoshikawa, Naoya Yamazaki, Tetsuya Tsuchida

    European journal of cancer (Oxford, England : 1990)　127　108-117　2020/03

    DOI： 10.1016/j.ejca.2019.12.018 　

    More details Close

    BACKGROUND: Cutaneous squamous cell carcinoma (cSCC) is the second most common type of skin cancer. Few patients with cSCC experience metastases, but the prognosis of advanced cSCC (acSCC) is dismal. Evidence regarding systemic therapy for acSCC is limited. Therefore, we aimed to determine the most effective systemic treatment for acSCC. PATIENTS AND METHODS: This retrospective study involved 16 Japanese institutions. We documented patient and tumour characteristics and disease course of patients with acSCC who received systemic therapy between 1st January 2006 and 31st December 2015. We compared the overall survival (OS) and progression-free survival (PFS) for (1) platinum versus non-platinum groups, (2) radiation plus chemotherapy first-line therapy (RCT) versus non-RCT groups and (3) platinum-based RCT versus non-platinum-based RCT groups. RESULTS: Although the use of platinum-based systemic therapy was not associated with statistically significant improvements in PFS and OS, there were significant differences between the RCT and non-RCT groups (PFS: p < 0.001, OS: p = 0.003). In the subgroup analysis, RCT significantly prolonged PFS and OS in the nodal SCC (nSCC) group. For the RCT and non-RCT groups, the median OS was 110 and 14 months, respectively, and the 5-year OS rate was 54% and 21%, respectively. CONCLUSION: RCT could improve OS in patients with nSCC. However, further multicenter prospective studies are needed to establish evidence for superiority of RCT.

  59. The efficacy of eribulin mesylate for patients with cutaneous angiosarcoma previously treated with taxane: a multi-center, prospective, observational study Peer-reviewed

    Fujisawa Y, Fujimura T, Matsushita S, Yamamoto Y, Uchi H, Otsuka A, Funakoshi T, Miyagi T, Hata H, Gosho M, Kambayashi Y, Aoki M, Yanagi T, Ohira A, Nakamura Y, Maeda T, Yoshino K

    British Journal of Dermatology　2020/03

  60. Japanese Dermatological Association Guidelines: Outlines of guidelines for cutaneous melanoma 2019. International-journal Peer-reviewed

    Yasuhiro Nakamura, Jun Asai, Hiroshi Igaki, Takashi Inozume, Kenjiro Namikawa, Ayato Hayashi, Satoshi Fukushima, Taku Fujimura, Takamichi Ito, Keisuke Imafuku, Ryota Tanaka, Yukiko Teramoto, Akane Minagawa, Takuya Miyagawa, Azusa Miyashita, Makoto Wada, Hiroshi Koga, Makoto Sugaya

    The Journal of dermatology　47　(2)　89-103　2020/02

    DOI： 10.1111/1346-8138.15151 　

    ISSN： 0385-2407

    More details Close

    With consideration of the ongoing developments in treatment options for cutaneous melanoma, the Japanese Skin Cancer Society published the first guidelines for cutaneous melanoma in 2007 and later revised them in 2015. Here, we report on an English version of the 2019 Japanese Melanoma Guidelines. In this latest edition, all processes were carried out according to the Grading of Recommendations, Assessment, Development and Evaluation system. A comprehensive published work search, systematic review and determination of recommendations in each clinical question were performed by a multidisciplinary expert panel consisting of dermatologists, a plastic and reconstructive surgeon, and a radiation oncologist. The advent of novel agents, such as immune checkpoint inhibitors and molecular-targeted agents, has drastically changed the nature of treatment for adjuvant and advanced-stage diseases among melanoma patients worldwide. Additionally, recent reports of clinical trials regarding surgical procedures and a better understanding of molecular biology and tumor immunology in clinical types of melanoma have had an impact on clinical practise. Based on these viewpoints, eight relevant clinical questions were raised in this report that aim to help clinicians select the appropriate therapeutic approach.

  61. Metastatic PRAME-Expressing Juvenile Spitzoid Melanoma on the Buttock

    Yusuke Muto, Taku Fujimura, Yumi Kambayashi, Kentaro Ohuchi, Ryo Amagai, Akira Hashimoto, Setsuya Aiba

    Case Reports in Oncology　1141-1144　2020

    Publisher: S. Karger AG

    DOI： 10.1159/000510261 　

    ISSN： 1662-6575

  62. IL-23 Expression in Stewart-Treves Syndrome: Two Case Reports and Immunohistochemical Investigation

    Saaya Yoshida, Taku Fujimura, Kentaro Ohuchi, Yumi Kambayashi, Yuichiro Segawa, Emi Yamazaki, Hisayuki Tono, Toshiya Takahashi, Kenichiro Tsuchiyama, Setsuya Aiba

    Case Reports in Oncology　13　(1)　462-467　2020

    Publisher: S. Karger AG

    DOI： 10.1159/000506975 　

    ISSN： 1662-6575

  63. Successful Treatment of a Patient with anti-PD1 Antibody-Resistant Advanced Mucosal Melanoma with Nivolumab, Ipilimumab plus Denosumab Combination Therapy

    Taku Fujimura, Yumi Kambayashi, Kentaro Ohuchi, Ryo Amagai, Yota Sato, Kayo Tanita, Akira Hashimoto, Setsuya Aiba

    Case Reports in Oncology　13　(1)　271-275　2020

    Publisher: S. Karger AG

    DOI： 10.1159/000506327 　

    ISSN： 1662-6575

  64. Editorial: Recent Developments in Therapies and Diagnostic Tools for Melanoma and Non-melanoma Skin Cancer. International-journal

    Taku Fujimura, Yasuhiro Fujisawa, Atsushi Otsuka, Nikolas K Haass

    Frontiers in medicine　7　613152-613152　2020

    DOI： 10.3389/fmed.2020.613152 　

  65. Possible Roles of Proinflammatory Signaling in Keratinocytes Through Aryl Hydrocarbon Receptor Ligands for the Development of Squamous Cell Carcinoma. International-journal

    Yota Sato, Taku Fujimura, Takanori Hidaka, Chunbing Lyu, Kayo Tanita, Shigeto Matsushita, Masayuki Yamamoto, Setsuya Aiba

    Frontiers in immunology　11　534323-534323　2020

    DOI： 10.3389/fimmu.2020.534323 　

    More details Close

    Aryl hydrocarbon receptor (AhR) provides a deeper insight into the pathogenesis of cutaneous squamous cell carcinoma (cSCC). AhR ligands, such as 6-formylindolo[3,2-b] carbazole (FICZ), and 7,12-Dimethylbenz[a]anthracene (DMBA), constitute major substrates for the cytochrome P450 (CYP) family, and influence the expression of various cytokine genes, including IL-17 and IL-23-related genes via the AhR. On the other hand, proinflammatory cytokines could drive tumor progression through the TRAF-ERK5 signaling pathway in cSCC. From the above findings, we hypothesized that AhR ligands might enhance the mRNA expression of proinflammatory cytokines via the AhR, leading to the development of cSCC. The purpose of this study was to investigate (1) the immunomodulatory effects of FICZ and DMBA on normal human keratinocytes (NHKCs), focusing on IL-17, and related cytokines/chemokines (IL-23, IL-36γ, and CCL20), (2) the expression of these factors in AhR-dependent pathways using a two-stage chemically induced skin carcinogenesis mouse model, and (3) the expression of these factors in lesion-affected skin in cSCC. Both FICZ and DMBA augmented the expression of CYP1A1, p19, CCL20, and IL-36γ mRNA in NHKCs in vitro. Moreover, the mRNA expression of these proinflammatory factors, as well as IL-17, in mouse cSCC is significantly decreased in the AhR-(fl/fl) Krt5-(Cre) mice compared to wild type mice, leading to a decrease in the number of developed cSCC lesions. Furthermore, CCL20, IL-23, as well as IL-17, are detected in the lesion-affected skin of cSCC patients. Our study demonstrates a possible mechanism for the development of cSCC involving AhR-mediated signaling by epidermal keratinocytes and recruitment of Th17 cells.

  66. Numerical Simulation of Effects of Bioheat Transfer Characteristics of Malignant Melanoma on Thermal Conductivity Measurements. International-journal Peer-reviewed

    Takahiro Okabe, Junnosuke Okajima, Taku Fujimura, Setsuya Aiba, Shigenao Maruyama

    Critical reviews in biomedical engineering　48　(2)　95-109　2020

    DOI： 10.1615/CritRevBiomedEng.2020033900 　

    More details Close

    In our previous study, we successfully detected a difference in the effective thermal conductivity between an invasive melanoma lesion and healthy skin, through clinical experiments conducted on melanoma patients. We found that the effective thermal conductivity of the lesions correlated with the tumor thickness, suggesting that it may be correlated with the prognostic risk of melanoma. However, the bioheat transfer mechanisms of the correlation remained unknown. The aim of this study was to numerically investigate the effects of the bioheat transfer characteristics of malignant melanoma on thermal conductivity measurements and explore the cause of the difference in the effective thermal conductivity between lesions and healthy skin. We used two different bioheat transfer models, the Pennes model and local thermal nonequilibrium model, and investigated the cause of the aforementioned differences by varying the bioheat transfer parameters associated with the thermophysical properties and blood flow of a tumor. The calculation results indicated that the contribution of the blood flow can be dominant in a measurement comprising the use of a guard-heated thermistor probe. Therefore, we found that it is necessary to take into consideration the contribution of the convective term to the effective thermal conductivity of the lesion in order to explain the clinical data of a Stage IV invasive melanoma.

  67. First-in-human clinical study of novel technique to diagnose malignant melanoma via thermal conductivity measurements Peer-reviewed

    Takahiro Okabe, Taku Fujimura, Junnosuke Okajima, Yumi Kambayashi, Setsuya Aiba, Shigenao Maruyama

    Scientific Reports　9　(1)　3853　2019/12/01

    DOI： 10.1038/s41598-019-40444-6 　

    eISSN： 2045-2322

  68. Variable indoleamine 2,3-dioxygenase expression in acral/mucosal melanoma and its possible link to immunotherapy. International-journal Peer-reviewed

    Natsuko Iga, Atsushi Otsuka, Masahiro Hirata, Tatsuki R Kataoka, Hiroyuki Irie, Chisa Nakashima, Shigeto Matsushita, Hiroshi Uchi, Yuki Yamamoto, Takeru Funakoshi, Yasuhiro Fujisawa, Koji Yoshino, Taku Fujimura, Hiroo Hata, Yoshihiro Ishida, Kenji Kabashima

    Cancer science　110　(11)　3434-3441　2019/11

    DOI： 10.1111/cas.14195 　

    ISSN： 1347-9032

    More details Close

    Immune checkpoint inhibitors have improved the prognosis of advanced melanoma. Although anti-programmed death ligand-1 (PD-L1) is a well-studied biomarker for response to anti-programmed death-1 PD-1 therapy in melanoma, its clinical relevance remains unclear. It has been established that the high expression of indoleamine 2,3-dioxygenase (IDO) is correlated to a response to anti-CTLA-4 treatment in melanoma. However, it is still unknown whether the IDO expression is associated with response to anti-PD-1 therapy in advanced melanoma. In addition, acral and mucosal melanomas, which comprise a great proportion of all melanomas in Asians, are genetically different subtypes from cutaneous melanomas; however, they have not been independently analyzed due to their low frequency in Western countries. To evaluate the association of IDO and PD-L1 expression with response to anti-PD-1 antibody in acral and mucosal melanoma patients, we analyzed 32 Japanese patients with acral and mucosal melanomas treated with anti-PD-1 antibody from the perspective of IDO and PD-L1 expression levels by immunohistochemistry (IHC). Multivariate Cox regression models showed that the low expression of IDO in tumors was associated with poor progression-free survival (HR = 0.33, 95% CI = 0.13-0.81, P = 0.016), whereas PD-L1 expression on tumors was not associated with progression-free survival. Significantly lower expression of IDO in tumors was found in non-responders compared to responders. Assessment of the IDO expression could be useful for the identification of suitable candidates for anti-PD-1 therapy among acral and mucosal melanomas patients. Further validation study is needed to estimate the clinical utility of our findings.

  69. Bexarotene Reduces Production of CCL22 From Tumor-Associated Macrophages in Cutaneous T-Cell Lymphoma Peer-reviewed

    Kayo Tanita, Taku Fujimura, Yota Sato, Chunbing Lyu, Yumi Kambayashi, Dai Ogata, Satoshi Fukushima, Azusa Miyashita, Hideki Nakajima, Motoki Nakamura, Akimichi Morita, Setsuya Aiba

    Frontiers in Oncology　9　907　2019/09/20

    DOI： 10.3389/fonc.2019.00907 　

    eISSN： 2234-943X

  70. Successful Treatment of Multiple Metastatic Melanoma with Nivolumab, Ipilimumab plus Denosumab Combined Therapy. Peer-reviewed

    Yoshida S, Fujimura T, Kambayashi Y, Amagai R, Hashimoto A, Aiba S

    Case reports in oncology　12　(3)　829-833　2019/09

    DOI： 10.1159/000504019 　

  71. Advanced Invasive Extramammary Paget's Disease Concomitant with Cecal Cancer Possessing Rare Variant of TP53 Single Nucleotide Polymorphism. Peer-reviewed

    Kambayashi Y, Fujimura T, Ohuchi K, Tono H, Ishida Y, Otsuka A, Aiba S

    Case reports in oncology　12　(3)　855-860　2019/09

    DOI： 10.1159/000504339 　

  72. A novel technique to diagnose non-melanoma skin cancer by thermal conductivity measurements: Correlations with cancer stromal factors. Peer-reviewed

    Fujimura T, Okabe T, Tanita K, Sato Y, Lyu C, Kambayashi Y, Maruyama S, Aiba S

    Experimental dermatology　28　(9)　1029-1035　2019/09

    DOI： 10.1111/exd.13997 　

    ISSN： 0906-6705

  73. Perifolliculitis capitis abscedens et suffodiens treatment with tumor necrosis factor inhibitors: A case report and review of published cases. Peer-reviewed

    Takahashi T, Yamasaki K, Terui H, Omori R, Tsuchiyama K, Fujimura T, Aiba S

    The Journal of dermatology　46　(9)　802-807　2019/09

    DOI： 10.1111/1346-8138.14998 　

    ISSN： 0385-2407

    eISSN： 1346-8138

  74. Significance of BRAF Kinase Inhibitors for Melanoma Treatment: From Bench to Bedside. International-journal Peer-reviewed

    Fujimura T, Fujisawa Y, Kambayashi Y, Aiba S

    Cancers　11　(9)　2019/09

    DOI： 10.3390/cancers11091342 　

    More details Close

    According to clinical trials, BRAF kinase inhibitors in combination with MEK kinase inhibitors are among the most promising chemotherapy regimens for the treatment of advanced BRAF-mutant melanoma, though the rate of BRAF mutation gene-bearing cutaneous melanoma is limited, especially in the Asian population. In addition, drug resistance sometimes abrogates the persistent efficacy of combined therapy with BRAF and MEK inhibitors. Therefore, recent pre-clinical study-based clinical trials have attempted to identify optimal drugs (e.g., immune checkpoint inhibitors or histone deacetylase (HDAC) inhibitors) that improve the anti-melanoma effects of BRAF and MEK inhibitors. In addition, the development of novel protocols to avoid resistance of BRAF inhibitors is another purpose of recent pre-clinical and early clinical trials. This review focuses on pre-clinical studies and early to phase III clinical trials to discuss the development of combined therapy based on BRAF inhibitors for BRAF-mutant advanced melanoma, as well as mechanisms of resistance to BRAF inhibitors.

  75. Malassezia-derived aryl hydrocarbon receptor ligands enhance the CCL20/Th17/soluble CD163 pathogenic axis in extra-mammary Paget's disease. International-journal Peer-reviewed

    Sato Y, Fujimura T, Tanita K, Chunbing L, Matsushita S, Fujisawa Y, Otsuka A, Yamamoto Y, Hidaka T, Aiba S

    Experimental dermatology　28　(8)　933-939　2019/08

    DOI： 10.1111/exd.13944 　

    ISSN： 0906-6705

    More details Close

    Malassezia yeast play a role in the pathogenesis of chronic dermatitis, especially in apocrine areas, by polarizing the local immunologic background to a Th2/Th17 state through aryl hydrocarbon receptor (AhR)-dependent pathways. Extra-mammary Paget's disease (EMPD) is an adenocarcinoma of apocrine origin, and except for cases associated with Malassezia yeast and their metabolites, the lesions typically develop in areas not exposed to environmental material. The purpose of this study was to investigate (a) the immunomodulatory effects of Malassezia metabolites on normal human keratinocytes (NHKCs), focusing on interleukin (IL)-17 and related cytokines/chemokines (IL-23, IL-36γ, CCL20), (b) the expression of these factors in lesion-affected skin in EMPD and (c) the activation of tumor-associated macrophages (TAMs) by these factors. Malassezia metabolites augmented the expression of cytochrome P450, family 1, subfamily A, polypeptide 1 (CYP1A1), CCL20 and IL-36γ mRNA in NHKCs in vitro. In lesion-affected skin of patients with EMPD, epidermal keratinocytes expressed CYP1A1 and CCL20. In addition, Paget cells expressed CCL20 and IL-23. IL-17-producing cells were distributed adjacent to Paget cells. Compared to healthy donors, patients with EMPD exhibited significantly increased serum levels of soluble (s)CD163, CXCL5, CXCL10 and CCL20. In addition, serum levels of sCD163 decreased significantly following tumor resection. Our study demonstrates a possible mechanism for the development of EMPD involving AhR-mediated signalling by epidermal keratinocytes and RANKL-induced recruitment of Th17 cells and TAMs.

  76. Severe rhabdomyolysis developing in an advanced melanoma patient treated by pembrolizumab followed by dabrafenib trametinib combined therapy. Peer-reviewed

    Irimada M, Fujimura T, Kambayashi Y, Tsukada A, Takahashi T, Hashimoto A, Aiba S

    The Journal of dermatology　46　(7)　e256-e258　2019/07

    DOI： 10.1111/1346-8138.14778 　

    ISSN： 0385-2407

  77. Successful treatment of unresectable recurrent programmed death ligand 1 moderately-expressing malignant melanoma of the nasal cavity with pembrolizumab monotherapy. Peer-reviewed

    Fujimura T, Kambayashi Y, Sato Y, Tanita K, Tono H, Lyu C, Takahashi T, Hashimoto A, Aiba S

    The Journal of dermatology　46　(7)　e260　2019/07

    DOI： 10.1111/1346-8138.14786 　

    ISSN： 0385-2407

  78. Successful treatment of microcystic adnexal carcinoma on the philtrum with oral S-1 monotherapy. Peer-reviewed

    Haga T, Fujimura T, Aiba S

    The Journal of dermatology　46　(6)　e208-e209　2019/06

    DOI： 10.1111/1346-8138.14770 　

    ISSN： 0385-2407

  79. Three cases of nivolumab therapy-failed advanced melanoma successfully controlled by ipilimumab with intensity-modulated radiotherapy. Peer-reviewed

    Amagai R, Fujimura T, Kambayashi Y, Sato Y, Tanita K, Hashimoto A, Aiba S

    The Journal of dermatology　46　(5)　449-452　2019/05

    DOI： 10.1111/1346-8138.14861 　

    ISSN： 0385-2407

  80. Clinical and histopathological characteristics and survival analysis of 4594 Japanese patients with melanoma. International-journal Peer-reviewed

    Yasuhiro Fujisawa, Shusuke Yoshikawa, Akane Minagawa, Tatsuya Takenouchi, Kenji Yokota, Hiroshi Uchi, Naoki Noma, Yasuhiro Nakamura, Jun Asai, Junji Kato, Susumu Fujiwara, Satoshi Fukushima, Jiro Uehara, Toshihiko Hoashi, Tatsuya Kaji, Taku Fujimura, Kenjiro Namikawa, Manabu Yoshioka, Naoki Murao, Dai Ogata, Kanako Matsuyama, Naohito Hatta, Yoshitsugu Shibayama, Toshiharu Fujiyama, Masashi Ishikawa, Daisuke Yamada, Akiko Kishi, Yoshiyuki Nakamura, Takatoshi Shimiauchi, Kazuyasu Fujii, Manabu Fujimoto, Hironobu Ihn, Norito Katoh

    Cancer medicine　8　(5)　2146-2156　2019/05

    DOI： 10.1002/cam4.2110 　

    More details Close

    BACKGROUND: The incidence of melanoma among those of an Asian ethnicity is lower than in Caucasians; few large-scale Asian studies that include follow-up data have been reported. OBJECTIVES: To investigate the clinical characteristics of Japanese patients with melanoma and to evaluate the prognostic factors. METHODS: Detailed patient information was collected from the database of Japanese Melanoma Study Group of the Japanese Skin Cancer Society. The American Joint Committee on Cancer seventh Edition system was used for TNM classification. The Kaplan-Meier method and Cox proportional hazards model were used to estimate the impact of clinical and histological parameters on disease-specific survival in patients with invasive melanoma. RESULTS: In total, 4594 patients were included in this analysis. The most common clinical type was acral lentiginous melanoma (40.4%) followed by superficial spreading melanoma (20.5%), nodular melanoma (10.0%), mucosal melanoma (9.5%), and lentigo maligna melanoma (8.1%). The 5-year disease-specific survival for each stage was as follows: IA = 98.0%, IB = 93.9%, IIA = 94.8%, IIB = 82.4%, IIC = 71.8%, IIIA = 75.0%, IIIB = 61.3%, IIIC = 41.7%, and IV = 17.7%. Although multivariate analysis showed that clinical classifications were not associated with survival across all stages, acral type was an independent poor prognostic factor in stage IIIA. CONCLUSIONS: Our study revealed the characteristics of melanoma in the Japanese population. The 5-year disease-specific survival of each stage showed a similar trend to that of Caucasians. While clinical classification was not associated with survival in any stages, acral type was associated with poor survival in stage IIIA. Our result might indicate the aggressiveness of acral type in certain populations.

  81. Classification of 3097 patients from the Japanese melanoma study database using the American joint committee on cancer eighth edition cancer staging system. International-journal Peer-reviewed

    Yasuhiro Fujisawa, Shusuke Yoshikawa, Akane Minagawa, Tatsuya Takenouchi, Kenji Yokota, Hiroshi Uchi, Naoki Noma, Yasuhiro Nakamura, Jun Asai, Junji Kato, Susumu Fujiwara, Satoshi Fukushima, Jiro Uehara, Toshihiko Hoashi, Tatsuya Kaji, Taku Fujimura, Kenjiro Namikawa, Manabu Yoshioka, Naoki Murata, Dai Ogata, Kanako Matsuyama, Naohito Hatta, Yoshitsugu Shibayama, Toshiharu Fujiyama, Masashi Ishikawa, Daisuke Yamada, Akiko Kishi, Yoshiyuki Nakamura, Takatoshi Shimiauchi, Kazuyasu Fujii, Manabu Fujimoto, Hironobu Ihn, Norito Katoh

    Journal of dermatological science　94　(2)　284-289　2019/05

    DOI： 10.1016/j.jdermsci.2019.04.003 　

    ISSN： 0923-1811

    More details Close

    BACKGROUND: The American Joint Committee on Cancer (AJCC) 8th Edition Cancer Staging System was implemented in 2018; however, it has not been validated in an Asian melanoma population. OBJECTIVE: The purpose of this study was to validate the new system using a cohort of Japanese melanoma patients. METHODS: The AJCC 7th and 8th Editions were used for TNM classification of patients in a database established by the Japanese Melanoma Study Group. Patient data with sufficient information to be applicable to the AJCC 8th staging were selected. The Kaplan-Meier method was used to estimate disease-specific survival and relapse-free survival. RESULTS: In total, data for 3097 patients were analyzed. The 5-year disease-specific survival according to the 7th and 8th Edition staging system were as follows: IA = 98.5%/97.9%; IB = 95.4%/96.2%; IIA = 94.2%/94.1%; IIB = 84.6%/84.4%; IIC = 72.2%/72.2%; IIIA = 76.2%/87.5%; IIIB = 60.7%/72.6%; IIIC = 42.0%/55.3% and IIID = none/26.0%. The 5-year relapse-free survival according to the 7th and 8th Edition staging was as follows: IA = 94.5%/92.7%; IB = 85.4%/85.3%; IIA = 80.1%/79.4%; IIB = 71.4%/70.6%; IIC = 56.8%/55.7%; IIIA = 56.8%/69.4%; IIIB = 42.6%/56.8%; IIIC = 20.0%/33.3% and IIID = none/6.5%. CONCLUSION: The results show that new staging system could efficiently classify our Japanese melanoma cohort. Although there was no difference in Stage I and II disease between the 7th and 8th Edition systems, we should be careful in managing Stage III disease since the survival curves of the 8th Edition staging were completely different from the 7th Edition. Moreover, our results indicate that adjuvant therapies for Stage IIB and IIC should be developed, since the relapse-free survival for these stages were equivalent to Stage IIIA and IIIB, respectively.

  82. Successful treatment of multiple eruptive adult xanthogranuloma concomitant with xanthelasma palpebrarum with probucol. Peer-reviewed

    Ishihara-Yusa S, Fujimura T, Lyu C, Sugawara M, Sakamoto K, Aiba S

    The Journal of dermatology　46　(10)　e362-e364　2019/05

    DOI： 10.1111/1346-8138.14903 　

    ISSN： 0385-2407

  83. Lichen planus pemphigoides developing from patient with non-small-cell lung cancer treated with nivolumab. Peer-reviewed

    Sato Y, Fujimura T, Mizuashi M, Aiba S

    The Journal of dermatology　46　(10)　e374-e375　2019/05

    DOI： 10.1111/1346-8138.14906 　

    ISSN： 0385-2407

  84. Pembrolizumab resolves adult ashy dermatosis developing in patients with squamous cell carcinoma of the lung. Peer-reviewed

    Takeda K, Fujimura T, Tsuchiyama K, Lyu C, Aiba S

    The Journal of dermatology　46　(3)　271-273　2019/03

    DOI： 10.1111/1346-8138.14775 　

    ISSN： 0385-2407

  85. Immune checkpoint inhibitor-induced vitiligo in advanced melanoma could be related to increased levels of CCL19 International-journal

    T. Fujimura, K. Tanita, Y. Sato, C. Lyu, Y. Kambayashi, Y. Fujisawa, H. Uchi, Y. Yamamoto, A. Otsuka, K. Yoshino, S. Matsushita, T. Funakoshi, S. Fukushima, H. Hata, A. Hashimoto, S. Aiba

    British Journal of Dermatology　182　(5)　1297-1300　2019

    DOI： 10.1111/bjd.18721 　

    ISSN： 0007-0963

    eISSN： 1365-2133

  86. 非侵襲熱物性計測による皮膚腫瘍の早期診断の可能性 Invited

    佐藤遥太, 藤村卓, 岡部孝裕, 圓山重直, 相場節也

    臨床皮膚科　73　(5)　69-73　2019

  87. Accumulation of exhausted CD8+ T cells in extramammary Paget's disease Peer-reviewed

    Natsuko Iga, Atsushi Otsuka, Yosuke Yamamoto, Chisa Nakashima, Tetsuya Honda, Akihiko Kitoh, Saeko Nakajima, Gyohei Egawa, Takashi Nomura, Teruki Dainichi, Shigeto Matsushita, Hideaki Tanizaki, Yuki Yamamoto, Takeru Funakoshi, Yasuhiro Fujisawa, Taku Fujimura, Hiroo Hata, Yoshihiro Ishida, Kenji Kabashima

    PLoS ONE　14　(1)　e0211135　2019/01

    DOI： 10.1371/journal.pone.0211135 　

    eISSN： 1932-6203

  88. Association of Baseline Serum Levels of CXCL5 With the Efficacy of Nivolumab in Advanced Melanoma. International-journal Peer-reviewed

    Fujimura T, Sato Y, Tanita K, Lyu C, Kambayashi Y, Amagai R, Otsuka A, Fujisawa Y, Yoshino K, Matsushita S, Uchi H, Yamamoto Y, Hata H, Funakoshi T, Nonomura Y, Tanaka R, Okuhira H, Wada N, Hashimoto A, Aiba S

    Frontiers in medicine　6　86-86　2019

    DOI： 10.3389/fmed.2019.00086 　

    More details Close

    Anti-programmed cell death protein 1 (PD1) antibodies are in wide use for the treatment of various cancers. PD1 antibody-based immunotherapy, co-administration of nivolumab and ipilimumab, is one of the optimal immunotherapies, especially in advanced melanoma with high tumor mutation burden. Since this combined therapy leads to a high frequency of serious immune-related adverse events (irAEs) in patients with advanced melanoma, biomarkers are needed to evaluate nivolumab efficacy to avoid serious irAEs caused by ipilimumab. This study analyzed baseline serum levels of CXCL5, CXCL10, and CCL22 in 46 cases of advanced cutaneous melanoma treated with nivolumab. Baseline serum levels of CXCL5 were significantly higher in responders than in non-responders. In contrast, there were no significant differences in baseline serum levels of CXCL10 and CCL22 between responders and non-responders. These results suggest that baseline serum levels of CXCL5 may be useful as a biomarker for identifying patients with advanced cutaneous melanoma most likely to benefit from anti-melanoma immunotherapy.

  89. Successful Treatment of Unresectable Advanced Melanoma by Administration of Nivolumab With Ipilimumab Before Primary Tumor Resection. Peer-reviewed

    Fujimura T, Kambayashi Y, Sato Y, Tanita K, Amagai R, Hashimoto A, Hidaka T, Aiba S

    Frontiers in medicine　6　140　2019

    DOI： 10.3389/fmed.2019.00140 　

  90. Biomarkers for Predicting Efficacies of Anti-PD1 Antibodies. Peer-reviewed

    Kambayashi Y, Fujimura T, Hidaka T, Aiba S

    Frontiers in medicine　6　174　2019

    DOI： 10.3389/fmed.2019.00174 　

  91. Aryl Hydrocarbon Receptor Modulates Carcinogenesis and Maintenance of Skin Cancers. Peer-reviewed

    Hidaka T, Fujimura T, Aiba S

    Frontiers in medicine　6　194　2019

    DOI： 10.3389/fmed.2019.00194 　

  92. Three patients with advanced cutaneous angiosarcoma treated with eribulin: investigation of serum soluble CD163 and chemokine (C-X-C motif) ligand 10 as possible biomarkers predicting the biological behaviour of angiosarcoma

    T. Fujimura, Y. Sato, Y. Kambayashi, K. Tanita, A. Tsukada, H. Terui, A. Hashimoto, S. Aiba

    British Journal of Dermatology　179　(6)　1392-1395　2018/12

    DOI： 10.1111/bjd.16676 　

    ISSN： 0007-0963

    eISSN： 1365-2133

  93. BRAF kinase inhibitors for treatment of melanoma: developments from early-stage animal studies to Phase II clinical trials. Peer-reviewed

    Fujimura T, Hidaka T, Kambayashi Y, Aiba S

    Expert opinion on investigational drugs　1-6　2018/12

    DOI： 10.1080/13543784.2019.1558442 　

    ISSN： 1354-3784

  94. Minocycline decreases Th2 chemokines from M2 macrophages: possible mechanisms for the suppression of bullous pemphigoid by traditional bullous disease drugs. Peer-reviewed

    Tanita K, Fujimura T, Sato Y, Lyu C, Aiba S

    Exp Dermatol　in press　(11)　1268-1272　2018/11

    DOI： 10.1111/exd.13779 　

    ISSN： 0906-6705

  95. Non-invasive measurement of effective thermal conductivity of human skin with a guard-heated thermistor probe Peer-reviewed

    Takahiro Okabe, Taku Fujimura, Junnosuke Okajima, Setsuya Aiba, Shigenao Maruyama

    International Journal of Heat and Mass Transfer　126　625-635　2018/11/01

    Publisher: Elsevier Ltd

    DOI： 10.1016/j.ijheatmasstransfer.2018.06.039 　

    ISSN： 0017-9310

  96. Eruptive keratoacanthoma with spontaneous regression arising from a cervical squamous cell carcinoma patient treated with nivolumab. Peer-reviewed

    Fujimura T, Lyu C, Tsukada A, Sato Y, Kambayashi Y, Aiba S

    The Journal of dermatology　2018/10

    DOI： 10.1111/1346-8138.14684 　

    ISSN： 0385-2407

  97. Killer immunoglobulin-like receptor genotype did not correlate with response to anti-PD-1 antibody treatment in a Japanese cohort. International-journal Peer-reviewed

    Ishida Y, Nakashima C, Kojima H, Tanaka H, Fujimura T, Matsushita S, Yamamoto Y, Yoshino K, Fujisawa Y, Otsuka A, Kabashima K

    Scientific reports　8　(1)　15962-15962　2018/10

    DOI： 10.1038/s41598-018-34044-z 　

    More details Close

    Immune checkpoint blockade (ICB) induces a remarkable response in patients with certain cancers. However, the response rate is not yet satisfactory. Biomarkers that help physicians identify patients who would benefit from ICB need to be developed. Killer immunoglobulin-like receptors (KIRs) are a class of receptors that are mainly expressed by natural killer cells. KIR genotypes have been shown to influence the outcomes of patients with neuroblastoma and hematopoietic malignancies. KIRs may thus influence the clinical outcomes of melanoma patients receiving nivolumab. We aimed to identify the KIR genotype, or KIR/KIR-ligand combinations, which influence the outcomes of melanoma patients receiving nivolumab. We genotyped 112 melanoma patients who were treated with nivolumab for KIR and human leukocyte antigen. The clinical records of the patients were analyzed to determine if they showed a response to nivolumab, and whether or not they experienced adverse events. Our analysis showed that no KIR gene was associated with a response to nivolumab. The KIR/KIR-ligand combination did not correlate with a response to nivolumab. KIR genes were not predictive of experiencing adverse events of grade 2 or greater. We conclude that the KIR genotype or KIR/KIR-ligand genotype do not show predictive value in melanoma patients receiving nivolumab.

  98. Breast Cancer Metastasis in the Skin with Hyperkeratotic Pigmentation Caused by Melanocyte Colonization. Peer-reviewed

    Ishihara-Yusa S, Fujimura T, Lyu C, Sugawara M, Sakamoto K, Aiba S

    Case reports in oncology　11　(3)　660-664　2018/09

    DOI： 10.1159/000493186 　

  99. Keratoacanthoma Centrifugum Marginatum with Spontaneous Regression and Its Possible Differential Diagnosis. Peer-reviewed

    Amagai R, Fujimura T, Kambayashi Y, Furudate S, Sato Y, Tanita K, Hashimoto A, Aiba S

    Case reports in oncology　11　(3)　671-675　2018/09

    DOI： 10.1159/000493089 　

    ISSN： 1662-6575

  100. Two cases of dabrafenib and trametinib therapy-failed advanced melanoma successfully controlled by nivolumab monotherapy. Peer-reviewed

    Sato Y, Fujimura T, Kambayashi Y, Tanita K, Tono H, Hashimoto A, Aiba S

    J Dermato　45　(9)　1105-1108　2018/09

  101. CD30-Positive Angioinvasive Lymphomatoid Papulosis (Type E) Developing from Parapsoriasis en Plaque. Peer-reviewed

    Fujimura T, Lyu C, Tsuchiyama K, Aiba S

    Case reports in oncology　11　(3)　850-854　2018/09

    DOI： 10.1159/000495689 　

  102. HLA-DRB1*04:05 in two cases of Vogt-Koyanagi-Harada disease-like uveitis developing from an advanced melanoma patient treated by sequential administration of nivolumab and dabrafenib/trametinib therapy. Peer-reviewed

    Fujimura T, Kambayashi Y, Tanita K, Sato Y, Hidaka T, Otsuka A, Tanaka H, Furudate S, Hashimoto A, Aiba S

    The Journal of dermatology　45　(6)　735-737　2018/06

    DOI： 10.1111/1346-8138.14273 　

    ISSN： 0385-2407

  103. Assessment of the methods used to detect HER2-positive advanced extramammary Paget’s disease Peer-reviewed

    Ikuko Hirai, Keiji Tanese, Yoshio Nakamura, Atsushi Otsuka, Yasuhiro Fujisawa, Yuki Yamamoto, Hiroo Hata, Taku Fujimura, Shigeto Matsushita, Koji Yoshino, Kaori Kameyama, Masayuki Amagai, Takeru Funakoshi

    Medical Oncology　35　(6)　92　2018/06/01

    Publisher: Humana Press Inc.

    DOI： 10.1007/s12032-018-1154-z 　

    ISSN： 1559-131X 1357-0560

  104. HLA-DRB1*04:05 in two cases of Vogt–Koyanagi–Harada disease-like uveitis developing from an advanced melanoma patient treated by sequential administration of nivolumab and dabrafenib/trametinib therapy Peer-reviewed

    Taku Fujimura, Yumi Kambayashi, Kayo Tanita, Yota Sato, Takanori Hidaka, Astushi Otsuka, Hidenori Tanaka, Sadanori Furudate, Akira Hashimoto, Setsuya Aiba

    Journal of Dermatology　45　(6)　735-737　2018/06/01

    Publisher: Blackwell Publishing Ltd

    DOI： 10.1111/1346-8138.14273 　

    ISSN： 1346-8138 0385-2407

  105. Widely Spread Unilateral Inflammatory Linear Verrucous Epidermal Nevus (ILVEN). Peer-reviewed

    Tanita K, Fujimura T, Sato Y, Lyu C, Aiba S

    Case reports in dermatology　10　(2)　170-175　2018/05

    DOI： 10.1159/000489876 　

  106. PD-L1-Expressing Radiation-Associated Angiosarcoma after Primary Breast Cancer. Peer-reviewed

    Takeda K, Fujimura T, Lyu C, Tsukada A, Tsuchiyama K, Hashimoto A, Aiba S

    Case reports in oncology　11　(2)　330-335　2018/05

    DOI： 10.1159/000489628 　

  107. Pigmented Epithelioid Melanocytoma (Animal Types of Melanoma) on the Nose. Peer-reviewed

    Ohuchi K, Fujimura T, Kambayashi Y, Tono H, Ohtake E, Hashimoto A, Aiba S

    Case reports in oncology　11　(2)　378-382　2018/05

    DOI： 10.1159/000490237 　

  108. Successful treatment of relapsed folliculotropic mycosis fungoides with mogamulizumab followed by intensity-modulated radiotherapy Peer-reviewed

    Taku Fujimura, Sadanori Furudate, Kayo Tanita, Yota Sato, Yumi Kambayashi, Takanori Hidaka, Setsuya Aiba

    Journal of Dermatology　45　(4)　e84-e85　2018/04/01

    Publisher: Blackwell Publishing Ltd

    DOI： 10.1111/1346-8138.14111 　

    ISSN： 1346-8138 0385-2407

  109. Cutaneous angiosarcoma: The possibility of new treatment options especially for patients with large primary tumor Peer-reviewed

    Yasuhiro Fujisawa, Koji Yoshino, Taku Fujimura, Yoshiyuki Nakamura, Naoko Okiyama, Yosuke Ishitsuka, Rei Watanabe, Manabu Fujimoto

    Frontiers in Oncology　8　46　2018/03/02

    Publisher: Frontiers Media S.A.

    DOI： 10.3389/fonc.2018.00046 　

    ISSN： 2234-943X

  110. Successful control of phototherapy-resistant lymphomatoid papulosis with oral bexarotene Peer-reviewed

    Taku Fujimura, Sadanori Furudate, Kayo Tanita, Yota Sato, Yumi Kambayashi, Takanori Hidaka, Setsuya Aiba

    Journal of Dermatology　45　(2)　e37-e38　2018/02/01

    Publisher: Blackwell Publishing Ltd

    DOI： 10.1111/1346-8138.14095 　

    ISSN： 1346-8138 0385-2407

  111. Severe erythema exudative multiforme developing from advanced melanoma treated with dabrafenib and trametinib followed by nivolumab Peer-reviewed

    Taku Fujimura, Yumi Kambayashi, Takanori Hidaka, Erika Tamabuchi, Eika Otake, Hisayuki Tono, Masato Mizuashi, Sadanori Furudate, Setsuya Aiba

    Journal of Dermatology　45　(2)　e35-e36　2018/02/01

    Publisher: Blackwell Publishing Ltd

    DOI： 10.1111/1346-8138.14085 　

    ISSN： 1346-8138 0385-2407

  112. PD-L1-expressing radiation-associated angiosarcoma after primary breast cancer. Peer-reviewed

    Takeda K, Fujimura T, Lyu C, Tsukada A, Tsuchiyama K, Hashimoto A, Aiba S

    Case Rep Oncol　11　(2)　330-335　2018/02

  113. Pigmented epithelioid melanocytoma (animal types of melanoma) on the nose. Peer-reviewed

    Ohuchi K, Fujimura T, Kambayashi Y, Tono H, Ohtake E, Hashimoto A, Aiba S

    Case Rep Oncol　11　(2)　378-382　2018/02

  114. Tumor-associated macrophages: Therapeutic targets for skin cancer Peer-reviewed

    Taku Fujimura, Yumi Kambayashi, Yasuhiro Fujisawa, Takanori Hidaka, Setsuya Aiba

    Frontiers in Oncology　8　3　2018/01/23

    Publisher: Frontiers Media S.A.

    DOI： 10.3389/fonc.2018.00003 　

    ISSN： 2234-943X

  115. Successful Treatment of Nivolumab-Resistant Multiple In-Transit Melanomas with Ipilimumab and Topical Imiquimod Peer-reviewed

    Taku Fujimura, Yumi Kambayashi, Yota Sato, Kayo Tanita, Sadanori Furudate, Akira Tsukada, Hisayuki Tono, Akira Hashimoto, Setsuya Aiba

    Case Reports in Oncology　11　(1)　1-5　2018/01/19

    Publisher: S. Karger AG

    DOI： 10.1159/000485612 　

    ISSN： 1662-6575

  116. Successful Treatment of Erythrodermic Mycosis Fungoides with Mogamulizumab Followed by Etoposide Monotherapy Peer-reviewed

    Taku Fujimura, Kayo Tanita, Yota Sato, Yumi Kambayashi, Sadanori Furudate, Akira Tsukada, Akira Hashimoto, Setsuya Aiba

    Case Reports in Oncology　11　(1)　29-32　2018/01/19

    Publisher: S. Karger AG

    DOI： 10.1159/000486278 　

    ISSN： 1662-6575

  117. Intensity-Modulated Radiotherapy Triggers Onset of Bullous Pemphigoid in a Patient with Advanced Melanoma Treated with Nivolumab Peer-reviewed

    Kayo Tanita, Taku Fujimura, Yumi Kambayashi, Akira Tsukada, Yota Sato, Akira Hashimoto, Setsuya Aiba

    Case Reports in Oncology　11　(1)　114-118　2018/01/19

    Publisher: S. Karger AG

    DOI： 10.1159/000487127 　

    ISSN： 1662-6575

  118. Successful Treatment of Advanced Primary Cutaneous Peripheral T-Cell Lymphoma with Oral Bexarotene Monotherapy Peer-reviewed

    Yota Sato, Taku Fujimura, Yumi Kambayashi, Akira Hashimoto, Setsuya Aiba

    Case Reports in Oncology　11　(1)　212-215　2018/01/19

    Publisher: S. Karger AG

    DOI： 10.1159/000488236 　

    ISSN： 1662-6575

  119. Increased serum production of soluble CD163 and CXCL5 in patients with moyamoya disease: Involvement of intrinsic immune reaction in its pathogenesis. International-journal Peer-reviewed

    Miki Fujimura, Taku Fujimura, Aya Kakizaki, Mika Sato-Maeda, Kuniyasu Niizuma, Yasutake Tomata, Setsuya Aiba, Teiji Tominaga

    Brain research　1679　39-44　2018/01/15

    DOI： 10.1016/j.brainres.2017.11.013 　

    ISSN： 0006-8993

    More details Close

    Moyamoya disease (MMD) is a rare cerebrovascular disease characterized by a progressive stenosis at the terminal portion of the internal carotid artery and an abnormal vascular network at the base of the brain. Although its etiology is still unknown, intrinsic immune reactions such as autoimmune response has been implicated in the pathogenesis of MMD. Recently, the RING finger protein 213 (RNF213) was found to be an important risk gene for MMD, and is predominantly expressed in blood cells and the spleen. Thus, we hypothesized that patients with MMD represent an intrinsic autoimmune status mediated by M2-polarized macrophages, which play an important role in tissue remodeling and angiogenesis. We compared the serum level of soluble (s)CD163, an activating marker for CD163+ M2-polarized macrophages that has been implicated in a variety of autoimmune disorders, between MMD patients and healthy controls. We also analyzed serum levels of CXCL5, an augmented cytokines that has been correlated with the severity of autoimmune diseases. As a result, the serum sCD163 levels of MMD patients (281,465 pg/ml) were significantly higher than those of healthy controls (174,842 pg/ml) (p = .004). The serum CXCL5 levels of MMD patients (679.02 pg/ml) were significantly higher than those of healthy controls (401.79 pg/ml) (p = .046). There were no differences in the serum sCD163 and CXCL5 levels between each genotype of the RNF213 polymorphism (wild-type or variant) among MMD patients. Although this is a pilot study and further validation with larger number of samples is necessary, our results indicate that patients with MMD may have increased autoimmune activity, and our results shed light on the pathogenesis of MMD via CD163+ M2-polarized macrophages.

  120. Cytotoxic antimelanoma drugs suppress the activation of M2 macrophages Peer-reviewed

    Taku Fujimura, Aya Kakizaki, Yumi Kambayashi, Yota Sato, Kayo Tanita, Chunbing Lyu, Sadanori Furudate, Setsuya Aiba

    Experimental Dermatology　27　(1)　64-70　2018/01/01

    Publisher: Blackwell Publishing Ltd

    DOI： 10.1111/exd.13417 　

    ISSN： 1600-0625 0906-6705

  121. Retrospective study of advanced melanoma patients treated with ipilimumab after nivolumab: Analysis of 60 Japanese patients. International-journal Peer-reviewed

    Fujisawa Y, Yoshino K, Otsuka A, Funakoshi T, Uchi H, Fujimura T, Matsushita S, Hata H, Okuhira H, Tanaka R, Nagai K, Ishida Y, Nakamura Y, Furudate S, Yamamura K, Imafuku K, Yamamoto Y

    Journal of dermatological science　89　(1)　60-66　2018/01

    DOI： 10.1016/j.jdermsci.2017.10.009 　

    ISSN： 0923-1811

    More details Close

    BACKGROUND: Due to resistance and immune-related adverse events (irAE) some melanoma patients require ipilimumab after nivolumab therapy. However, little is known about the result of this switching. OBJECTIVE: Investigate the outcome of ipilimumab switching in Japanese patients. METHODS: We retrospectively collected 60 patients who were treated with ipilimumab after nivolumab from 9 institutes in Japan. Information of the primary tumor, treatment, response, irAE), and survival was collected. RESULTS: In our cohort, acral lentiginous and mucosal melanoma accounted for 53% of the cases. The most common reason for initiating ipilimumab was disease progression (93%). Median interval from the last nivolumab administration to first ipilimumab administration was 29days. Only 38% of patients completed 4 injections of ipilimumab. The best overall response was 3.6%. IrAE occurred in 78% of patients and 70% of those were of grade 3/4 (G3/4) and 31% of patients experienced 2 or more irAEs. An within interval of 28days or less between the last nivolumab administration and ipilimumab administration was correlated with the development of G3/4 pyrexia and 3 or more irAEs, but irAE occurrence did not affect survival. Multivariate analysis showed that endocrine irAE (relative risk=0.22, P=0.015) and skin irAE (relative risk=2.78, P=0.048) were significant factors associated with survival. CONCLUSION: In our study, the response ratio to ipilimumab after nivolumab was unsatisfactory and associated with a high frequency of severe irAEs. As there are few second-line treatment options for patients with BRAF wild-type advanced melanoma after nivolumab failure, patients should be closely monitored if ipilimumab is initiated.

  122. The expression of matrix metalloproteinases in receptor activator of nuclear factor kappa-B ligand (RANKL)-expressing cancer of apocrine origin Peer-reviewed

    Yumi Kambayashi, Taku Fujimura, Sadanori Furudate, Chunbing Lyu, Takanori Hidaka, Aya Kakizaki, Yota Sato, Kayo Tanita, Setsuya Aiba

    Anticancer Research　38　(1)　113-120　2018/01/01

    Publisher: International Institute of Anticancer Research

    DOI： 10.21873/anticanres.12198 　

    ISSN： 1791-7530 0250-7005

  123. Serum levels of soluble CD163 and CXCL5 may be predictive markers for immune-related adverse events in patients with advanced melanoma treated with nivolumab: A pilot study Peer-reviewed

    Taku Fujimura, Yota Sato, Kayo Tanita, Yumi Kambayashi, Atsushi Otsuka, Yasuhiro Fujisawa, Koji Yoshino, Shigeto Matsushita, Takeru Funakoshi, Hiroo Hata, Yuki Yamamoto, Hiroshi Uchi, Yumi Nonomura, Ryota Tanaka, Megumi Aoki, Keisuke Imafuku, Hisako Okuhira, Sadanori Furudate, Takanori Hidaka, Setsuya Aiba

    Oncotarget　9　(21)　15542-15551　2018

    Publisher: Impact Journals LLC

    DOI： 10.18632/oncotarget.24509 　

    ISSN： 1949-2553

  124. Serum Level of Soluble CD163 May Be a Predictive Marker of the Effectiveness of Nivolumab in Patients With Advanced Cutaneous Melanoma. International-journal Peer-reviewed

    Fujimura T, Sato Y, Tanita K, Kambayashi Y, Otsuka A, Fujisawa Y, Yoshino K, Matsushita S, Funakoshi T, Hata H, Yamamoto Y, Uchi H, Nonomura Y, Tanaka R, Aoki M, Imafuku K, Okuhira H, Wada N, Irie H, Hidaka T, Hashimoto A, Aiba S

    Frontiers in oncology　8　530-530　2018

    DOI： 10.3389/fonc.2018.00530 　

    More details Close

    Antibodies against programmed cell death protein 1, such as nivolumab and pembrolizumab, are widely used for treating various cancers, including advanced melanoma. Nivolumab significantly prolongs survival in patients with metastatic melanoma, and sequential administration with lipilimumab may improve outcomes when switched at the appropriate time. Biomarkers are therefore needed to evaluate nivolumab efficacy soon after first administration. This study analyzed serum levels of soluble cluster of differentiation 163 (sCD163) in 59 cases of advanced cutaneous melanoma and 16 cases of advanced mucosal melanoma treated using nivolumab. Serum levels of sCD163 were significantly increased after 6 weeks in responders compared to non-responders after initial administration of nivolumab for cutaneous melanoma. In contrast, no significant difference between responders and non-responders was seen among patients with non-cutaneous melanoma. These results suggest that sCD163 may be useful as a biomarker for selecting patients with advanced cutaneous melanoma most likely to benefit from anti-melanoma immunotherapy.

  125. Baseline neutrophil to lymphocyte ratio and serum LDH level associated with outcome of nivolumab immunotherapy in Japanese advanced melanoma population. Peer-reviewed

    Fujisawa Y, Yoshino K, Otsuka A, Funakoshi T, Fujimura T, Yamamoto Y, Hata H, Tanaka R, Yamaguchi K, Nonomura Y, Hirai I, Furudate S, Okuhira H, Imafuku K, Aoki M, Matsushita S

    Brit J Dermatol　179　(1)　213-215　2018/01

  126. Serum levels of soluble CD163 and CXCL5 may be predictive markers for immune-related adverse events in patients with advanced melanoma treated with nivolumab: A pilot study Peer-reviewed

    Taku Fujimura, Yota Sato, Kayo Tanita, Yumi Kambayashi, Atsushi Otsuka, Yasuhiro Fujisawa, Koji Yoshino, Shigeto Matsushita, Takeru Funakoshi, Hiroo Hata, Yuki Yamamoto, Hiroshi Uchi, Yumi Nonomura, Ryota Tanaka, Megumi Aoki, Keisuke Imafuku, Hisako Okuhira, Sadanori Furudate, Takanori Hidaka, Setsuya Aiba

    Oncotarget　9　(21)　15542-15551　2018

    Publisher: Impact Journals LLC

    DOI： 10.18632/oncotarget.24509 　

    ISSN： 1949-2553

  127. Assessment of the methods detecting HER2-positive advanced extramammary Paget’s disease. International-journal Peer-reviewed

    Hiraii I, Tanese K, Nakamura Y, Otsuka A, Fujisawa, Yamamoto Y, Hata H, Fujimura T, Matsushita S, Yoshino K, Kameyama K, Amagai M, Funakoshi T

    Medical Oncology　35　(6)　92-92　2018

    DOI： 10.1007/s12032-018-1154-z 　

    More details Close

    The human epidermal growth factor receptor 2 (HER2) is recognized as an oncogene as well as a therapeutic target in various cancers. Certain patients with advanced extramammary Paget's disease (EMPD) have also been reported to express HER2, which is therefore considered a therapeutic target for EMPD. However, an accurate methodology to determine HER2-positive EMPD has not been established. To assess the optimal methods for detection of HER2-positive EMPD, 73 EMPD samples were analyzed by immunohistochemical (IHC) staining, fluorescence in situ hybridization (FISH), and the HER2 testing algorithm for breast cancer of the American Society of Clinical Oncology/College of American Pathologists, which combined the results of IHC staining and FISH. The results showed discordance in the rate of positive IHC staining and FISH results. While 68.6% (24/35) of the metastatic samples showed equivocal or positive IHC staining, only 37.1% (13/35) were positive by FISH. To assess the accuracy of these methods, the degree of HER2 expression detected by each method was correlated with the staining profiles of activated downstream signaling pathways involving phosphorylated p44/42 MAPK (Thr202/Tyr204) (p-ERK1/2) and phosphorylated AKT (Ser473) (p-AKT). Among 16 lymph node metastasis samples, all HER2-positive samples as determined by the testing algorithm stained positively for both p-ERK1/2 and p-AKT. On the other hand, 10-14.3% of the samples determined by FISH or IHC showed negative staining for p-ERK1/2 and p-AKT. The results showed that combining the results of IHC and FISH according to the HER2 testing algorithm is a useful method for accurately evaluating HER2-positive EMPD.

  128. A possible interaction between periostin and CD163+ skin-resident macrophages in pemphigus vulgaris and bullous pemphigoid Peer-reviewed

    Taku Fujimura, Aya Kakizaki, Sadanori Furudate, Setsuya Aiba

    Experimental Dermatology　26　(12)　1193-1198　2017/12/01

    Publisher: Blackwell Publishing Ltd

    DOI： 10.1111/exd.13157 　

    ISSN： 1600-0625 0906-6705

  129. Fluctuations in routine blood count might signal severe immune-related adverse events in melanoma patients treated with nivolumab Peer-reviewed

    Yasuhiro Fujisawa, Koji Yoshino, Atsushi Otsuka, Takeru Funakoshi, Taku Fujimura, Yuki Yamamoto, Hiroo Hata, Masahiko Gosho, Ryota Tanaka, Kei Yamaguchi, Yumi Nonomura, Ikuko Hirai, Sadanori Furudate, Hisako Okuhira, Keisuke Imafuku, Megumi Aoki, Shigeto Matsushita

    JOURNAL OF DERMATOLOGICAL SCIENCE　88　(2)　225-231　2017/11

    DOI： 10.1016/j.jdermsci.2017.07.007 　

    ISSN： 0923-1811

    eISSN： 1873-569X

  130. Keratoacanthoma, palmoplantar keratoderma developing in an advanced melanoma patient treated with vemurafenib regressed by blockade of mitogen-activated protein kinase kinase signaling Peer-reviewed

    Sadanori Furudate, Taku Fujimura, Yumi Kambayashi, Takanori Hidaka, Yota Sato, Kayo Tanita, Akira Hashimoto, Setsuya Aiba

    JOURNAL OF DERMATOLOGY　44　(9)　e226-e227　2017/09

    DOI： 10.1111/1346-8138.13898 　

    ISSN： 0385-2407

    eISSN： 1346-8138

  131. Phase I study of nivolumab combined with IFN-beta for patients with advanced melanoma Peer-reviewed

    Taku Fujimura, Takanori Hidaka, Yumi Kambayashi, Sadanori Furudate, Aya Kakizaki, Hisayuki Tono, Akira Tsukada, Takahiro Haga, Akira Hashimoto, Ryo Morimoto, Takuhiro Yamaguchi, Tadao Takano, Setsuya Aiba

    ONCOTARGET　8　(41)　71181-71187　2017/09

    DOI： 10.18632/oncotarget.17090 　

    ISSN： 1949-2553

    eISSN： 1949-2553

  132. Immunomodulatory Effect of Imiquimod Through CCL22 Produced by Tumor-associated Macrophages in B16F10 Melanomas Peer-reviewed

    Sadanori Furudate, Taku Fujimura, Yumi Kambayashi, Aya Kakizaki, Takanori Hidaka, Setsuya Aiba

    ANTICANCER RESEARCH　37　(7)　3461-3471　2017/07

    DOI： 10.21873/anticanres.11714 　

    ISSN： 0250-7005

    eISSN： 1791-7530

  133. The Immunological Roles of Periostin/Tumor-Associated Macrophage Axis in Development of Dermatofibrosarcoma Protuberans Peer-reviewed

    Taku Fujimura, Aya Kakizaki, Yota Sato, Kayo Tanita, Sadanori Furudate, Setsuya Aiba

    ANTICANCER RESEARCH　37　(6)　2867-2873　2017/06

    DOI： 10.21873/anticanres.11639 　

    ISSN： 0250-7005

    eISSN： 1791-7530

  134. Successful treatment of multiple in-transit melanomas on the leg with intensity-modulated radiotherapy and immune checkpoint inhibitors: Report of two cases Peer-reviewed

    Taku Fujimura, Yumi Kambayashi, Sadanori Furudate, Takanori Hidaka, Yota Sato, Kayo Tanita, Hisayuki Tono, Akira Tsukada, Akira Hashimoto, Setsuya Aiba

    JOURNAL OF DERMATOLOGY　44　(5)　592-595　2017/05

    DOI： 10.1111/1346-8138.13707 　

    ISSN： 0385-2407

    eISSN： 1346-8138

  135. Phospho-STAT5B Expression Is a Prognostic Marker for Merkel Cell Carcinoma Peer-reviewed

    Taku Fujimura, Sadanori Furudate, Yumi Kambayahsi, Aya Kakizaki, Yuki Yamamoto, Hisako Okuhira, Noriki Fujimoto, Setsuya Aiba

    ANTICANCER RESEARCH　37　(5)　2335-2341　2017/05

    DOI： 10.21873/anticanres.11571 　

    ISSN： 0250-7005

    eISSN： 1791-7530

  136. Retrospective Investigation of Cutaneous Squamous Cell Carcinoma on the Lip Treated with Peplomycin Administered Through a Superficial Temporal Artery Peer-reviewed

    Taku Fujimura, Kazuhiro Takahashi, Yumi Kambayashi, Sadanori Furudate, Takanori Hidaka, Aya Kakizaki, Akiko Watabe, Takahiro Haga, Akira Hashimoto, Setsuya Aiba

    ANTICANCER RESEARCH　37　(4)　1885-1889　2017/04

    DOI： 10.21873/anticanres.11526 　

    ISSN： 0250-7005

    eISSN： 1791-7530

  137. Isolated adrenocorticotropic hormone deficiency possibly caused by nivolumab in a metastatic melanoma patient Peer-reviewed

    Taku Fujimura, Yumi Kambayashi, Sadanori Furudate, Aya Kakizaki, Takanori Hidaka, Takahiro Haga, Akira Hashimoto, Ryo Morimoto, Setsuya Aiba

    JOURNAL OF DERMATOLOGY　44　(3)　E13-E14　2017/03

    DOI： 10.1111/1346-8138.13532 　

    ISSN： 0385-2407

    eISSN： 1346-8138

  138. Possible mechanisms of the crosstalk between Langerhans cells and regulatory T cells in extramammary Paget disease by receptor activator of nuclear factor kappa B (RANK) ligand/RANK pathways Peer-reviewed

    T. Fujimura, Y. Kambayashi, S. Furudate, A. Kakizaki, T. Hidaka, S. Aiba

    British Journal of Dermatology　176　(2)　387-394　2017/02/01

    Publisher: Blackwell Publishing Ltd

    DOI： 10.1111/bjd.14864 　

    ISSN： 1365-2133 0007-0963

  139. Successful Treatment of Advanced Primary Cutaneous Apocrine Carcinoma on the Scrotum with Systemic Chemotherapy and Radiotherapy Followed by Denosumab Peer-reviewed

    Sadanori Furudate, Taku Fujimura, Akira Tsukada, Yota Sato, Takanori Hidaka, Kayo Tanita, Yumi Kambayashi, Takahiro Haga, Akira Hashimoto, Setsuya Aiba

    Case Reports in Oncology　10　(1)　52-56　2017/01/06

    Publisher: S. Karger AG

    DOI： 10.1159/000455091 　

    ISSN： 1662-6575

  140. Recurrent Multiple Squamous Cell Carcinomas on the Scalp in a Patient with Juvenile Dermatomyositis Peer-reviewed

    Yota Sato, Taku Fujimura, Yumi Kambayashi, Akira Tsukada, Takanori Hidaka, Kayo Tanita, Takahiro Haga, Akira Hashimoto, Setsuya Aiba

    Case Reports in Oncology　10　(1)　106-111　2017/01/06

    Publisher: S. Karger AG

    DOI： 10.1159/000456001 　

    ISSN： 1662-6575

  141. Successful Treatment of Primary Cutaneous Peripheral T-Cell Lymphoma Presenting Acquired Ichthyosis with Oral Bexarotene Monotherapy Peer-reviewed

    Kayo Tanita, Taku Fujimura, Yota Sato, Takanori Hidaka, Sadanori Furudate, Yumi Kambayashi, Akira Tsukada, Akira Hashimoto, Setsuya Aiba

    Case Reports in Oncology　10　(1)　328-332　2017/01/06

    Publisher: S. Karger AG

    DOI： 10.1159/000468981 　

    ISSN： 1662-6575

  142. Sarcoidosis-Lymphoma Syndrome Associated with Folliculotropic Peripheral T Cell Lymphoma Not Otherwise Specified Peer-reviewed

    Saaya Yoshida, Taku Fujimura, Yumi Kambayashi, Sadanori Furudate, Masato Mizuashi, Setsuya Aiba

    Case Reports in Oncology　10　(1)　372-376　2017/01/06

    Publisher: S. Karger AG

    DOI： 10.1159/000472249 　

    ISSN： 1662-6575

  143. AhR links atopic dermatitis and air pollution via Artemin induction

    Hidaka T, Ogawa E, Kobayashi EH, Suzuki T, Funayama R, Nagashima T, Fujimura T, Aiba S, Nakayama K, Okuyama R, Yamamoto M

    Nat Immunol　18　64-73　2017

  144. Infiltration of PD-1-positive cells in combination with tumor site PD-L1 expression is a positive prognostic factor in cutaneous angiosarcoma. International-journal Peer-reviewed

    Yuki Honda, Atsushi Otsuka, Sachiko Ono, Yosuke Yamamoto, Judith A Seidel, Satoshi Morita, Masahiro Hirata, Tatsuki R Kataoka, Tatsuya Takenouchi, Kazuyasu Fujii, Takuro Kanekura, Yuko Okubo, Kenzo Takahashi, Teruki Yanagi, Daichi Hoshina, Hiroo Hata, Riichiro Abe, Taku Fujimura, Takeru Funakoshi, Koji Yoshino, Mamiko Masuzawa, Yasuyuki Amoh, Ryota Tanaka, Yasuhiro Fujisawa, Tetsuya Honda, Kenji Kabashima

    Oncoimmunology　6　(1)　e1253657　2017

    DOI： 10.1080/2162402X.2016.1253657 　

    ISSN： 2162-4011

    More details Close

    Cutaneous angiosarcoma (CAS) is a malignant sarcoma with poor prognosis. Programmed cell death-1 (PD-1)/programmed cell death-1 ligand-1 (PD-L1) expression reflects antitumor immunity, and is associated with patient prognosis in various cancers. The purpose of this study is to investigate the relationship between PD-1/PD-L1 expression and CAS prognosis. CAS cases (n = 106) were immunohistochemically studied for PD-L1 and PD-1 expression, and the correlation with patient prognosis was analyzed. PD-L1 expression was assessed by flow cytometry on three CAS cell lines with or without IFNγ stimulation. A total of 30.2% of patients' samples were positive for PD-L1, and 17.9% showed a high infiltration of PD-1-positive cells. Univariate analysis showed a significant relationship between a high infiltration of PD-1-positive cells with tumor site PD-L1 expression and favorable survival in stage 1 patients (p = 0.014, log-rank test). Multivariable Cox-proportional hazard regression analysis also showed that patients with a high infiltration of PD-1-positive cells with tumor site PD-L1 expression were more likely to have favorable survival, after adjustment with possible confounders (hazard ratio (HR) = 0.38, p = 0.021, 95% confidence interval (CI) 0.16-0.86). Immunofluorescence staining of CAS samples revealed that PD-L1-positive cells were adjacent to PD-1-positive cells and/or tumor stroma with high IFNγ expression. In vitro stimulation with IFNγ increased PD-L1 expression in two out of three established CAS cell lines. Our results suggest that PD-1/PD-L1 expression is related to CAS progression, and the treatment with anti-PD-1 antibodies could be a new therapeutic option for CAS.

  145. The aryl hydrocarbon receptor AhR links atopic dermatitis and air pollution via induction of the neurotrophic factor artemin Peer-reviewed

    Takanori Hidaka, Eisaku Ogawa, Eri H. Kobayashi, Takafumi Suzuki, Ryo Funayama, Takeshi Nagashima, Taku Fujimura, Setsuya Aiba, Keiko Nakayama, Ryuhei Okuyama, Masayuki Yamamoto

    NATURE IMMUNOLOGY　18　(1)　64-73　2017/01

    DOI： 10.1038/ni.3614 　

    ISSN： 1529-2908

    eISSN： 1529-2916

  146. Peripheral blood Th9 cells are a possible pharmacodynamic biomarker of nivolumab treatment efficacy in metastatic melanoma patients Peer-reviewed

    Yumi Nonomura, Atsushi Otsuka, Chisa Nakashima, Judith A. Seidel, Akihiko Kitoh, Teruki Dainichi, Saeko Nakajima, Yu Sawada, Shigeto Matsushita, Megumi Aoki, Tatsuya Takenouchi, Taku Fujimura, Naohito Hatta, Satoshi Koreeda, Satoshi Fukushima, Tetsuya Honda, Kenji Kabashima

    OncoImmunology　5　(12)　e1248327　2016/12/01

    DOI： 10.1080/2162402X.2016.1248327 　

    ISSN： 2162-4011

    eISSN： 2162-402X

  147. Investigation of Effect of Skin Structure and Temperature Distribution in Body on Non-invasive Measurement of Effective Thermal Conductivity of Human Skin Peer-reviewed

    Takahiro Okabe, Junnosuke Okajima, Taku Fujimura, Atsuki Komiya, Setsuya Aiba, Shigenao Maruyama

    Proceedings of the Fourth International Forum on Heat Transfer　2016/11

  148. Effect of Thermal Penetration Depth on Diagnosis of Skin Cancer by Thermophysical Property Measurement,

    Takahiro Okabe, Junnosuke Okajima, Taku Fujimura, Atsuki Komiya, Setsuya Aiba, Shigenao Maruyama

    Proceedings of 13th International Conference on Flow Dynamics　2016/10/11

  149. Intralymphatic histiocytosis comprises M2 macrophages in superficial dermal lymphatics with or without smooth muscles Peer-reviewed

    Noriki Fujimoto, Gen Nakanishi, Toshiaki Manabe, Taku Fujimura, Toshihiro Tanaka

    JOURNAL OF CUTANEOUS PATHOLOGY　43　(10)　898-902　2016/10

    DOI： 10.1111/cup.12754 　

    ISSN： 0303-6987

    eISSN： 1600-0560

  150. Estrogen receptor beta in Merkel cell carcinoma: its possible roles in pathogenesis Peer-reviewed

    Abdullah Azmahani, Yasuhiro Nakamura, Hirotaka Ishida, Keel M. McNamara, Taku Fujimura, Takahiro Haga, Akira Hashimoto, Setsuya Aiba, Hironobu Sasano

    HUMAN PATHOLOGY　56　128-133　2016/10

    DOI： 10.1016/j.humpath.2016.06.005 　

    ISSN： 0046-8177

    eISSN： 1532-8392

  151. Sequential therapy with nivolumab followed by ipilimumab induces complete response in metastatic melanoma of the lung but with severe hepatotoxicities Peer-reviewed

    Sadanori Furudate, Taku Fujimura, Yumi Kambayashi, Takanori Hidaka, Akira Hashimoto, Setsuya Aiba

    Case Reports in Oncology　9　(3)　644-649　2016/09/13

    Publisher: S. Karger AG

    DOI： 10.1159/000450974 　

    ISSN： 1662-6575

  152. Multiple metastasized extramammary Paget's disease cured with bisphosphonate risedronate sodium after CyberKnife radiosurgery and docetaxel chemotherapy Peer-reviewed

    Taku Fujimura, Sadanori Furudate, Yumi Kambayashi, Aya Kakizaki, Takahiro Haga, Akira Hashimoto, Setsuya Aiba

    DERMATOLOGICA SINICA　34　(3)　155-157　2016/09

    DOI： 10.1016/j.dsi.2016.02.001 　

    ISSN： 1027-8117

    eISSN： 2223-330X

  153. Tumor-associated macrophages in skin: How to treat their heterogeneity and plasticity Peer-reviewed

    Taku Fujimura, Aya Kakizaki, Sadanori Furudate, Yumi Kambayashi, Setsuya Aiba

    JOURNAL OF DERMATOLOGICAL SCIENCE　83　(3)　167-173　2016/09

    DOI： 10.1016/j.jdermsci.2016.05.015 　

    ISSN： 0923-1811

    eISSN： 1873-569X

  154. RANKL expression is a useful marker for differentiation of pagetoid squamous cell carcinoma in situ from extramammary Paget disease Peer-reviewed

    Taku Fujimura, Yumi Kambayashi, Aya Kakizaki, Sadanori Furudate, Setsuya Aiba

    JOURNAL OF CUTANEOUS PATHOLOGY　43　(9)　772-775　2016/09

    DOI： 10.1111/cup.12743 　

    ISSN： 0303-6987

    eISSN： 1600-0560

  155. Epidermotropic diffuse large B-cell lymphoma infiltrating the umbilicus, presenting as Sister Mary Joseph's nodule Peer-reviewed

    S. Furudate, T. Fujimura, M. Ishibashi, S. Aiba

    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY　30　(9)　1622-1624　2016/09

    DOI： 10.1111/jdv.13217 　

    ISSN： 0926-9959

    eISSN： 1468-3083

  156. Tumor-associated M2 macrophages in mycosis fungoides acquire immunomodulatory function by interferon alpha and interferon gamma Peer-reviewed

    Sadanori Furudate, Taku Fujimura, Aya Kakizaki, Takanori Hidaka, Masayuki Asano, Setsuya Aiba

    JOURNAL OF DERMATOLOGICAL SCIENCE　83　(3)　182-189　2016/09

    DOI： 10.1016/j.jdermsci.2016.05.004 　

    ISSN： 0923-1811

    eISSN： 1873-569X

  157. Temporal profile of magnetic resonance angiography and decreased ratio of regulatory T cells after immunological adjuvant administration to mice lacking RNF213, a susceptibility gene for moyamoya disease. Peer-reviewed

    Kanoke A, Fujimura M, Niizuma K, Fujimura T, Kakizaki A, Ito A, Sakata H, Sato-Maeda M, Kure S, Tominaga T

    Brain research　1642　1-9　2016/07

    DOI： 10.1016/j.brainres.2016.03.009 　

    ISSN： 0006-8993

  158. Hypopigmented mycosis fungoides: An immunological investigation of tumor-infiltrating T cells Peer-reviewed

    Mei Nasu-Tababuchi, Taku Fujimura, Aya Kakizaki, Kosuke Shido, Naokazu Hatchome, Yoshiyuki Kusakari, Setsuya Aiba

    DERMATOLOGICA SINICA　34　(2)　96-98　2016/06

    DOI： 10.1016/j.dsi.2015.08.006 　

    ISSN： 1027-8117

    eISSN： 2223-330X

  159. Contact immunotherapy enhances the therapeutic effects of nivolumab in treating in-transit melanoma: Two cases reports Peer-reviewed

    Taku Fujimura, Sadanori Furudate, Aya Kakizaki, Yumi Kambayashi, Takahiro Haga, Akira Hashimoto, Setsuya Aiba

    JOURNAL OF DERMATOLOGY　43　(6)　686-689　2016/06

    DOI： 10.1111/1346-8138.13229 　

    ISSN： 0385-2407

    eISSN： 1346-8138

  160. Receptor activator of nuclear factor kappa-B ligand (RANKL)/RANK signaling promotes cancer-related inflammation through M2 macrophages Peer-reviewed

    Taku Fujimura, Yumi Kambayashi, Sadanori Furudate, Aya Kakizaki, Takanori Hidaka, Masayuki Asano, Setsuya Aiba

    EXPERIMENTAL DERMATOLOGY　25　(5)　397-399　2016/05

    DOI： 10.1111/exd.12949 　

    ISSN： 0906-6705

    eISSN： 1600-0625

  161. The possible interaction between periostin expressed by cancer stroma and tumor-associated macrophages in developing mycosis fungoides Peer-reviewed

    Sadanori Furudate, Taku Fujimura, Aya Kakizaki, Yumi Kambayashi, Masayuki Asano, Akiko Watabe, Setsuya Aiba

    EXPERIMENTAL DERMATOLOGY　25　(2)　107-112　2016/02

    DOI： 10.1111/exd.12873 　

    ISSN： 0906-6705

    eISSN： 1600-0625

  162. Myeloid Derived Suppressor Cells Peer-reviewed

    Taku Fujimura, Alexander H. Enk

    Immunology of the Skin: Basic and Clinical Sciences in Skin Immune Responses　179-192　2016/01/01

    Publisher: Springer Japan

    DOI： 10.1007/978-4-431-55855-2_11 　

  163. Peripheral blood Th9 cells are a possible pharmacodynamic biomarker of nivolumab treatment efficacy in metastatic melanoma patients Peer-reviewed

    Yumi Nonomura, Atsushi Otsuka, Chisa Nakashima, Judith A. Seidel, Akihiko Kitoh, Teruki Dainichi, Saeko Nakajima, Yu Sawada, Shigeto Matsushita, Megumi Aoki, Tatsuya Takenouchi, Taku Fujimura, Naohito Hatta, Satoshi Koreeda, Satoshi Fukushima, Tetsuya Honda, Kenji Kabashima

    ONCOIMMUNOLOGY　5　(12)　2016

    DOI： 10.1080/2162402X.2016.1248327 　

    ISSN： 2162-402X

  164. Plexiform Fibrohistiocytic Tumor on the Ear: Case Report and Immunohistochemical Investigation of Stromal Factor. Peer-reviewed

    Shido K, Fujimura T, Kakizaki A, Furudate S, Asano M, Aiba S

    Case reports in dermatology　8　(1)　26-30　2016/01

    DOI： 10.1159/000444045 　

    ISSN： 1662-6567

  165. Periostin in the Cancer Stroma of Mycosis Fungoides Palmaris et Plantaris: A Case Report and Immunohistochemical Study. Peer-reviewed

    Tanita K, Fujimura T, Kakizaki A, Furudate S, Mizuashi M, Watabe A, Aiba S

    Case reports in dermatology　8　(1)　31-35　2016/01

    DOI： 10.1159/000444162 　

    ISSN： 1662-6567

  166. Merkel Cell Carcinoma with Spontaneous Regression: A Case Report and Immunohistochemical Study. Peer-reviewed

    Terui H, Fujimura T, Kakizaki A, Furudate S, Aiba S

    Case reports in dermatology　8　(1)　52-58　2016/01

    DOI： 10.1159/000444317 　

    ISSN： 1662-6567

  167. Response to the comment by Kan Wu Peer-reviewed

    Taku Fujimura

    Acta Dermato-Venereologica　96　(4)　573　2016

    Publisher: Medical Journals/Acta D-V

    DOI： 10.2340/00015555-2327 　

    ISSN： 1651-2057 0001-5555

  168. M2-Polarized Macrophages Compose Lupus Vulgaris Arising from a Bacillus Calmette-Guérin Vaccination Site Peer-reviewed

    Yota Sato, Taku Fujimura, Sadanori Furudate, Aya Kakizaki, Osamu Iizawa, Setsuya Aiba

    Case Reports in Dermatology　8　(2)　202-206　2016

    Publisher: S. Karger AG

    DOI： 10.1159/000447709 　

    ISSN： 1662-6567

  169. RANKL-Expressing Ectopic Extramammary Paget's Disease on the Lower Abdomen Peer-reviewed

    Akiko Hagiwara-Takita, Taku Fujimura, Aya Kakizaki, Setsuya Aiba

    Case Reports in Dermatology　8　(2)　130-135　2016

    Publisher: S. Karger AG

    DOI： 10.1159/000445992 　

    ISSN： 1662-6567

  170. Multifocal BRAFV600E-Mutated Melanoma in situ on the Foot Peer-reviewed

    Eimei Iwama, Taku Fujimura, Yoshiyuki Kusakari, Takahiro Haga, Setsuya Aiba

    Case Reports in Dermatology　7　(3)　322-327　2015/12/01

    Publisher: S. Karger AG

    DOI： 10.1159/000441601 　

    ISSN： 1662-6567

  171. Adult Onset of BRAFV600E-Mutated Langerhans Cell Histiocytosis with Cutaneous Involvement Successfully Diagnosed by Immunohistochemical Staining Peer-reviewed

    Hisayuki Tono, Taku Fujimura, Aya Kakizaki, Sadanori Furudate, Masaya Ishibashi, Setsuya Aiba

    Case Reports in Dermatology　7　(3)　237-240　2015/12/01

    Publisher: S. Karger AG

    DOI： 10.1159/000440643 　

    ISSN： 1662-6567

  172. Immunomodulatory effect of peritumorally administered interferon-beta on melanoma through tumor-associated macrophages. Peer-reviewed

    Kakizaki A, Fujimura T, Furudate S, Kambayashi Y, Yamauchi T, Yagita H, Aiba S

    Oncoimmunology　4　(11)　e1047584　2015/11

    DOI： 10.1080/2162402X.2015.1047584 　

    ISSN： 2162-4011

  173. Androgen receptor, androgen-producing enzymes and their transcription factors in extramammary Paget disease Peer-reviewed

    Abdullah Azmahani, Yasuhiro Nakamura, Yohei Ozawa, Keely M. McNamara, Taku Fujimura, Takahiro Haga, Akira Hashimoto, Setsuya Aiba, Hironobu Sasano

    HUMAN PATHOLOGY　46　(11)　1662-1669　2015/11

    DOI： 10.1016/j.humpath.2015.07.007 　

    ISSN： 0046-8177

    eISSN： 1532-8392

  174. Receptor Activator of NF-kappa B Ligand Promotes the Production of CCL17 from RANK+M2 Macrophages Peer-reviewed

    Taku Fujimura, Yumi Kambayashi, Sadanori Furudate, Masayuki Asano, Aya Kakizaki, Setsuya Aiba

    JOURNAL OF INVESTIGATIVE DERMATOLOGY　135　(11)　2884-2887　2015/11

    DOI： 10.1038/jid.2015.209 　

    ISSN： 0022-202X

    eISSN： 1523-1747

  175. The Possible Interaction between Receptor Activator of Nuclear Factor Kappa-B Ligand Expressed by Extramammary Paget Cells and its Ligand on Dermal Macrophages Peer-reviewed

    Yumi Kambayashi, Taku Fujimura, Sadanori Furudate, Masayuki Asano, Aya Kakizaki, Setsuya Aiba

    JOURNAL OF INVESTIGATIVE DERMATOLOGY　135　(10)　2547-2550　2015/10

    DOI： 10.1038/jid.2015.199 　

    ISSN： 0022-202X

    eISSN： 1523-1747

  176. Successful control of recurrent angiosarcoma in the external auditory canal with CyberKnife radiosurgery and bisphosphonate risedronate sodium Peer-reviewed

    Eimei Iwama, Taku Fujimura, Akira Hashimoto, Yukikazu Numata, Takahiro Haga, Setsuya Aiba

    DERMATOLOGICA SINICA　33　(3)　163-165　2015/09

    DOI： 10.1016/j.dsi.2014.12.003 　

    ISSN： 1027-8117

    eISSN： 2223-330X

  177. Immunohistochemical similarities between lichen sclerosus et atrophicus and morphea: A case study Peer-reviewed

    Aya Kakizaki, Taku Fujimura, Sadanori Furudate, Yumi Kambayashi, Setsuya Aiba

    Case Reports in Dermatology　7　(1)　39-45　2015/05/22

    Publisher: S. Karger AG

    DOI： 10.1159/000381010 　

    ISSN： 1662-6567

  178. Merkel cell carcinoma concomitant with invasive Bowen's disease: Immunohistochemical investigation of tumor-infiltrating leukocytes Peer-reviewed

    Hisayuki Tono, Taku Fujimura, Eimei Iwama, Yoshiyuki Kusakari, Sadanori Furudate, Yumi Kambayashi, Takahiro Haga, Akira Hashimoto, Setsuya Aiba

    Case Reports in Dermatology　7　(1)　1-6　2015/05/22

    Publisher: S. Karger AG

    DOI： 10.1159/000371732 　

    ISSN： 1662-6567

  179. Adult-onset acquired partial lipodystrophy accompanied by rheumatoid arthritis Peer-reviewed

    Yusuke Muto, Taku Fujimura, Aya Kakizaki, Kenichiro Tsuchiyama, Yoshiyuki Kusakari, Setsuya Aiba

    Case Reports in Dermatology　7　(1)　70-74　2015/05/22

    Publisher: S. Karger AG

    DOI： 10.1159/000381844 　

    ISSN： 1662-6567

  180. Psoriasiform drug eruption caused by abatacept: Immunohistochemical investigation of STAT signaling Peer-reviewed

    Kayo Tanita, Taku Fujimura, Aya Kakizaki, Sadanori Furudate, Yoshiyuki Kusakari, Setsuya Aiba

    Case Reports in Dermatology　7　(2)　166-170　2015/05/07

    Publisher: S. Karger AG

    DOI： 10.1159/000437415 　

    ISSN： 1662-6567

  181. 表皮向性を認めた膵原発diffuse large B cell lymphomaの臍部への皮膚浸潤の1例

    古舘 禎騎, 藤村 卓, 石橋 昌也, 相場 節也

    日本皮膚科学会雑誌　125　(4)　946-946　2015/04

    Publisher: (公社)日本皮膚科学会

    ISSN： 0021-499X

    eISSN： 1346-8146

  182. 臍部の皮膚浸潤を認めた表皮向性diffuse large B cell lymphoma(DLBCL)の1例

    古舘 禎騎, 藤村 卓, 石橋 昌也, 相場 節也

    日本皮膚科学会雑誌　125　(3)　451-451　2015/03

    Publisher: (公社)日本皮膚科学会

    ISSN： 0021-499X

    eISSN： 1346-8146

  183. Comparison of CD163(+) Macrophages and CD206(+) Cells in Lesional Skin of CD30(+) Lymphoproliferative Disorders of Lymphomatoid Papulosis and Primary Cutaneous Anaplastic Large-cell Lymphoma Peer-reviewed

    Aya Kakizaki, Taku Fujimura, Yumi Kambayashi, Sadanori Furudate, Mitsuko Kawano, Kouetsu Ogasawara, Setsuya Aiba

    ACTA DERMATO-VENEREOLOGICA　95　(5)　600-602　2015

    DOI： 10.2340/00015555-2016 　

    ISSN： 0001-5555

    eISSN： 1651-2057

  184. Acquired Idiopathic Generalised Anhidrosis: An Immunohistopathological Investigation of Peri-glands Infiltrated with Immunoreactive Cells Peer-reviewed

    Eimei Iwama, Taku Fujimura, Kayo Tanita, Masaya Ishibashi, Akiko Watabe, Setsuya Aiba

    ACTA DERMATO-VENEREOLOGICA　95　(6)　743-744　2015

    DOI： 10.2340/00015555-2034 　

    ISSN： 0001-5555

    eISSN： 1651-2057

  185. Immunomodulatory Effects of Peplomycin on Immunosuppressive and Cytotoxic Cells in the Lesional Skin of Cutaneous Squamous Cell Carcinoma Peer-reviewed

    Taku Fujimura, Yumi Kambayashi, Sadanori Furudate, Aya Kakizaki, Takahiro Haga, Akira Hashimoto, Setsuya Aiba

    DERMATOLOGY　230　(3)　250-255　2015

    DOI： 10.1159/000369166 　

    ISSN： 1018-8665

    eISSN： 1421-9832

  186. Immunomodulatory effect of peritumorally administered interferon-beta on melanoma through tumor-associated macrophages Peer-reviewed

    Aya Kakizaki, Taku Fujimura, Sadanori Furudate, Yumi Kambayashi, Takeshi Yamauchi, Hideo Yagita, Setsuya Aiba

    ONCOIMMUNOLOGY　4　(11)　e1047584-e1047584　2015

    DOI： 10.1080/2162402X.2015.1047584 　

    ISSN： 2162-402X

  187. Increased vascular MMP-9 in mice lacking RNF213: moyamoya disease susceptibility gene. International-journal Peer-reviewed

    Sonobe S, Fujimura M, Niizuma K, Fujimura T, Furudate S, Nishijima Y, Kure S, Tominaga T

    Neuroreport　25　(18)　1442-1446　2014/12

    DOI： 10.1097/WNR.0000000000000289 　

    ISSN： 0959-4965

    More details Close

    Moyamoya disease (MMD) is a chronic occlusive cerebrovascular disease with unknown etiology. Recent genetic studies have identified RNF213 as an important susceptibility gene for MMD. To evaluate the role of RNF213 in vascular remodeling, RNF213 knockout mice (RNF213-/-) and their wild-type littermates (WT) were subjected to common carotid artery ligation to induce vascular hyperplasia. We examined the vascular expression of matrix metalloproteinase (MMP)-9, known to be increased in MMD. MMP-9 expression was significantly higher in RNF213-/- mice than in wild-type mice 1 and 7 days after common carotid artery ligation. The vascular wall was significantly thinner in RNF213-/- mice at 14 days. The increased vascular expression of MMP-9 and subsequent vascular wall thinning in RNF213-/- mice could reflect the early characteristic of MMD, consistent with the recently proposed constrictive remodeling theory.

  188. Isolated collagenoma developing on the scalp Peer-reviewed

    Toshiya Takahashi, Taku Fujimura, Yumi Kambayashi, Yukikazu Numata, Setsuya Aiba

    EUROPEAN JOURNAL OF DERMATOLOGY　24　(6)　704-706　2014/12

    DOI： 10.1684/ejd.2014.2445 　

    ISSN： 1167-1122

    eISSN： 1952-4013

  189. 外陰部有棘細胞癌にneoadjuvant chemotherpyが著効し、寛解を得た一例

    志藤 光介, 沼田 透効, 石原 志乃, 玉渕 恵里佳, 高橋 隼也, 藤村 卓, 芳賀 貴裕, 橋本 彰, 山崎 研志, 相場 節也

    日本皮膚悪性腫瘍学会学術大会プログラム・抄録集　30回　148-148　2014/07

    Publisher: (一社)日本皮膚悪性腫瘍学会

  190. メルケル細胞癌におけるエトポシド単剤療法 その免疫学的検討

    神林 由美, 藤村 卓, 古舘 禎騎, 柿崎 彩, 沼田 透効, 芳賀 貴裕, 橋本 彰, 相場 節也

    日本皮膚悪性腫瘍学会学術大会プログラム・抄録集　30回　125-125　2014/07

    Publisher: (一社)日本皮膚悪性腫瘍学会

  191. Infantile cellular schwannoma developing on the skin with atypical clinical features Peer-reviewed

    Taku Fujimura, Hachiro Tagami, Setsuya Aiba

    Case Reports in Dermatology　6　(2)　185-188　2014/05/22

    Publisher: S. Karger AG

    DOI： 10.1159/000365861 　

    ISSN： 1662-6567

  192. Keratoacanthoma accompanied by multiple lung squamous cell carcinomas developing in a renal transplant recipient Peer-reviewed

    Sadanori Furudate, Taku Fujimura, Aya Kakizaki, Yumi Kambayashi, Akira Hashimoto, Setsuya Aiba

    Case Reports in Dermatology　6　(2)　169-175　2014/05/22

    Publisher: S. Karger AG

    DOI： 10.1159/000365626 　

    ISSN： 1662-6567

  193. Successful treatment of eccrine porocarcinoma metastasized to a cervical lymph node with cyberknife radiosurgery Peer-reviewed

    Taku Fujimura, Akira Hashimoto, Sadanori Furudate, Yumi Kambayashi, Takahiro Haga, Setsuya Aiba

    Case Reports in Dermatology　6　(2)　159-163　2014/05/22

    Publisher: S. Karger AG

    DOI： 10.1159/000365348 　

    ISSN： 1662-6567

  194. Dermoscopy findings of hidroacanthoma simplex Peer-reviewed

    Yota Sato, Taku Fujimura, Erika Tamabuchi, Takahiro Haga, Setsuya Aiba

    Case Reports in Dermatology　6　(2)　154-158　2014/05/22

    Publisher: S. Karger AG

    DOI： 10.1159/000363369 　

    ISSN： 1662-6567

  195. Successful treatment of two cases of squamous cell carcinoma on the ear with intra-arterial administration of peplomycin through a superficial temporal artery Peer-reviewed

    Takahiro Haga, Taku Fujimura, Izuho Takeuchi, Masatoshi Deguchi, Setsuya Aiba

    Case Reports in Dermatology　6　(3)　207-212　2014/05/22

    Publisher: S. Karger AG

    DOI： 10.1159/000367804 　

    ISSN： 1662-6567

  196. A possible mechanism in the recruitment of eosinophils and Th2 cells through CD163(+) M2 macrophages in the lesional skin of eosinophilic cellulitis Peer-reviewed

    Taku Fujimura, Yumi Kambayashi, Sadanori Furudate, Aya Kakizaki, Setsuya Aiba

    EUROPEAN JOURNAL OF DERMATOLOGY　24　(2)　180-185　2014/03

    DOI： 10.1684/ejd.2014.2283 　

    ISSN： 1167-1122

    eISSN： 1952-4013

  197. Comparison of CD163+CD206+M2 Macrophages in the Lesional Skin of Bullous Pemphigoid and Pemphigus Vulgaris: The Possible Pathogenesis of Bullous Pemphigoid Peer-reviewed

    Sadanori Furudate, Taku Fujimura, Yumi Kambayashi, Aya Kakizaki, Setsuya Aiba

    DERMATOLOGY　229　(4)　369-378　2014

    DOI： 10.1159/000365946 　

    ISSN： 1018-8665

    eISSN： 1421-9832

  198. Induction of CD163(+) M2 Macrophages in the Lesional Skin of Eosinophilic Pustular Folliculitis Peer-reviewed

    Akiko Hagiwara, Taku Fujimura, Sadanori Furudate, Yumi Kambayashi, Saori Kagatani, Setsuya Aiba

    ACTA DERMATO-VENEREOLOGICA　94　(1)　104-106　2014

    DOI： 10.2340/00015555-1612 　

    ISSN： 0001-5555

    eISSN： 1651-2057

  199. Generalized Granulomatous Dermatitis Accompanied by Myelodysplastic Syndrome Peer-reviewed

    Akiko Hagiwara, Taku Fujimura, Sadanori Furudate, Yumi Kambayashi, Yukikazu Numata, Takahiro Haga, Setsuya Aiba

    ACTA DERMATO-VENEREOLOGICA　94　(2)　223-224　2014

    DOI： 10.2340/00015555-1656 　

    ISSN： 0001-5555

    eISSN： 1651-2057

  200. Immunosuppressive and Cytotoxic Cells in Invasive versus Non-invasive Bowen's Disease Peer-reviewed

    Sadanori Furudate, Taku Fujimura, Yumi Kambayashi, Takahiro Haga, Akira Hashimoto, Setsuya Aiba

    ACTA DERMATO-VENEREOLOGICA　94　(3)　337-339　2014

    DOI： 10.2340/00015555-1729 　

    ISSN： 0001-5555

    eISSN： 1651-2057

  201. Successful Treatment of Adult Onset Langerhans Cell Histiocytosis with Bi-weekly Administration of Pegylated Interferon-alpha Peer-reviewed

    Sadanori Furudate, Taku Fujimura, Yumi Kambayashi, Mitsuko Kawano, Kouetsu Ogasawara, Akira Tsukada, Erika Tamabuchi, Takahiro Haga, Akira Hashimoto, Setsuya Aiba

    ACTA DERMATO-VENEREOLOGICA　94　(5)　611-612　2014

    DOI： 10.2340/00015555-1807 　

    ISSN： 0001-5555

    eISSN： 1651-2057

  202. Expression of CD39/Entpd1 on granuloma-composing cells and induction of Foxp3-positive regulatory T cells in sarcoidosis Peer-reviewed

    T. Fujimura, Y. Kambayashi, S. Aiba

    CLINICAL AND EXPERIMENTAL DERMATOLOGY　38　(8)　883-889　2013/12

    DOI： 10.1111/ced.12094 　

    ISSN： 0307-6938

    eISSN： 1365-2230

  203. 結節性痒疹におけるM2マクロファージの役割

    神林 由美, 藤村 卓, 古舘 禎騎, 柿崎 彩, 高橋 佐和子, 鈴木 弘実, 相場 節也

    Journal of Environmental Dermatology and Cutaneous Allergology　7　(5)　448-448　2013/11

    Publisher: (一社)日本皮膚アレルギー・接触皮膚炎学会

    ISSN： 1882-0123

  204. 皮膚リンパ腫の進展 インターフェロン療法 臨床的有効性と作用機序の検討

    藤村 卓, 古舘 禎騎, 神林 由美, 塚田 全, 沼田 透効, 芳賀 貴裕, 橋本 彰, 相場 節也

    Skin Cancer　28　(2)　139-140　2013/11

    Publisher: (一社)日本皮膚悪性腫瘍学会

    DOI： 10.5227/skincancer.28.139 　

    ISSN： 0915-3535

    eISSN： 1884-3549

  205. Successful treatment of syringotropic CD8+mycosis fungoides accompanied by hypohidrosis with vorinostat and retinoids Peer-reviewed

    Aya Kakizaki, Taku Fujimura, Masato Mizuashi, Akiko Watabe, Yumi Kambayashi, Setsuya Aiba

    AUSTRALASIAN JOURNAL OF DERMATOLOGY　54　(4)　E82-E84　2013/11

    DOI： 10.1111/j.1440-0960.2012.00944.x 　

    ISSN： 0004-8380

    eISSN： 1440-0960

  206. Immunosuppression-associated eosinophilic pustular folliculitis (IS-EPF) developing after Highly Active Anti-Retroviral Therapy (HAART): the possible mechanisms through CD163(+) M2 macrophages Peer-reviewed

    Shuko Okada, Taku Fujimura, Sadanori Furudate, Yumi Kambayashi, Katsuko Kikuchi, Setsuya Aiba

    EUROPEAN JOURNAL OF DERMATOLOGY　23　(5)　713-714　2013/09

    DOI： 10.1684/ejd.2013.2117 　

    ISSN： 1167-1122

    eISSN： 1952-4013

  207. Induction of IL-17 producing cells and FoxP3+regulatory T cells in areas of skin affected by localized pemphigus foliaceus Peer-reviewed

    Gen-ichi Tojo, Taku Fujimura, Sadanori Furudate, Yumi Kambayashi, Akiko Watabe, Akira Hashimoto, Setsuya Aiba

    EUROPEAN JOURNAL OF DERMATOLOGY　23　(5)　711-712　2013/09

    DOI： 10.1684/ejd.2013.2116 　

    ISSN： 1167-1122

    eISSN： 1952-4013

  208. Successful local control of cutaneous Merkel cell carcinoma on the eyelid with CyberKnife radiosurgery Peer-reviewed

    Akira Tuskada, Taku Fujimura, Akira Hashimoto, Yumi Kambayashi, Sadanori Furudate, Takahiro Haga, Setsuya Aiba

    EUROPEAN JOURNAL OF DERMATOLOGY　23　(5)　725-726　2013/09

    DOI： 10.1684/ejd.2013.2123 　

    ISSN： 1167-1122

    eISSN： 1952-4013

  209. 鼻部に生じたPseudolymphomaの2例

    三井 英俊, 笹井 収, 古舘 禎騎, 藤村 卓, 相場 節也

    日本皮膚科学会雑誌　123　(4)　501-501　2013/04

    Publisher: (公社)日本皮膚科学会

    ISSN： 0021-499X

    eISSN： 1346-8146

  210. Granulysin-Bearing Cells in the Skin Lesions of Acute Graft-versus-Host Disease: Possible Mechanisms for Hypohidrosis in Graft-versus-Host Disease. Peer-reviewed

    Furudate S, Fujimura T, Kambayashi Y, Aiba S

    Case Reports in Dermatology　5　(1)　88-92　2013/04

    DOI： 10.1159/000350561. 　

  211. Successful treatment of plasmacytosis circumorificialis with topical tacrolimus: two case reports and an immunohistochemical study. Peer-reviewed

    Fujimura T, Furudate S, Ishibashi M, Kambayashi Y, Tojo G, Wakusawa C, Mayama H, Aiba S

    Case Reports in Dermatology　5　(1)　79-83　2013/03/20

    DOI： 10.1159/000350184. 　

  212. Profiles of cytotoxic T lymphocytes in cutaneous lymphoid hyperplasia of the face. Peer-reviewed

    Furudate S, Fujimura T, Kambayashi Y, Aiba S

    Case Reports in Dermatology　5　(1)　88-92　2013/03/20

    DOI： 10.1159/000350567. 　

  213. Basal cell carcinoma arising from xeroderma pigmentosum: a case report and an immunohistochemical study. Peer-reviewed

    Furudate S, Fujimura T, Tojo G, Haga T, Aiba S

    Case Reports in Dermatology　5　(1)　64-68　2013/03/09

    DOI： 10.1159/000350182. 　

  214. Pigmented epithelioid melanocytoma: Immunohistochemical profiles of tumour-infiltrating histiocytes Peer-reviewed

    Anna Sadayasu, Taku Fujimura, Takahiro Haga, Yumi Kambayashi, Sadanori Furudate, Setsuya Aiba

    Acta Dermato-Venereologica　93　(4)　481-482　2013

    DOI： 10.2340/00015555-1507 　

    ISSN： 0001-5555 1651-2057

  215. Pigmented Necrobiosis Lipoidica Accompanied by Insulin-dependent Diabetes Mellitus Induces CD163(+) Proinflammatory Macrophages and Interleukin-17-producing Cells Peer-reviewed

    Chihiro Wakusawa, Taku Fujimura, Yumi Kambayashi, Sadanori Furudate, Akira Hashimoto, Setsuya Aiba

    ACTA DERMATO-VENEREOLOGICA　93　(4)　475-476　2013

    DOI： 10.2340/00015555-1502 　

    ISSN： 0001-5555

    eISSN： 1651-2057

  216. Immunomodulatory Effect of Bisphosphonate Risedronate Sodium on CD163(+) Arginase 1(+) M2 Macrophages: The Development of a Possible Supportive Therapy for Angiosarcoma Peer-reviewed

    Taku Fujimura, Yumi Kambayashi, Sadanori Furudate, Aya Kakizaki, Setsuya Aiba

    CLINICAL & DEVELOPMENTAL IMMUNOLOGY　2013　325412-325412　2013

    DOI： 10.1155/2013/325412 　

    ISSN： 1740-2522

    eISSN： 1740-2530

  217. A case of almost unilateral focal dermal hypoplasia resulting from a novel mutation in the PORCN gene Peer-reviewed

    Masayuki Asano, Taku Fujimura, Chihiro Wakusawa, Yoko Aoki, Yoichi Matsubara, Setsuya Aiba

    Acta Dermato-Venereologica　93　(1)　120-121　2013

    DOI： 10.2340/00015555-1399 　

    ISSN： 0001-5555 1651-2057

  218. Granulomatous pigmented purpuric dermatitis associated with primary Sjögren's syndrome Peer-reviewed

    Chihiro Wakusawa, Taku Fujimura, Takahiro Haga, Setsuya Aiba

    Acta Dermato-Venereologica　93　(1)　95-96　2013

    DOI： 10.2340/00015555-1380 　

    ISSN： 0001-5555 1651-2057

  219. Squamous Cell Carcinoma Arising from Keratitis-Ichthyosis-Deafness Syndrome Peer-reviewed

    Hiroshi Mayama, Taku Fujimura, Masayuki Asano, Yumi Kambayashi, Yukikazu Numata, Setsuya Aiba

    ACTA DERMATO-VENEREOLOGICA　93　(5)　583-584　2013

    DOI： 10.2340/00015555-1535 　

    ISSN： 0001-5555

    eISSN： 1651-2057

  220. Potential use of bisphosphonates in invasive extramammary paget's disease: An immunohistochemical investigation Peer-reviewed

    Taku Fujimura, Sadanori Furudate, Yumi Kambayashi, Setsuya Aiba

    Clinical and Developmental Immunology　2013　164982　2013

    DOI： 10.1155/2013/164982 　

    ISSN： 1740-2522 1740-2530

  221. Multiple low-grade fibromyxoid sarcoma on the upper arms with atypical histological presentation Peer-reviewed

    Sadanori Furudate, Taku Fujimura, Yumi Kambayashi, Akira Tsukada, Yukikazu Numata, Setsuya Aiba

    Case Reports in Dermatology　5　(2)　152-155　2013

    Publisher: S. Karger AG

    DOI： 10.1159/000351791 　

    ISSN： 1662-6567

  222. In vivo imaging demonstrates ATP release from murine keratinocytes and its involvement in cutaneous inflammation after tape stripping Peer-reviewed

    Toshiya Takahashi, Yutaka Kimura, Kazuki Niwa, Yoshihiro Ohmiya, Taku Fujimura, Kenshi Yamasaki, Setsuya Aiba

    Journal of Investigative Dermatology　133　(10)　2407-2415　2013

    Publisher: Nature Publishing Group

    DOI： 10.1038/jid.2013.163 　

    ISSN： 1523-1747 0022-202X

  223. Comparison of Immunosuppressive and Cytotoxic Cells in Angiosarcoma: Development of a Possible Supportive Therapy for Angiosarcoma Peer-reviewed

    Yumi Kambayashi, Taku Fujimura, Sadanori Furudate, Akira Hashimoto, Takahiro Haga, Setsuya Aiba

    DERMATOLOGY　227　(1)　14-20　2013

    DOI： 10.1159/000351316 　

    ISSN： 1018-8665

    eISSN： 1421-9832

  224. Comparison of Interleukin-17-Producing Cells in Different Clinical Types of Alopecia Areata Peer-reviewed

    Genichi Tojo, Taku Fujimura, Mitsuko Kawano, Kouetsu Ogasawara, Yumi Kambayashi, Sadanori Furudate, Masato Mizuashi, Setsuya Aiba

    DERMATOLOGY　227　(1)　78-82　2013

    DOI： 10.1159/000353159 　

    ISSN： 1018-8665

    eISSN： 1421-9832

  225. Eosinophilic cellulitis induced by subcutaneous administration of interferon-β Peer-reviewed

    Yumi Kambayashi, Taku Fujimura, Masaya Ishibashi, Takahiro Haga, Setsuya Aiba

    Acta Dermato-Venereologica　93　(6)　755-756　2013

    DOI： 10.2340/00015555-1611 　

    ISSN： 0001-5555 1651-2057

  226. Comparison of Immunosuppressive and Immunomodulatory Cells in Keratoacanthoma and Cutaneous Squamous Cell Carcinoma Peer-reviewed

    Yumi Kambayashi, Taku Fujimura, Setsuya Aiba

    ACTA DERMATO-VENEREOLOGICA　93　(6)　663-668　2013

    DOI： 10.2340/00015555-1597 　

    ISSN： 0001-5555

    eISSN： 1651-2057

  227. Immunomodulatory Effect of Bisphosphonate Risedronate Sodium on CD163(+) Arginase 1(+) M2 Macrophages: The Development of a Possible Supportive Therapy for Angiosarcoma Peer-reviewed

    Taku Fujimura, Yumi Kambayashi, Sadanori Furudate, Aya Kakizaki, Setsuya Aiba

    CLINICAL & DEVELOPMENTAL IMMUNOLOGY　325412　2013

    DOI： 10.1155/2013/325412 　

    ISSN： 1740-2522

    eISSN： 1740-2530

  228. 【おさえておきたい、リンパ腫の鑑別と治療】 (Part2)菌状息肉症・セザリー症候群の治療(case14) インターフェロン-α療法が奏効した菌状息肉症 Invited

    藤村 卓

    Visual Dermatology　11　(9)　956-957　2012/08

  229. Basal cell carcinoma with spontaneous regression: A case report and immunohistochemical study Peer-reviewed

    Taku Fujimura, Aya Kakizaki, Yumi Kambayashi, Setsuya Aiba

    Case Reports in Dermatology　4　(2)　125-132　2012/05

    DOI： 10.1159/000339621 　

    ISSN： 1662-6567

  230. Phaeohyphomycosis caused by phaeoacremoniumrubrigenum in an immunosuppressive patient: A case report and review of the literature Peer-reviewed

    Sadanori Furudate, Shu Sasai, Yukikazu Numata, Taku Fujimura, Setsuya Aiba

    Case Reports in Dermatology　4　(2)　119-124　2012/05

    DOI： 10.1159/000339622 　

    ISSN： 1662-6567

  231. Successful treatment of granuloma faciale with topical tacrolimus: A case report and immunohistochemical study Peer-reviewed

    Gen-Ichi Tojo, Taku Fujimura, Yumi Kambayashi, Katsuko Kikuchi, Setsuya Aiba

    Case Reports in Dermatology　4　(2)　158-162　2012/05

    DOI： 10.1159/000341196 　

    ISSN： 1662-6567

  232. Dermoscopy findings of pseudolymphomatous folliculitis Peer-reviewed

    Taku Fujimura, Takanori Hidaka, Akira Hashimoto, Setsuya Aiba

    Case Reports in Dermatology　4　(2)　154-157　2012/05

    DOI： 10.1159/000341194 　

    ISSN： 1662-6567

  233. Systemic lupus erythematosus accompanied by psoriasis induces IL-27-producing cells in both affected areas of the skin Peer-reviewed

    Gen-Ichi Tojo, Taku Fujimura, Yumi Kambayashi, Setsuya Aiba

    Case Reports in Dermatology　4　(2)　181-185　2012/05

    DOI： 10.1159/000342803 　

    ISSN： 1662-6567

  234. Profiles of tumor-infiltrating lymphocytes in a case of trichilemmal carcinoma with spontaneous regression Peer-reviewed

    Sadanori Furudate, Taku Fujimura, Akira Tsukada, Yukikazu Numata, Yumi Kambayashi, Setsuya Aiba

    Case Reports in Dermatology　4　(3)　215-221　2012/04/20

    Publisher: S. Karger AG

    DOI： 10.1159/000343881 　

    ISSN： 1662-6567

  235. Bullous pemphigoid accompanied by aplastic anemia: The induction of IL-17-producing cells in the affected areas of the skin Peer-reviewed

    Taku Fujimura, Aya Kakizaki, Yumi Kambayashi, Sadanori Furudate, Setsuya Aiba

    Case Reports in Dermatology　4　(3)　211-214　2012/04/20

    Publisher: S. Karger AG

    DOI： 10.1159/000343882 　

    ISSN： 1662-6567

  236. Basosquamous cell carcinoma developing from a renal transplantation recipient Peer-reviewed

    Akira Tsukada, Taku Fujimura, Sadanori Furudate, Yumi Kambayashi, Akira Hashimoto, Setsuya Aiba

    Case Reports in Dermatology　4　(3)　227-232　2012/04/20

    Publisher: S. Karger AG

    DOI： 10.1159/000345095 　

    ISSN： 1662-6567

  237. Cutaneous squamous cell carcinoma developing from recessive dystrophic epidermolysis bullosa: A case report and an immunohistochemical study Peer-reviewed

    Akira Tsukada, Taku Fujimura, Sadanori Furudate, Yumi Kambayashi, Yukikazu Numata, Takahiro Haga, Akira Hashimoto, Setsuya Aiba

    Case Reports in Dermatology　4　(3)　197-201　2012/04/20

    Publisher: S. Karger AG

    DOI： 10.1159/000343082 　

    ISSN： 1662-6567

  238. Successful treatment of adult-onset erythromelalgia with steroid pulse and pregabalin Peer-reviewed

    Aya Kakizaki, Taku Fujimura, Yumi Kambayashi, Akiko Watabe, Setsuya Aiba

    Case Reports in Dermatology　4　(3)　242-246　2012/04/20

    Publisher: S. Karger AG

    DOI： 10.1159/000345377 　

    ISSN： 1662-6567

  239. Regulatory T Cells Stimulate B7-H1 Expression in Myeloid-Derived Suppressor Cells in ret Melanomas Peer-reviewed

    Taku Fujimura, Sabine Ring, Viktor Umansky, Karsten Mahnke, Alexander H. Enk

    JOURNAL OF INVESTIGATIVE DERMATOLOGY　132　(4)　1239-1246　2012/04

    DOI： 10.1038/jid.2011.416 　

    ISSN： 0022-202X

  240. Successful treatment of MMP-9-expressing angiosarcoma with low-dose docetaxel and bisphosphonate Peer-reviewed

    Masaya Ishibashi, Taku Fujimura, Akira Hashimoto, Takahiro Haga, Kaoru Onami, Akira Tsukada, Yumi Kambayashi, Takanori Hidaka, Sadanori Furudate, Ryoko Shimada, Setsuya Aiba

    Case Reports in Dermatology　4　(1)　5-9　2012/01

    DOI： 10.1159/000335999 　

    ISSN： 1662-6567

  241. Pseudolymphomatous folliculitis on the nose Peer-reviewed

    Aya Kakizaki, Taku Fujimura, Ikuko Numata, Akira Hashimoto, Setsuya Aiba

    Case Reports in Dermatology　4　(1)　27-30　2012/01

    DOI： 10.1159/000336207 　

    ISSN： 1662-6567

  242. Cutaneous lymphadenoma: A case report and immunohistochemical study Peer-reviewed

    Taku Fujimura, Aya Itoigawa, Takahiro Haga, Setsuya Aiba

    Case Reports in Dermatology　4　(1)　50-55　2012/01

    DOI： 10.1159/000337196 　

    ISSN： 1662-6567

  243. Comparison of Foxp3(+) Regulatory T cells and CD163(+) Macrophages in Invasive and Non-invasive Extramammary Paget's Disease Peer-reviewed

    Taku Fujimura, Yumi Kambayashi, Takanori Hidaka, Akira Hashimoto, Takahiro Haga, Setsuya Aiba

    ACTA DERMATO-VENEREOLOGICA　92　(6)　625-628　2012

    DOI： 10.2340/00015555-1453 　

    ISSN： 0001-5555

  244. Extranodal T-cell/Histiocyte-rich Large B-cell Lymphoma Presenting Primarily on the Skin Peer-reviewed

    Yumi Kambayashi, Taku Fujimura, Akira Tsukada, Akira Hashimoto, Setsuya Aiba

    ACTA DERMATO-VENEREOLOGICA　92　(6)　637-639　2012

    DOI： 10.2340/00015555-1435 　

    ISSN： 0001-5555

  245. Successful Treatment of Pigmented Dermatofibrosarcoma Protuberance on the Nasal Root with CyberKnife Radiosurgery Peer-reviewed

    Takanori Hidaka, Taku Fujimura, Akira Hashimoto, Setsuya Aiba

    ACTA DERMATO-VENEREOLOGICA　92　(6)　658-659　2012

    DOI： 10.2340/00015555-1357 　

    ISSN： 0001-5555

  246. CD163(+) Adult Xanthogranuloma Arising from Merkel Cell Carcinoma Treated with Local Radiotherapy Peer-reviewed

    Ryoko Shimada, Taku Fujimura, Yumi Kambayashi, Tomoyuki Ohtani, Mei Nasu, Yukikazu Numata, Takahiro Haga, Akira Hashimoto, Setsuya Aiba

    ACTA DERMATO-VENEREOLOGICA　92　(6)　631-632　2012

    DOI： 10.2340/00015555-1356 　

    ISSN： 0001-5555

  247. Successful Treatment of HER-2-Positive Metastatic Apocrine Carcinoma of the Skin with Lapatinib and Capecitabine Peer-reviewed

    Takanori Hidaka, Taku Fujimura, Akiko Watabe, Akira Hashimoto, Tahahiro Haga, Kaoru Onami, Masato Mizuashi, Setsuya Aiba

    ACTA DERMATO-VENEREOLOGICA　92　(6)　654-655　2012

    DOI： 10.2340/00015555-1354 　

    ISSN： 0001-5555

  248. Myeloid sarcoma in a one-month-old infant Peer-reviewed

    Chihiro Wakusawa, Taku Fujimura, Akira Hashimoto, Setsuya Aiba

    Case Reports in Dermatology　3　(3)　219-222　2011/09

    DOI： 10.1159/000333206 　

    ISSN： 1662-6567

  249. Therapy-resistant, spontaneously remitting generalized neutrophilic eccrine hidradenitis in a healthy patient decreases the expression of dermcidin in affected eccrine glands Peer-reviewed

    Yumi Kambayashi, Taku Fujimura, Kenshi Yamasaki, Setsuya Aiba

    Case Reports in Dermatology　3　(3)　228-234　2011/09

    DOI： 10.1159/000334737 　

    ISSN： 1662-6567

  250. Blastic plasmacytoid dendritic cell neoplasm on the scalp Peer-reviewed

    Sawako Fukushi, Taku Fujimura, Setsuya Aiba

    Case Reports in Dermatology　3　(3)　240-243　2011/09

    DOI： 10.1159/000334927 　

    ISSN： 1662-6567

  251. Rapid growth of dermatofibrosarcoma protuberans associated with bilateral adrenalectomy for Cushing's syndrome Peer-reviewed

    Sadanori Furudate, Taku Fujimura, Akira Hashimoto, Setsuya Aiba

    Case Reports in Dermatology　3　(2)　113-117　2011/05

    DOI： 10.1159/000329000 　

    ISSN： 1662-6567

  252. A synthetic NOD2 agonist, muramyl dipeptide (MDP)-Lys (L18) and IFN-beta synergistically induce dendritic cell maturation with augmented IL-12 production and suppress melanoma growth Peer-reviewed

    Taku Fujimura, Kenshi Yamasaki, Takanori Hidaka, Yumiko Ito, Setsuya Aiba

    JOURNAL OF DERMATOLOGICAL SCIENCE　62　(2)　107-115　2011/05

    DOI： 10.1016/j.jdermsci.2011.02.002 　

    ISSN： 0923-1811

  253. Malignant fibrous histiocytoma with in-transit metastasis Peer-reviewed

    Taku Fujimura, Masayuki Sugawara, Takahiro Haga, Yoshiyuki Kariya, Ryuhei Okuyama, Hachiro Tagami, Setsuya Aiba

    Case Reports in Dermatology　3　(2)　164-169　2011/05

    DOI： 10.1159/000331324 　

    ISSN： 1662-6567

  254. A synthetic NOD2 agonist, muramyl dipeptide (MDP)-Lys (L18) and IFN-beta synergistically induce dendritic cell maturation with augmented IL-12 production and suppress melanoma growth Peer-reviewed

    Taku Fujimura, Kenshi Yamasaki, Takanori Hidaka, Yumiko Ito, Setsuya Aiba

    JOURNAL OF DERMATOLOGICAL SCIENCE　62　(2)　107-115　2011/05

    DOI： 10.1016/j.jdermsci.2011.02.002 　

    ISSN： 0923-1811

  255. Perilesional treatment of metastatic melanoma with interferon-beta Peer-reviewed

    T. Fujimura, R. Okuyama, T. Ohtani, Y. Ito, T. Haga, A. Hashimoto, S. Aiba

    CLINICAL AND EXPERIMENTAL DERMATOLOGY　34　(7)　793-799　2009/10

    DOI： 10.1111/j.1365-2230.2009.03207.x 　

    ISSN： 0307-6938

  256. Papuloerythroderma associated with monoclonal gammopathy of undetermined significance Peer-reviewed

    Taku Fujimura, Ryuhei Okuyama, Eisaku Ogawa, Setsuya Aiba

    JOURNAL OF DERMATOLOGY　36　(4)　228-231　2009/04

    DOI： 10.1111/j.1346-8138.2009.00628.x 　

    ISSN： 0385-2407

  257. TGF-beta 1 dampens the susceptibility of dendritic cells to environmental stimulation, leading to the requirement for danger signals for activation Peer-reviewed

    Tomoyuki Ohtani, Masato Mizuashi, Satoshi Nakagawa, Yoshinori Sasaki, Taku Fujimura, Ryuhei Okuyama, Setsuya Aiba

    IMMUNOLOGY　126　(4)　485-499　2009/04

    DOI： 10.1111/j.1365-2567.2008.02919.x 　

    ISSN： 0019-2805

  258. Profiles of Foxp3+ regulatory T cells in eczematous dermatitis, psoriasis vulgaris and mycosis fungoides Peer-reviewed

    T. Fujimura, R. Okuyama, Y. Ito, S. Aiba

    BRITISH JOURNAL OF DERMATOLOGY　158　(6)　1256-1263　2008/06

    DOI： 10.1111/j.1365-2133.2008.08504.x 　

    ISSN： 0007-0963

  259. Angioleiomyoma with the features of the dermatofibroma Peer-reviewed

    Taku Fujimura, Ryuhei Okuyama, Hachiro Tagami, Setsuya Aiba

    JOURNAL OF DERMATOLOGY　35　(2)　124-125　2008/02

    DOI： 10.1111/j.1346-8138.2008.00428.x 　

    ISSN： 0385-2407

  260. Therapy-resistant skin ulcers on hypoplastic leg associated with neurofibromatosis type 1 Peer-reviewed

    Taku Fujimura, Ryuhei Okuyama, Setsuya Aiba

    JOURNAL OF DERMATOLOGY　35　(2)　120-121　2008/02

    DOI： 10.1111/j.1346-8138.2008.00430.x 　

    ISSN： 0385-2407

    eISSN： 1346-8138

  261. Inhibitory Effect of Tumor(murine B16 melanoma) by Self-control Heater for Hyperthermia Peer-reviewed

    田倉哲也, 佐藤文博, 松木英敏, 藤村卓, 相場節也, 佐藤忠邦

    Journal of the Magnetics Society of Japan　32　(3)　439-443　2008

    Publisher: The Magnetics Society of Japan (MSJ)

    DOI： 10.3379/msjmag.32.439 　

    ISSN： 1882-2924

    More details Close

    Hyperthermia is a method of treating cancer that uses heat to destroy tumors. Soft heating has been proposed as one method of treating hyperthermia. This is where the thermosensitive ferrite inserted into the tumor as a heating element produces heat in a high-frequency magnetic field. We applied soft heating in this study. Heat element developed can control temperature automatically, referring the Curie-point of the thermosensitive ferrite. The heat element consists of a thermosensitive ferrite and metal ring coated on it. The purpose of the metal ring wrapped to ferrite is to increase heat quantity compared with that of ferrite alone. The effect of the heat element in murine B-16 Melanoma model is examined. As a result, the tumors of mice were locally heated to the point at which tumor is necrotized.

  262. A case of pencil-core granuloma Peer-reviewed

    Masayuki Sugawara, Ryuhei Okuyama, Taku Fujimura, Takahiro Haga, Setsuya Aiba

    Nishinihon Journal of Dermatology　70　(3)　265-268　2008

    DOI： 10.2336/nishinihonhifu.70.265 　

    ISSN： 0386-9784

  263. Interferon-alpha is effective for CD4+, CCR4-mycosis fungoides Peer-reviewed

    Taku Fujimura, Ryuhei Okuyama, Akiko Watabe, Akira Hashimoto, Hachiro Tagami, Setsuya Aiba

    INTERNATIONAL JOURNAL OF DERMATOLOGY　46　(4)　435-438　2007/04

    DOI： 10.1111/j.1365-4632.2007.03221.x 　

    ISSN： 0011-9059

  264. A case of interdigital verrucous carcinoma: Preservation of the digits with minimal excision after selective intra-arterial infusion chemotherapy Peer-reviewed

    Taku Fujimura, Ryuhei Okuyama, Akira Hashimoto, Satoshi Hasegawa, Mariko Takayama, Hiroshi Watanabe, Setsuya Aiba

    Nishinihon Journal of Dermatology　69　(3)　269-272　2007

    DOI： 10.2336/nishinihonhifu.69.269 　

    ISSN： 0386-9784

  265. Inhibitory effect of the polyinosinic-polycytidylic acid/cationic liposome on the progression of murine B16F10 melanoma Peer-reviewed

    Taku Fujimura, Satoshi Nakagawa, Tomoyuki Ohtani, Yumiko Ito, Setsuya Aiba

    EUROPEAN JOURNAL OF IMMUNOLOGY　36　(12)　3371-3380　2006/12

    DOI： 10.1002/eji.2006360531 　

    ISSN： 0014-2980

  266. 成人発症の腹壁遠心性脂肪萎縮症の1例 Peer-reviewed

    加賀谷沙織, 藤村卓, 松永純, 相場節也

    臨床皮膚科　60　(7)　592-594　2006/06

    Publisher:

    DOI： 10.11477/mf.1412100944 　

    ISSN： 0021-4973

  267. Regulatory T cell-like activity of Foxp3(+) adult T cell leukemia cells Peer-reviewed

    SM Chen, N Ishii, S Ine, S Ikeda, T Fujimura, LC Ndhlovu, P Soroosh, K Tada, H Harigae, J Kameoka, N Kasai, T Sasaki, K Sugamura

    INTERNATIONAL IMMUNOLOGY　18　(2)　269-277　2006/02

    DOI： 10.1093/intimm/dxh366 　

    ISSN： 0953-8178

  268. Effective control of rush progression of CD8+mycosis fungoides with pegylated interferon Peer-reviewed

    T Fujimura, R Okuyama, A Hashimoto, H Watanabe, S Nakagawa, H Tagami, S Aiba

    ACTA DERMATO-VENEREOLOGICA　86　(2)　161-162　2006

    DOI： 10.2340/00015555-0017 　

    ISSN： 0001-5555

  269. Generalized mucinosis in a patient with erythroderma Peer-reviewed

    T Fujimura, R Okuyama, S Nakagawa, T Terui, S Aiba

    DERMATOLOGY　212　(4)　366-369　2006

    DOI： 10.1159/000092288 　

    ISSN： 1018-8665

  270. Two cases of dermatomyositis with cytomegalovirus infection Peer-reviewed

    Akira Hashimoto, Ryuhei Okuyama, Satoshi Hasegawa, Hiroshi Watanabe, Taku Fujimura, Yutaka Kimura, Hachiro Tagami, Setsuya Aiba

    Nishinihon Journal of Dermatology　68　(3)　251-255　2006

    DOI： 10.2336/nishinihonhifu.68.251 　

    ISSN： 0386-9784

  271. Two cases of dermatomyositis with cytomegalovirus infection Peer-reviewed

    Akira Hashimoto, Ryuhei Okuyama, Satoshi Hasegawa, Hiroshi Watanabe, Taku Fujimura, Yutaka Kimura, Hachiro Tagami, Setsuya Aiba

    Nishinihon Journal of Dermatology　68　(3)　251-255　2006

    DOI： 10.2336/nishinihonhifu.68.251 　

    ISSN： 0386-9784

  272. Development of a novel Ag-specific immunotherapy using CpG oligodeoxynucleotides in a new, unique mouse cutaneous eosinophilic inflammation model Peer-reviewed

    T Kootiratrakarn, T Fujimura, K Sano, R Okuyama, S Aiba, H Tagami, T Terui

    EUROPEAN JOURNAL OF IMMUNOLOGY　35　(11)　3277-3286　2005/11

    DOI： 10.1002/eji.200526274 　

    ISSN： 0014-2980

  273. Development of a novel Ag-specific immunotherapy using CpG oligodeoxynucleotides in a new, unique mouse cutaneous eosinophilic inflammation model. Peer-reviewed

    Kootiratrakarn T, Fujimura T, Sano K, Okuyama R, Aiba S, Tagami H, Terui T

    Eur J Immunol　35　(11)　3277-3286　2005/10/24

    DOI： 10.1002/eji.200526274 　

  274. Myxofibrosarcoma (myxoid malignant fibrous histiocytoma) showing cutaneous presentation: report of two cases Peer-reviewed

    T Fujimura, R Okuyama, T Terui, K Okuno, A Masu, T Masu, S Chiba, T Kunii, H Tagami, S Aiba

    JOURNAL OF CUTANEOUS PATHOLOGY　32　(7)　512-515　2005/08

    DOI： 10.1111/j.0303-6987.2005.00368.x 　

    ISSN： 0303-6987

  275. Generation of leukemia-specific T-helper type 1 cells applicable to human leukemia cell-therapy Peer-reviewed

    T Fujimura, K Chamoto, T Tsuji, T Sato, H Yokouchi, S Aiba, H Tagami, J Tanaka, M Imamura, Y Togashi, T Koda, T Nishimura

    IMMUNOLOGY LETTERS　93　(1)　17-25　2004/04

    DOI： 10.1016/j.imlet.2004.01.013 　

    ISSN： 0165-2478

  276. Generation of leukemia-specific T-helper type 1 cells applicable to human leukemia cell-therapy Peer-reviewed

    T Fujimura, K Chamoto, T Tsuji, T Sato, H Yokouchi, S Aiba, H Tagami, J Tanaka, M Imamura, Y Togashi, T Koda, T Nishimura

    IMMUNOLOGY LETTERS　93　(1)　17-25　2004/04

    DOI： 10.1016/j.imlet.2004.01.013 　

    ISSN： 0165-2478

  277. Neurofibromatosis 1 associated with an intracranial artery abnormality, moyamoya disease and bilateral congenital large hairy pigmented macules Peer-reviewed

    T Fujimura, T Terui, Y Kusaka, H Tagami

    BRITISH JOURNAL OF DERMATOLOGY　150　(3)　611-613　2004/03

    DOI： 10.1046/j.1365-2133.2004.05819.x 　

    ISSN： 0007-0963

    eISSN： 1365-2133

  278. CCR4 expression by atypical T cells in systemic pilotropic lymphoma: Its behavior under treatment with interferon gamma, topical PUVA and systemic retinoid Peer-reviewed

    T Fujimura, S Aiba, Y Yoshino, S Kuroki, Y Kimura, K Kikuchi, T Kunii, J Matsunaga, K Matsushima, H Tagami

    DERMATOLOGY　208　(3)　221-226　2004

    DOI： 10.1159/000077303 　

    ISSN： 1018-8665

  279. 項頸部に生じた巨大頭部乳頭状皮膚炎 外科的治療法と術後管理の検討 Peer-reviewed

    藤村卓, 橋本彰, 高橋和宏, 国井隆英, 黒澤昌啓, 照井正, 田上八朗

    臨床皮膚科　57　(13)　1172-1174　2003/12

    Publisher:

    DOI： 10.11477/mf.1412101480 　

    ISSN： 0021-4973

  280. 項頸部に生じた巨大頭部乳頭状皮膚炎 外科的治療法と術後管理の検討 Peer-reviewed

    藤村卓, 橋本彰, 高橋和宏, 国井隆英, 黒澤昌啓, 照井正, 田上八朗

    臨床皮膚科　57　(13)　1172-1174　2003/04

    DOI： 10.11477/mf.1412101480 　

  281. カラーアトラス 原発部が組織学的に自然消退像を示した転移性悪性黒色腫 Peer-reviewed

    青山浩明渡部晶子, 芳賀貴浩, 藤村卓, 舩山道隆, 千葉敏彦, 豊島勝, 加藤泰三

    臨床皮膚科　57　(4)　334-335　2003/04

    DOI： 10.11477/mf.1412101198 　

  282. Disseminated papular interstitial elastolytic giant cell granuloma Peer-reviewed

    T Fujimura, T Terui, H Tagami

    ACTA DERMATO-VENEREOLOGICA　83　(3)　234-235　2003

    DOI： 10.1080/00015550310007337 　

    ISSN： 0001-5555

  283. 前頭部に生じたproliferating trichilemmal cystの1例 Ki-S5の染色態度の検討 Peer-reviewed

    藤村卓, 舩山道隆, 高橋和宏, 照井正, 田上八朗

    臨床皮膚科　56　(11)　952-954　2002/10

    Publisher:

    DOI： 10.11477/mf.1412904116 　

    ISSN： 0021-4973

  284. 上口唇に生じたintravascular papillary endothelial hyperplasiaの1例 CD34,第VIII因子の染色態度の検討 Peer-reviewed

    藤村卓, 橋本彰, 高橋和宏, 川村真樹, 照井正, 田上八朗

    臨床皮膚科　56　(1)　71-73　2002/04

    Publisher:

    DOI： 10.11477/mf.1412903826 　

    ISSN： 0021-4973

  285. 前頭部に生じたproliferating trichilemmal cystの1例 Ki-S5の染色態度の検討 Peer-reviewed

    藤村卓, 舩山道隆, 高橋和宏, 照井正, 田上八朗

    臨床皮膚科　56　(11)　952-954　2002/04

    DOI： 10.11477/mf.1412904116 　

  286. 前胸部に生じた悪性青色母斑の1例 Peer-reviewed

    藤村卓, 舩山道隆, 金生英雄, 中川聡

    皮膚科の臨床　43　(7)　863-865　2002/04

  287. 上口唇に生じたintravascular papillary endothelial hyperplasiaの1例 CD34,第VIII因子の染色態度の検討 Peer-reviewed

    藤村卓, 橋本彰, 高橋和宏, 川村真樹, 照井正, 田上八朗

    臨床皮膚科　56　(1)　71-73　2002/01

    Publisher:

    DOI： 10.11477/mf.1412903826 　

    ISSN： 0021-4973

  288. Acute hemorrhagic edema in a four-year-old Japanese boy Peer-reviewed

    T Fujimura, M Funayama, H Tagami

    JOURNAL OF DERMATOLOGY　28　(5)　279-281　2001/05

    ISSN： 0385-2407

  289. Erythematous swelling of the lip associated with Sjogren's syndrome and mimicking cheilitis granulomatosa Peer-reviewed

    T Fujimura, S Aiba, T Suetake, H Tagami

    JOURNAL OF DERMATOLOGY　28　(1)　47-49　2001/01

    ISSN： 0385-2407

Show all ︎Show first 5

Misc. 137

  1. モガムリズマブ療法後のエトポシド療法が著効した皮膚T細胞リンパ腫の3例

    大内 謙太郎, 藤村 卓, 神林 由美, 佐藤 遥太, 谷田 佳世, 武田 佳奈, 橋本 彰, 相場 節也

    日本皮膚科学会雑誌　129　(9)　1913-1913　2019/08

    Publisher: (公社)日本皮膚科学会

    ISSN： 0021-499X

  2. 日本皮膚科学会ガイドライン 皮膚悪性腫瘍ガイドライン第3版 メラノーマ診療ガイドライン2019

    中村 泰大, 浅井 純, 井垣 浩, 猪爪 隆史, 並川 健二郎, 林 礼人, 福島 聡, 藤村 卓, 伊東 孝通, 今福 惠輔, 田中 亮多, 寺本 由紀子, 皆川 茜, 宮川 卓也, 宮下 梓, 和田 誠, 古賀 弘志, 菅谷 誠, 公益社団法人日本皮膚科学会, 一般社団法人日本皮膚悪性腫瘍学会, 皮膚悪性腫瘍診療ガイドライン改訂委員会(メラノーマ診療ガイドライングループ)

    日本皮膚科学会雑誌　129　(9)　1759-1843　2019/08

    Publisher: (公社)日本皮膚科学会

    ISSN： 0021-499X

    eISSN： 1346-8146

  3. イピリムマブ・低線量放射線併用療法が有効であった抗PD-1抗体抵抗性根治切除不能悪性黒色腫の2例

    天貝 諒, 藤村 卓, 神林 由美, 佐藤 遥太, 谷田 佳世, 遠野 久幸, 橋本 彰, 相場 節也

    西日本皮膚科　81　(3)　250-250　2019/06

    Publisher: 日本皮膚科学会-西部支部

    ISSN： 0386-9784

  4. 進行期悪性黒色腫の抗PD1抗体治療における効果予測システムの開発

    藤村 卓, 佐藤 遥太, 谷田 佳世, 神林 由美, 大塚 篤司, 藤澤 康弘, 吉野 公二, 松下 茂人, 日高 高徳, 相場 節也

    日本皮膚科学会雑誌　129　(5)　1176-1176　2019/05

    Publisher: (公社)日本皮膚科学会

    ISSN： 0021-499X

  5. 右鼻腔悪性黒色腫の術後再発に対してペンブロリズマブが奏効した1例

    入間田 萌花, 藤村 卓, 神林 由美, 佐藤 遥太, 谷田 佳世, 遠野 久幸, 橋本 彰, 相場 節也

    日本皮膚悪性腫瘍学会学術大会プログラム・抄録集　35回　125-125　2019/04

    Publisher: (一社)日本皮膚悪性腫瘍学会

  6. 血清因子による抗PD1抗体治療効果予測法の開発

    藤村 卓, 佐藤 遥太, 谷田 佳世, 神林 由美, 大塚 篤司, 藤澤 康弘, 吉野 公二, 松下 茂人, 日高 高徳, 相場 節也

    日本皮膚悪性腫瘍学会学術大会プログラム・抄録集　35回　160-160　2019/04

    Publisher: (一社)日本皮膚悪性腫瘍学会

  7. 適正使用の手引き モガムリズマブ(遺伝子組換え)製剤の皮膚リンパ腫使用に係る指針

    戸倉 新樹, 宮垣 朝光, 米倉 健太郎, 藤村 卓, 阿部 理一郎, 菅谷 誠, 日本皮膚科学会皮膚リンパ腫治療安全性検討Working Group

    日本皮膚科学会雑誌　129　(3)　331-332　2019/03

    Publisher: (公社)日本皮膚科学会

    ISSN： 0021-499X

    eISSN： 1346-8146

  8. 進化し続ける悪性黒色腫の治療 理想的免疫療法をめざして

    藤村 卓

    Skin Cancer　33　(2)　112-115　2018/10

    Publisher: (一社)日本皮膚悪性腫瘍学会

    ISSN： 0915-3535

  9. CD56陽性皮膚T細胞リンパ腫6例の後方視的解析(A clinicopathological analysis of CD56-positive cutaneous T cell lymphoma)

    大地 哲朗, 福原 規子, 佐野 沙矢香, 那須 健太郎, 小林 匡洋, 市川 聡, 沖津 庸子, 大西 康, 藤原 実名美, 藤村 卓, 一迫 玲, 張替 秀郎

    臨床血液　59　(9)　1549-1549　2018/09

    Publisher: (一社)日本血液学会-東京事務局

    ISSN： 0485-1439

    eISSN： 1882-0824

  10. CD56陽性皮膚T細胞リンパ腫6例の後方視的解析(A clinicopathological analysis of CD56-positive cutaneous T cell lymphoma)

    大地 哲朗, 福原 規子, 佐野 沙矢香, 那須 健太郎, 小林 匡洋, 市川 聡, 沖津 庸子, 大西 康, 藤原 実名美, 藤村 卓, 一迫 玲, 張替 秀郎

    臨床血液　59　(9)　1549-1549　2018/09

    Publisher: (一社)日本血液学会-東京事務局

    ISSN： 0485-1439

  11. 【アトピーとリンフォーマの接点】 微小環境から考えるアトピーと皮膚T細胞リンパ腫の共通点

    藤村 卓

    皮膚アレルギーフロンティア　16　(2)　79-82　2018/07

    Publisher: (株)メディカルレビュー社

    ISSN： 1348-7280

  12. モガムリズマブ投与後の局所サイバーナイフが著効した毛包向性菌状息肉症の1例

    谷田 佳世, 藤村 卓, 佐藤 遥太, 日高 高徳, 古舘 禎騎, 神林 由美, 橋本 彰, 相場 節也

    西日本皮膚科　80　(3)　284-284　2018/06

    Publisher: 日本皮膚科学会-西部支部

    ISSN： 0386-9784

  13. メルケル細胞癌におけるpSTAT5B発現意義の検討

    佐藤 遥太, 藤村 卓, 古舘 禎騎, 神林 由美, 山本 有紀, 藤本 徳毅, 相場 節也

    西日本皮膚科　80　(3)　275-275　2018/06

    Publisher: 日本皮膚科学会-西部支部

    ISSN： 0386-9784

  14. メルケル細胞癌におけるpSTAT5B発現意義の検討

    佐藤 遥太, 藤村 卓, 古舘 禎騎, 神林 由美, 山本 有紀, 藤本 徳毅, 相場 節也

    西日本皮膚科　80　(3)　275-275　2018/06

    Publisher: 日本皮膚科学会-西部支部

    ISSN： 0386-9784

    eISSN： 1880-4047

  15. モガムリズマブ投与後の局所サイバーナイフが著効した毛包向性菌状息肉症の1例

    谷田 佳世, 藤村 卓, 佐藤 遥太, 日高 高徳, 古舘 禎騎, 神林 由美, 橋本 彰, 相場 節也

    西日本皮膚科　80　(3)　284-284　2018/06

    Publisher: 日本皮膚科学会-西部支部

    ISSN： 0386-9784

    eISSN： 1880-4047

  16. ダブラフェニブ・トラメチニブ療法中に生じた重症多形滲出性紅斑の1例

    神林 由美, 藤村 卓, 水芦 政人, 日高 高徳, 遠野 久幸, 大竹 映香, 玉渕 恵里佳, 中嶋 夏磯, 佐々木 留伊, 相場 節也

    西日本皮膚科　80　(3)　291-291　2018/06

    Publisher: 日本皮膚科学会-西部支部

    ISSN： 0386-9784

  17. アブスコパル効果とその周辺 進化し続ける悪性黒色腫の治療 理想的免疫療法をめざして

    藤村 卓

    日本皮膚悪性腫瘍学会学術大会プログラム・抄録集　34回　76-76　2018/06

    Publisher: (一社)日本皮膚悪性腫瘍学会

  18. モガムリズマブで治療したCCR4陽性菌状息肉症の3例

    谷田 佳世, 藤村 卓, 神林 由美, 佐藤 遥太, 遠野 久幸, 塚田 全, 橋本 彰, 相場 節也

    日本皮膚悪性腫瘍学会学術大会プログラム・抄録集　34回　130-130　2018/06

    Publisher: (一社)日本皮膚悪性腫瘍学会

  19. イピリムマブ、イミキモド併用療法が著効を示した悪性黒色腫多発in-transit転移の1例

    大内 謙太郎, 藤村 卓, 神林 由美, 佐藤 遥太, 谷田 佳世, 塚田 全, 遠野 久幸, 橋本 彰, 相場 節也

    日本皮膚悪性腫瘍学会学術大会プログラム・抄録集　34回　141-141　2018/06

    Publisher: (一社)日本皮膚悪性腫瘍学会

  20. 東北大学におけるニボルマブ、ダブラフェニブ・トラメチニブ連続投与が著効した悪性黒色腫の4例

    佐藤 遥太, 藤村 卓, 谷田 佳世, 神林 由美, 塚田 全, 遠野 久幸, 橋本 彰, 相場 節也

    日本皮膚悪性腫瘍学会学術大会プログラム・抄録集　34回　147-147　2018/06

    Publisher: (一社)日本皮膚悪性腫瘍学会

  21. 盲腸癌を合併した浸潤性乳房外パジェット病の1例

    神林 由美, 藤村 卓, 大内 謙太郎, 佐々木 留伊, 大竹 映香, 遠野 久幸, 浅野 雅之, 相場 節也

    日本皮膚悪性腫瘍学会学術大会プログラム・抄録集　34回　176-176　2018/06

    Publisher: (一社)日本皮膚悪性腫瘍学会

  22. ペンプロリズマブ投与後に白斑が拡大し,色素異常性固定紅斑が消退した1例

    武田 佳奈, 土山 健一郎, 藤村 卓, 相場 節也

    日本皮膚科学会雑誌　128　(5)　1213-1213　2018/05

    Publisher: (公社)日本皮膚科学会

    ISSN： 0021-499X

  23. ニボルマブ治療後にイピリムマブ治療を受けた進行期悪性黒色腫症例60例の後ろ向き臨床研究

    吉野 公二, 藤澤 康弘, 大塚 篤司, 舩越 建, 内 博史, 藤村 卓, 松下 茂人, 秦 洋郎, 山本 有紀, Japan Skin Cancer Network, JSCa

    日本皮膚科学会雑誌　128　(5)　1231-1231　2018/05

    Publisher: (公社)日本皮膚科学会

    ISSN： 0021-499X

  24. 投与前の好中球/リンパ球比と血清LDH値はニボルマブによる治療結果と相関する

    藤澤 康弘, 吉野 公二, 大塚 篤司, 舩越 建, 藤村 卓, 山本 有紀, 秦 洋郎, 松下 茂人

    日本皮膚科学会雑誌　128　(5)　1231-1231　2018/05

    Publisher: (公社)日本皮膚科学会

    ISSN： 0021-499X

  25. 免疫チェックポイント阻害薬による免疫関連副作用の予測システムの開発

    藤村 卓, 佐藤 遥太, 谷田 佳世, 神林 由美, 大塚 篤司, 藤澤 康弘, 吉野 公二, 松下 茂人, 舩越 建, 相場 節也

    日本皮膚科学会雑誌　128　(5)　1231-1231　2018/05

    Publisher: (公社)日本皮膚科学会

    ISSN： 0021-499X

  26. 非侵襲熱物性計測による皮膚腫瘍の早期診断手法の開発

    佐藤 遥太, 藤村 卓, 岡部 孝裕, 谷田 佳世, 神林 由美, 圓山 重直, 相場 節也

    日本皮膚科学会雑誌　128　(5)　1232-1232　2018/05

    Publisher: (公社)日本皮膚科学会

    ISSN： 0021-499X

  27. ニボルマブ,ダブラフェニブ+トラメチニブの連続投与によりぶどう膜炎を生じた悪性黒色腫の2例

    谷田 佳世, 藤村 卓, 神林 由美, 武田 佳奈, 遠野 久幸, 佐藤 遥太, 塚田 全, 橋本 彰, 大友 孝昭, 相場 節也

    日本皮膚科学会雑誌　128　(5)　1233-1233　2018/05

    Publisher: (公社)日本皮膚科学会

    ISSN： 0021-499X

    eISSN： 1346-8146

  28. がん治療をリードする皮膚腫瘍学:全てのがんの克服を目指して 進化する悪性黒色腫治療 複合免疫療法の可能性

    藤村 卓

    日本臨床皮膚科医会雑誌　35　(2)　269-269　2018/04

    Publisher: 日本臨床皮膚科医会

    ISSN： 1349-7758

  29. 東北大学皮膚科における皮膚T細胞リンパ腫に対するベキサロテン使用経験

    佐藤 遥太, 藤村 卓, 谷田 佳世, 神林 由美, 橋本 彰, 相場 節也

    日本臨床皮膚科医会雑誌　35　(2)　387-387　2018/04

    Publisher: 日本臨床皮膚科医会

    ISSN： 1349-7758

  30. 悪性黒色腫の骨転移に対してデノスマブが有効であった1例

    秦 洋郎, 前田 拓哉, 今福 恵輔, 北村 真也, 柳 輝希, 藤村 卓, 清水 宏

    日本臨床皮膚科医会雑誌　35　(2)　388-388　2018/04

    Publisher: 日本臨床皮膚科医会

    ISSN： 1349-7758

    eISSN： 1882-272X

  31. 非侵襲熱物性計測による悪性黒色腫の早期診断手法の開発

    藤村 卓, 岡部 孝裕, 神林 由美, 佐藤 遥太, 谷田 佳世, 圓山 重直, 相場 節也

    日本臨床皮膚科医会雑誌　35　(2)　389-389　2018/04

    Publisher: 日本臨床皮膚科医会

    ISSN： 1349-7758

  32. 乳癌術後放射線療法後に生じた胸部血管肉腫の1例

    武田 佳奈, 藤村 卓, 山崎 絵美, 八丁目 直和, 塚田 全, 土山 健一郎, 橋本 彰, 相場 節也

    日本臨床皮膚科医会雑誌　35　(2)　390-390　2018/04

    Publisher: 日本臨床皮膚科医会

    ISSN： 1349-7758

  33. ベキサロテンで寛解維持中のリンパ腫様丘疹症の1例

    武田 佳奈, 藤村 卓, 古舘 禎騎, 神林 由美, 日高 高徳, 谷田 佳世, 佐藤 遥太, 塚田 全, 橋本 彰, 相場 節也

    日本皮膚科学会雑誌　128　(3)　429-429　2018/03

    Publisher: (公社)日本皮膚科学会

    ISSN： 0021-499X

    eISSN： 1346-8146

  34. 皮膚悪性リンパ腫が疑われた、ケラトアカントーマの1例

    天貝 諒, 古舘 禎騎, 山下 千佳紗, 武田 佳奈, 山崎 絵美, 玉渕 めい, 土山 健一郎, 浅野 雅之, 藤村 卓, 橋本 彰, 菊地 克子, 相場 節也

    日本皮膚科学会雑誌　128　(2)　233-233　2018/02

    Publisher: (公社)日本皮膚科学会

    ISSN： 0021-499X

    eISSN： 1346-8146

  35. 当科における皮膚T細胞リンパ腫に対するベキサロテン使用経験

    藤村 卓, 谷田 佳世, 佐藤 遥太, 古館 禎騎, 神林 由美, 橋本 彰, 相場 節也

    日本皮膚科学会雑誌　128　(1)　60-60　2018/01

    Publisher: (公社)日本皮膚科学会

    ISSN： 0021-499X

  36. Non-Invasive Detection of Skin Tumor by Thermal Conductivity Measurement: Experiments on a Skin Mimicking Phantom

    K. Kudo, T. Okabe, K. Fumoto, J. Okajima, T. Fujimura, M. Shirota, T. Inamura, S. Aiba, S. Maruyama

    Proceedings of 14th International Conference on Flow Dynamics　806-807　2017/11

  37. 皮膚リンパ腫は難しくない 進化する皮膚T細胞リンパ腫の治療 治療選択における免疫学的背景の重要性

    藤村 卓

    日本臨床皮膚科医会雑誌　34　(6)　726-731　2017/11

    Publisher: 日本臨床皮膚科医会

    ISSN： 1349-7758

  38. Safety dose and prediction of immune-related adverse event of nivolumab combined with IFN-beta in patients with advanced melanoma

    T. Fujimura, Y. Kambayashi, S. Furudate, T. Hidaka, K. Tanita, Y. Sato, S. Aiba

    JOURNAL OF INVESTIGATIVE DERMATOLOGY　137　(10)　S282-S282　2017/10

    ISSN： 0022-202X

    eISSN： 1523-1747

  39. Immunomodulatory effects of bexarotene on tumor-associated macrophages in patients with mycosis fungoides

    K. Tanita, T. Fujimura, Y. Sato, C. Lyu, Y. Kambayashi, S. Furudate, S. Aiba

    JOURNAL OF INVESTIGATIVE DERMATOLOGY　137　(10)　S291-S291　2017/10

    ISSN： 0022-202X

    eISSN： 1523-1747

  40. ニボルマブ抵抗性悪性黒色腫に対するイピリムマブの効果

    内 博史, 藤澤 康弘, 吉野 公二, 大塚 篤司, 舩越 建, 藤村 卓, 松下 茂人, 山本 有紀, 秦 洋郎

    日本癌治療学会学術集会抄録集　55回　P122-5　2017/10

    Publisher: (一社)日本癌治療学会

  41. 悪性黒色腫の治療 複合がん免疫療法とその可能性

    藤村 卓

    Skin Cancer　32　(2)　106-111　2017/10

    Publisher: (一社)日本皮膚悪性腫瘍学会

    DOI： 10.5227/skincancer.32.106 　

    ISSN： 0915-3535

  42. Amelanotic primary dermal melanoma with V600E BRAF mutation

    Miho Kabuto, Noriki Fujimoto, Kazuya Teramura, Takeshi Nakanishi, Taku Fujimura, Toshiaki Manabe, Toshihiro Tanaka

    DERMATOLOGICA SINICA　35　(2)　110-111　2017/06

    DOI： 10.1016/j.dsi.2016.10.001 　

    ISSN： 1027-8117

    eISSN： 2223-330X

  43. 悪性黒色腫治療の過去、現在そして未来

    藤村 卓

    Skin Surgery　26　(2)　65-72　2017/06

    Publisher: 日本臨床皮膚外科学会

    ISSN： 0918-9688

  44. 36 gamma stimulates tumor-associated macrophages to recruit IL-17 producing cells in cutaneous squamous cell carcinoma

    Y. Sato, T. Fujimura, K. Tanita, C. Lyu, T. Yamauchi, S. Aiba

    JOURNAL OF INVESTIGATIVE DERMATOLOGY　137　(5)　S19-S19　2017/05

    ISSN： 0022-202X

    eISSN： 1523-1747

  45. Phase I study of the nivolumab combined with IFN-B in patients with advanced melanoma

    T. Fujimura, Y. Kambayashi, S. Furudate, T. Hidaka, S. Aiba

    JOURNAL OF INVESTIGATIVE DERMATOLOGY　137　(5)　S48-S48　2017/05

    ISSN： 0022-202X

    eISSN： 1523-1747

  46. 悪性黒色腫 複合がん免疫療法の模索

    藤村 卓

    日本皮膚科学会雑誌　127　(6)　1351-1351　2017/05

    Publisher: (公社)日本皮膚科学会

    ISSN： 0021-499X

  47. 自己免疫性水疱症におけるペリオスチンとマクロファージの役割

    柿崎 彩, 藤村 卓, 古舘 禎騎, 相場 節也

    日本皮膚科学会雑誌　127　(6)　1376-1376　2017/05

    Publisher: (公社)日本皮膚科学会

    ISSN： 0021-499X

    eISSN： 1346-8146

  48. 悪性黒色腫の治療 複合がん免疫療法とその可能性

    藤村 卓

    日本皮膚悪性腫瘍学会学術大会プログラム・抄録集　33回　67-67　2017/05

    Publisher: (一社)日本皮膚悪性腫瘍学会

  49. ダブラフェニブ+トラメチニブ併用療法が著効した悪性黒色腫胆嚢転移の1例

    谷田 佳世, 藤村 卓, 遠野 久幸, 佐藤 遥太, 日高 高徳, 古舘 禎騎, 神林 由美, 塚田 全, 橋本 彰, 相場 節也

    日本皮膚悪性腫瘍学会学術大会プログラム・抄録集　33回　157-157　2017/05

    Publisher: (一社)日本皮膚悪性腫瘍学会

  50. BRAF阻害剤により角化性結節と掌蹠角化症が出現しBRAF/MEK阻害剤変更後に消退傾向を示した悪性黒色腫の1例

    古舘 禎騎, 藤村 卓, 遠野 久幸, 玉渕 めい, 神林 由美, 橋本 彰, 相場 節也

    日本皮膚悪性腫瘍学会学術大会プログラム・抄録集　33回　163-163　2017/05

    Publisher: (一社)日本皮膚悪性腫瘍学会

  51. Chemoradiotherapyが著効したRANKL陽性陰部アポクリン腺癌の1例

    塚田 全, 藤村 卓, 佐藤 遥太, 大竹 映香, 古舘 禎騎, 土山 健一郎, 芳賀 貴裕, 橋本 彰, 相場 節也, 齋藤 涼子

    日本皮膚悪性腫瘍学会学術大会プログラム・抄録集　33回　191-191　2017/05

    Publisher: (一社)日本皮膚悪性腫瘍学会

  52. 悪性黒色腫 新たな複合がん免疫療法の開発

    藤村 卓

    日本皮膚科学会雑誌　127　(5)　1072-1072　2017/05

    Publisher: (公社)日本皮膚科学会

    ISSN： 0021-499X

  53. 東北大学で施行した進行期悪性黒色腫に対するイピリムマブ投与7症例の検討

    古舘 禎騎, 藤村 卓, 神林 由美, 塚田 全, 遠野 久幸, 日高 高徳, 佐藤 遥太, 谷田 佳世, 橋本 彰, 相場 節也

    日本皮膚科学会雑誌　127　(5)　1140-1140　2017/05

    Publisher: (公社)日本皮膚科学会

    ISSN： 0021-499X

    eISSN： 1346-8146

  54. ベムラフェニブ・ラッシュに発症したケラトアカントーマの1例 その免疫学的背景の検討

    佐藤 遥太, 藤村 卓, 谷田 佳世, 古舘 禎騎, 神林 由美, 日高 高徳, 遠野 久幸, 塚田 全, 橋本 彰, 相場 節也

    日本皮膚科学会雑誌　127　(5)　1142-1142　2017/05

    Publisher: (公社)日本皮膚科学会

    ISSN： 0021-499X

    eISSN： 1346-8146

  55. ベキサロテンが著効した魚鱗癬様皮疹を呈する皮膚末梢T細胞リンパ腫の1例

    谷田 佳世, 藤村 卓, 遠野 久幸, 佐藤 遥太, 日高 高徳, 古舘 禎騎, 神林 由美, 塚田 全, 橋本 彰, 相場 節也

    日本皮膚科学会雑誌　127　(5)　1151-1151　2017/05

    Publisher: (公社)日本皮膚科学会

    ISSN： 0021-499X

    eISSN： 1346-8146

  56. 皮膚リンパ腫は難しくない 進化する皮膚T細胞リンパ腫の治療 治療選択における免疫学的背景の重要性

    藤村 卓

    日本臨床皮膚科医会雑誌　34　(2)　215-215　2017/04

    Publisher: 日本臨床皮膚科医会

    ISSN： 1349-7758

  57. 話題のくすり イピリムマブ 悪性黒色腫に対する有効性

    藤村 卓

    日本病院薬剤師会雑誌　53　(4)　480-483　2017/04

    Publisher: (一社)日本病院薬剤師会

    ISSN： 1341-8815

  58. シスプラチンとドキソルビシン併用による化学療法と放射線治療の併用により陰茎を温存できた陰茎基部有棘細胞癌の1例

    志藤 光介, 浅野 雅之, 沼田 透効, 芳賀 貴裕, 橋本 彰, 藤村 卓, 相場 節也

    臨床皮膚科　71　(3)　250-254　2017/03

    Publisher: (株)医学書院

    ISSN： 0021-4973

  59. 悪性黒色腫に対する化学療法薬が腫瘍免疫に与える影響

    柿崎 彩, 藤村 卓, 古舘 禎騎, 神林 由美, 日高 高徳, 佐藤 遥太, 谷田 佳世, 相場 節也

    日本皮膚科学会雑誌　127　(2)　210-210　2017/02

    Publisher: (公社)日本皮膚科学会

    ISSN： 0021-499X

    eISSN： 1346-8146

  60. 根治切除不能悪性黒色腫16例に対するニボルマブの使用経験

    藤村 卓, 古舘 禎騎, 神林 由美, 日高 高徳, 佐藤 遥太, 谷田 佳世, 遠野 久幸, 塚田 全, 芳賀 貴裕, 橋本 彰, 相場 節也

    日本皮膚科学会雑誌　127　(2)　227-227　2017/02

    Publisher: (公社)日本皮膚科学会

    ISSN： 0021-499X

    eISSN： 1346-8146

  61. Acral lentigenous melanoma developing from the skin of bullous congenital ichthyosiform erythroderma

    Yusuke Muto, Taku Fujimura, Aya Kakizaki, Hisayuki Tono, Kenichiro Tsuchiyama, Setsuya Aiba

    DERMATOLOGICA SINICA　34　(4)　219-220　2016/12

    DOI： 10.1016/j.dsi.2016.05.002 　

    ISSN： 1027-8117

    eISSN： 2223-330X

  62. 頭頸部メルケル細胞癌の放射線治療経験

    山本 貴也, 角谷 倫之, 松下 晴雄, 藤村 卓, 片桐 佑, 福井 勝哉, 中島 祐二朗, 久保園 正樹, 佐藤 清和, 武田 賢, 相場 節也, 神宮 啓一

    臨床放射線　61　(13)　1781-1786　2016/12

    Publisher: 金原出版(株)

    ISSN： 0009-9252

  63. 頭部瘢痕性脱毛に有棘細胞癌を多発した若年性皮膚筋炎の一例

    佐藤 遥太, 神林 由美, 塚田 全, 藤村 卓, 芳賀 貴裕, 菊地 克子, 相場 節也, 萩野谷 和裕

    Journal of Environmental Dermatology and Cutaneous Allergology　10　(4)　460-460　2016/10

    Publisher: (一社)日本皮膚アレルギー・接触皮膚炎学会

    ISSN： 1882-0123

  64. IFN-beta augments the anti-tumor effects of PD-1 Abs in melanoma: the possible immunotherapy for metastatic melanoma

    A. Kakizaki, T. Fujimura, S. Furudate, Y. Kambayashi, S. Aiba

    JOURNAL OF INVESTIGATIVE DERMATOLOGY　136　(9)　S238-S238　2016/09

    ISSN： 0022-202X

    eISSN： 1523-1747

  65. A possible interaction between periostin and CD163+skin-resident macrophages in pemphigus vulgaris and bullous pemphigoid

    T. Fujimura, A. Kakizaki, S. Furudate, S. Aiba

    JOURNAL OF INVESTIGATIVE DERMATOLOGY　136　(9)　S204-S204　2016/09

    ISSN： 0022-202X

    eISSN： 1523-1747

  66. ニボルマブ、イピリムマブ連続投与が著効した転移性悪性黒色腫の1例

    古舘 禎騎, 藤村 卓, 神林 由美, 日高 高徳, 遠野 久幸, 塚田 全, 浅野 雅之, 芳賀 貴裕, 橋本 彰, 相場 節也

    日本皮膚科学会雑誌　126　(9)　1728-1728　2016/08

    Publisher: (公社)日本皮膚科学会

    ISSN： 0021-499X

    eISSN： 1346-8146

  67. 隆起性皮膚線維肉腫におけるcancer stromaの検討

    佐藤 遥太, 藤村 卓, 柿崎 彩, 古舘 禎騎, 相場 節也

    日本皮膚科学会雑誌　126　(5)　957-957　2016/05

    Publisher: (公社)日本皮膚科学会

    ISSN： 0021-499X

    eISSN： 1346-8146

  68. 悪性黒色腫治療戦略 更なる発展のために

    藤村 卓

    日本皮膚悪性腫瘍学会学術大会プログラム・抄録集　32回　100-100　2016/05

    Publisher: (一社)日本皮膚悪性腫瘍学会

  69. 悪性黒色腫に対する抗PD-1抗体、IFN-β併用療法の可能性

    柿崎 彩, 藤村 卓, 古舘 禎騎, 神林 由美, 相場 節也

    日本皮膚悪性腫瘍学会学術大会プログラム・抄録集　32回　120-120　2016/05

    Publisher: (一社)日本皮膚悪性腫瘍学会

  70. 菌状息肉症における腫瘍随伴性マクロファージの役割

    古舘 禎騎, 藤村 卓, 柿崎 彩, 神林 由美, 浅野 雅之, 相場 節也

    日本皮膚悪性腫瘍学会学術大会プログラム・抄録集　32回　130-130　2016/05

    Publisher: (一社)日本皮膚悪性腫瘍学会

  71. 乳房外パジェット病における免疫寛容のメカニズム

    神林 由美, 藤村 卓, 古舘 禎騎, 浅野 雅之, 日高 高徳, 柿崎 彩, 相場 節也

    日本皮膚悪性腫瘍学会学術大会プログラム・抄録集　32回　139-139　2016/05

    Publisher: (一社)日本皮膚悪性腫瘍学会

  72. 進化する悪性黒色腫治療戦略 基礎から臨床へ

    藤村 卓

    Skin Surgery　25　(1)　35-35　2016/02

    Publisher: 日本臨床皮膚外科学会

    ISSN： 0918-9688

  73. Comment: Clinical Pathology Correlation: Clinical First, then Pathology, and Lastly Immunochemistry Response

    Taku Fujimura

    ACTA DERMATO-VENEREOLOGICA　96　(4)　573-573　2016

    ISSN： 0001-5555

    eISSN： 1651-2057

  74. 水疱性類天疱瘡治療薬のCD163+CD206+Arginase1+M2マクロファージへの影響の検討

    柿崎 彩, 藤村 卓, 古舘 禎騎, 相場 節也

    Journal of Environmental Dermatology and Cutaneous Allergology　9　(5)　470-470　2015/11

    Publisher: (一社)日本皮膚アレルギー・接触皮膚炎学会

    ISSN： 1882-0123

  75. 表皮細胞におけるpSTAT染色パターンからみる炎症性皮膚疾患

    神林 由美, 藤村 卓, 浅野 雅之, 柿崎 彩, 相場 節也

    Journal of Environmental Dermatology and Cutaneous Allergology　9　(5)　471-471　2015/11

    Publisher: (一社)日本皮膚アレルギー・接触皮膚炎学会

    ISSN： 1882-0123

  76. Hypopigmented mycosis fungoidesの1例 その免疫学的背景の解析

    玉渕 めい, 藤村 卓, 柿崎 彩, 志藤 光介, 八丁目 直和, 草刈 良之, 相場 節也

    Skin Cancer　30　(2)　144-144　2015/11

    Publisher: (一社)日本皮膚悪性腫瘍学会

    DOI： 10.5227/skincancer.30.144 　

    ISSN： 0915-3535

  77. Aryl hydrocarbon receptor activation at keratinocyte leads to atopic dermatitis-like lesion via artemin induction

    T. Hidaka, E. Ogawa, E. Kobayashi, T. Suzuki, T. Fujimura, S. Aiba, R. Okuyama, M. Yamamoto

    JOURNAL OF INVESTIGATIVE DERMATOLOGY　135　S2-S2　2015/09

    ISSN： 0022-202X

    eISSN： 1523-1747

  78. Topical administration of imiquimod modifies the profiles of tumor-associated macrophages in B16F10 melanomas.

    T. Fujimura, S. Furudate, Y. Kambayashi, A. Kakizaki, S. Aiba

    JOURNAL OF INVESTIGATIVE DERMATOLOGY　135　S22-S22　2015/09

    ISSN： 0022-202X

    eISSN： 1523-1747

  79. Tumor-associated macrophages and stromal factors play roles in developing mycosis fungoides in the different stages

    S. Furudate, T. Fujimura, A. Kakizaki, Y. Kambayashi, S. Aiba

    JOURNAL OF INVESTIGATIVE DERMATOLOGY　135　S78-S78　2015/09

    ISSN： 0022-202X

    eISSN： 1523-1747

  80. M２マクロファージ：皮膚疾患における役割

    藤村 卓

    皮膚病診療　37　(8)　733-738　2015/08/01

    Publisher: 丸善出版

    ISSN： 0387-7531

  81. Hypopigmented mycosis fungoidesの一例 その免疫学的背景の解析

    玉渕 めい, 藤村 卓, 柿崎 彩, 志藤 光介, 八丁目 直和, 草刈 良之, 相場 節也

    日本皮膚悪性腫瘍学会学術大会プログラム・抄録集　31回　127-127　2015/07

    Publisher: (一社)日本皮膚悪性腫瘍学会

  82. 根治切除不能悪性黒色腫8例に対する抗PD-1抗体の使用経験

    藤村 卓, 古舘 禎騎, 神林 由美, 志藤 光介, 芳賀 貴裕, 橋本 彰, 相場 節也

    日本皮膚悪性腫瘍学会学術大会プログラム・抄録集　31回　144-144　2015/07

    Publisher: (一社)日本皮膚悪性腫瘍学会

  83. 乳房外パジェット病治療における抗RANKL抗体製剤の可能性

    神林 由美, 藤村 卓, 古舘 禎騎, 浅野 雅之, 柿崎 彩, 相場 節也

    日本皮膚悪性腫瘍学会学術大会プログラム・抄録集　31回　154-154　2015/07

    Publisher: (一社)日本皮膚悪性腫瘍学会

  84. PORCN遺伝子異常を認めたGoltz症候群の1例

    浅野 雅之, 藤村 卓, 涌澤 千尋, 菊地 克子, 山崎 研志, 相場 節也, 齋藤 牧子

    日本皮膚科学会雑誌　125　(7)　1433-1433　2015/06

    Publisher: (公社)日本皮膚科学会

    ISSN： 0021-499X

  85. 自然消退傾向を示した鼻尖部Peripheral T cell lymphomaの1例

    柿崎 彩, 藤村 卓, 沼田 郁子, 橋本 彰, 相場 節也

    日本皮膚科学会雑誌　125　(7)　1434-1434　2015/06

    Publisher: (公社)日本皮膚科学会

    ISSN： 0021-499X

  86. Granulomatous pigmented purpuric dermatosisの1例

    涌澤 千尋, 藤村 卓, 芳賀 貴裕, 相場 節也

    日本皮膚科学会雑誌　125　(7)　1435-1435　2015/06

    Publisher: (公社)日本皮膚科学会

    ISSN： 0021-499X

  87. 4mmデルマパンチによる皮膚生検で診断できたIntravascular large B cell lymphomaの1例

    柿崎 彩, 藤村 卓, 島田 遼子, 水芦 政人, 菊地 克子, 相場 節也, 日高 高徳

    日本皮膚科学会雑誌　125　(7)　1436-1436　2015/06

    Publisher: (公社)日本皮膚科学会

    ISSN： 0021-499X

  88. 生涯、襁褓を着用してきた中年女性の外陰部に生じていた多発性表皮嚢腫

    田上 八朗, 岩崎 鋼, 藤村 卓

    日本皮膚科学会雑誌　125　(7)　1439-1439　2015/06

    Publisher: (公社)日本皮膚科学会

    ISSN： 0021-499X

  89. 特発性後天性全身性無汗症に免疫学的考察を加えた1例

    岩間 英明, 藤村 卓, 谷田 佳世, 石橋 昌也, 芳賀 貴裕, 渡部 晶子, 相場 節也

    日本皮膚科学会雑誌　125　(7)　1446-1446　2015/06

    Publisher: (公社)日本皮膚科学会

    ISSN： 0021-499X

  90. 痒疹様の皮疹を呈したランゲルハンス細胞組織球症の1例

    遠野 久幸, 藤村 卓, 石橋 昌也, 相場 節也

    日本皮膚科学会雑誌　125　(7)　1447-1447　2015/06

    Publisher: (公社)日本皮膚科学会

    ISSN： 0021-499X

  91. BRAF V600E遺伝子変異を認めたmulti-spotted malignant melanoma in situの1例

    岩間 英明, 藤村 卓, 高橋 隼也, 古舘 禎騎, 神林 由美, 柿崎 彩, 草刈 良之, 芳賀 貴裕, 橋本 彰, 相場 節也

    日本皮膚科学会雑誌　125　(4)　941-941　2015/04

    Publisher: (公社)日本皮膚科学会

    ISSN： 0021-499X

    eISSN： 1346-8146

  92. Isolated collagenomaの1例とその免疫組織学的所見

    高橋 隼也, 藤村 卓, 神林 由美, 沼田 透効, 相場 節也

    日本皮膚科学会雑誌　125　(4)　928-928　2015/04

    Publisher: (公社)日本皮膚科学会

    ISSN： 0021-499X

  93. CD30+ lymphoporliferative disorderにおける腫瘍内浸潤マクロファージの検討

    藤村 卓, 柿崎 彩, 古舘 禎騎, 神林 由美, 相場 節也

    皮膚の科学　14　(1)　45-45　2015/02

    Publisher: 日本皮膚科学会-大阪地方会・京滋地方会

    ISSN： 1347-1813

    eISSN： 1883-9614

  94. Receptor activator of nuclear factor kappa-B ligand (RANKL) promotes the recruitment of regulatory T cells (Tregs) through M2 macrophages in extramammary Paget's disease

    Y. Kambayashi, T. Fujimura, S. Furudate, M. Asano, A. Kakizaki, S. Aiba

    JOURNAL OF INVESTIGATIVE DERMATOLOGY　134　S74-S74　2014/09

    ISSN： 0022-202X

    eISSN： 1523-1747

  95. Receptor activator of nuclear factor kappa-B ligand (RANKL)/RANK signaling promotes cancer-related inflammation through M2 macrophages

    T. Fujimura, Y. Kambayashi, S. Furudate, A. Kakizaki, M. Asano, S. Aiba

    JOURNAL OF INVESTIGATIVE DERMATOLOGY　134　S74-S74　2014/09

    ISSN： 0022-202X

    eISSN： 1523-1747

  96. CD163(+)CD206(+)Arginase 1(+) M2 macrophages in mycosis fungoides aquired immunostimulatory function by interferon alpha2a

    S. Furudate, T. Fujimura, Y. Kambayashi, A. Kakizaki, S. Aiba

    JOURNAL OF INVESTIGATIVE DERMATOLOGY　134　S71-S71　2014/09

    ISSN： 0022-202X

    eISSN： 1523-1747

  97. 円形脱毛症各種病型におけるIL-17産生細胞比率の検討

    古舘 禎騎, 藤村 卓, 東條 玄一, 神林 由美, 水芦 政人, 相場 節也

    日本皮膚科学会雑誌　124　(9)　1783-1784　2014/08

    Publisher: (公社)日本皮膚科学会

    ISSN： 0021-499X

    eISSN： 1346-8146

  98. 悪性黒色腫in-transit転移に対するIFN-β療法 その免疫学的意義

    藤村 卓, 柿崎 彩, 古舘 禎騎, 神林 由美, 沼田 透効, 芳賀 貴裕, 橋本 彰, 相場 節也

    日本皮膚悪性腫瘍学会学術大会プログラム・抄録集　30回　123-123　2014/07

    Publisher: (一社)日本皮膚悪性腫瘍学会

  99. 血管肉腫 その免疫学的背景の検討

    柿崎 彩, 藤村 卓, 神林 由美, 古舘 禎騎, 沼田 透効, 芳賀 貴裕, 橋本 彰, 相場 節也

    西日本皮膚科　76　(3)　291-291　2014/06

    Publisher: 日本皮膚科学会-西部支部

    ISSN： 0386-9784

    eISSN： 1880-4047

  100. 水疱性類天疱瘡におけるCD163陽性M2マクロファージの検討

    古舘 禎騎, 藤村 卓, 神林 由美, 柿崎 彩, 相場 節也

    西日本皮膚科　76　(3)　276-276　2014/06

    Publisher: 日本皮膚科学会-西部支部

    ISSN： 0386-9784

    eISSN： 1880-4047

  101. 【樹状細胞とランゲルハンス細胞】 炎症性角化症と樹状細胞、ランゲルハンス細胞

    藤村 卓, 相場 節也

    炎症と免疫　22　(3)　171-175　2014/04

    Publisher: (株)先端医学社

    ISSN： 0918-8371

  102. 炎症性角化症と樹状細胞、ランゲルハンス細胞

    藤村 卓, 相場節也

    炎症と免疫　22　(3)　21-25　2014/03

    Publisher: 先端医学社

  103. PEG-IFNα2a(ペガシス)皮下注で著明な改善を認めたランゲルハンス細胞組織球症の1例

    古舘 禎騎, 藤村 卓, 神林 由美, 玉渕 恵里佳, 塚田 全, 沼田 透効, 芳賀 貴裕, 橋本 彰, 相場 節也

    日本皮膚科学会雑誌　124　(2)　207-208　2014/02

    Publisher: (公社)日本皮膚科学会

    ISSN： 0021-499X

    eISSN： 1346-8146

  104. 陰嚢部および両下腿に生じた硬化性脂肪肉芽腫の1例

    柿崎 彩, 藤村 卓, 高橋 佐和子, 古舘 禎騎, 神林 由美, 相場 節也

    日本皮膚科学会雑誌　124　(2)　203-203　2014/02

    Publisher: (公社)日本皮膚科学会

    ISSN： 0021-499X

    eISSN： 1346-8146

  105. 水疱性類天疱瘡におけるCD163陽性M2マクロファージの検討

    柿崎 彩, 藤村 卓, 古館 禎騎, 神林 由美, 相場 節也

    Journal of Environmental Dermatology and Cutaneous Allergology　7　(5)　475-475　2013/11

    Publisher: (一社)日本皮膚アレルギー・接触皮膚炎学会

    ISSN： 1882-0123

  106. 血管肉腫 その免疫学的検討と新規治療法の開発

    柿崎 彩, 藤村 卓, 神林 由美, 古舘 禎騎, 沼田 透効, 芳賀 貴裕, 橋本 彰, 相場 節也

    日本皮膚悪性腫瘍学会学術大会プログラム・抄録集　29回　127-127　2013/08

    Publisher: (一社)日本皮膚悪性腫瘍学会

  107. Bowen病における病期進行と免疫担当細胞の関連の検討

    古舘 禎騎, 藤村 卓, 神林 由美, 相場 節也

    日本皮膚悪性腫瘍学会学術大会プログラム・抄録集　29回　116-116　2013/08

    Publisher: (一社)日本皮膚悪性腫瘍学会

  108. 皮膚リンパ腫の進展 インターフェロン療法 臨床的有効性と作用機序の検討

    藤村 卓, 古舘 禎騎, 神林 由美, 塚田 全, 沼田 透効, 芳賀 貴裕, 橋本 彰, 相場 節也

    日本皮膚悪性腫瘍学会学術大会プログラム・抄録集　29回　64-64　2013/08

    Publisher: (一社)日本皮膚悪性腫瘍学会

  109. 再生不良性貧血に合併した水疱性類天疱瘡の1例

    古舘 禎騎, 藤村 卓, 柿崎 彩, 神林 由美, 塚田 全, 沼田 透効, 相場 節也

    西日本皮膚科　75　(3)　272-272　2013/06

    Publisher: 日本皮膚科学会-西部支部

    ISSN： 0386-9784

    eISSN： 1880-4047

  110. Imiquimod with dacarbazine diferentiates B7H1-expressing MDSC into IFN-gamma producing macrophages in B16F10 melanoma

    T. Fujimura, Y. Kambayashi, S. Furudate, N. Ishii, S. Aiba

    JOURNAL OF INVESTIGATIVE DERMATOLOGY　133　S3-S3　2013/05

    ISSN： 0022-202X

  111. Comparison of immunosuppressive cells and cytoloxic cells in cutaneous angiosarcoma: The development of novel supportive therapy for cutaneous angiosarcoma

    Y. Kambayashi, T. Fujimura, S. Furudate, Y. Kimura, A. Hashimoto, T. Haga, S. Aiba

    JOURNAL OF INVESTIGATIVE DERMATOLOGY　133　S168-S168　2013/05

    ISSN： 0022-202X

  112. 皮膚偽リンパ腫および頭部皮膚B細胞リンパ腫における細胞傷害性T細胞の検討

    古舘 禎騎, 藤村 卓, 神林 由美, 芳賀 貴裕, 橋本 彰, 相場 節也

    日本皮膚科学会雑誌　123　(5)　983-983　2013/04

    Publisher: (公社)日本皮膚科学会

    ISSN： 0021-499X

    eISSN： 1346-8146

  113. 先天性表皮水疱症より発症した有棘細胞癌 自己水疱蓋グラフト、パンチグラフトの有用性の検討

    塚田 全, 藤村 卓, 古舘 禎騎, 神林 由美, 沼田 透効, 渡部 晶子, 橋本 彰, 相場 節也

    日本皮膚科学会雑誌　123　(5)　974-974　2013/04

    Publisher: (公社)日本皮膚科学会

    ISSN： 0021-499X

    eISSN： 1346-8146

  114. Crosstalk between regulatory T cells (Tregs) and myeloid derived suppressor cells (MDSCs) during melanoma growth

    Taku Fujimura, Yumi Kambayashi, Setsuya Aiba

    ONCOIMMUNOLOGY　1　(8)　1433-1434　2012/11

    DOI： 10.4161/onci.21176 　

    ISSN： 2162-4011

  115. 【アトピー性皮膚炎の今】 アトピー性皮膚炎 T細胞サブセットの役割

    藤村 卓, 相場 節也

    皮膚アレルギーフロンティア　10　(3)　169-173　2012/11

    Publisher: (株)メディカルレビュー社

    ISSN： 1348-7280

  116. Imiquimod augments the expression of B7H1 on CD11b+Gr1+myeloid derived suppressor cells (MDSCs) in B16F10 melanoma

    T. Fujimura, Y. Kambayashi, S. Aiba

    JOURNAL OF INVESTIGATIVE DERMATOLOGY　132　S127-S127　2012/09

    ISSN： 0022-202X

  117. Comparison of immunosuppressive cells and immunomodulatory cells in kerartoacanthoma and cutaneous squamous cell carcinoma

    Y. Kambayashi, T. Fujimura, S. Aiba

    JOURNAL OF INVESTIGATIVE DERMATOLOGY　132　S40-S40　2012/09

    ISSN： 0022-202X

  118. T-cell/Histiocyte-Rich B-Cell Lymphoma (THRLBCL) primarily presenting on the skin: a case report and immunohistochemical study

    Yumi Kambayashi, Taku Fujimura, Akira Tsukada, Akira Hashimoto, Setsuya Aiba

    JOURNAL OF DERMATOLOGY　39　96-96　2012/06

    ISSN： 0385-2407

  119. Cutaneous lymphadenoma: a case report and immunohistochemical study

    Taku Fujimura, Yumi Kambayashi, Takahiro Haga, Setsuya Aiba

    JOURNAL OF DERMATOLOGY　39　88-88　2012/06

    ISSN： 0385-2407

  120. 東北大学病院皮膚科における血管肉腫の治療変遷と予後に関する検討

    芳賀 貴裕, 神林 由美, 塚田 全, 石橋 昌也, 藤村 卓, 橋本 彰, 相場 節也

    日本皮膚悪性腫瘍学会学術大会プログラム・抄録集　28回　132-132　2012/06

    Publisher: (一社)日本皮膚悪性腫瘍学会

  121. 放射線治療後にxanthogranulomaが出現したMerkel細胞癌の1例

    島田 遼子, 藤村 卓, 那須 めい, 沼田 透効, 玉渕 恵里佳, 大谷 朋之, 神林 由美, 芳賀 貴裕, 相場 節也

    日本皮膚科学会雑誌　122　(4)　1235-1235　2012/04

    Publisher: (公社)日本皮膚科学会

    ISSN： 0021-499X

  122. 皮膚疾患と樹状細胞 骨髄由来抑制細胞(MDSC)と樹状細胞 腫瘍内での免疫寛容成立に果たす役割 (日本皮膚科学会雑誌)

    藤村卓

    日本皮膚科学会雑誌　121　(13)　3243-3246　2011/12

  123. 皮膚疾患と樹状細胞 骨髄由来抑制細胞(MDSC)と樹状細胞 腫瘍内での免疫寛容成立に果たす役割

    藤村 卓

    日本皮膚科学会雑誌　121　(13)　3243-3246　2011/12

    Publisher: (公社)日本皮膚科学会

    ISSN： 0021-499X

  124. The profiles of tumor infiltrating lymphocytes in squamous cell carcinoma on the lips after treated with intra-arterial peplomycin administration

    Taku Fujimura, Yumi Kanbayashi, Akira Hashimoto, Takahiro Haga, Yumiko Ito, Setsuya Aiba

    JOURNAL OF INVESTIGATIVE DERMATOLOGY　131　S37-S37　2011/09

    ISSN： 0022-202X

  125. 【自己免疫性疾患としての乾癬 病態と治療】 制御性T細胞と乾癬 (アレルギー・免疫)

    藤村卓, 相場節也

    アレルギー・免疫　18　(1)　40-46　2010/12

  126. 【自己免疫性疾患としての乾癬 病態と治療】 制御性T細胞と乾癬

    藤村 卓, 相場 節也

    アレルギー・免疫　18　(1)　40-46　2010/12

    Publisher: (株)医薬ジャーナル社

    ISSN： 1344-6932

  127. Cross-talk of novel phenotypes of MDSC and regulatory T cells (Tregs) during the melanoma growth

    Taku Fujimura, Karsten Mahnke, Sabine Ring, Viktor Umansky, Setsuya Aiba, Alexander Enk

    JOURNAL OF INVESTIGATIVE DERMATOLOGY　130　S33-S33　2010/09

    ISSN： 0022-202X

  128. Myeloid derived suppressor cells and their role in tolerance induction in cancer

    Taku Fujimura, Karsten Mahnke, Alexander H. Enk

    JOURNAL OF DERMATOLOGICAL SCIENCE　59　(1)　1-6　2010/07

    DOI： 10.1016/j.jdermsci.2010.05.001 　

    ISSN： 0923-1811

  129. Profiles of Foxp3+ regulatory T-cells (Tregs) in Bowen's disease and squamous cell carcinoma

    T. Fujimura, R. Okuyama, T. Hidaka, Y. Ito, S. Aiba

    JOURNAL OF INVESTIGATIVE DERMATOLOGY　128　S170-S170　2008/04

    ISSN： 0022-202X

  130. The immunohistological demonstration of cutaneous CD4+CD25+FoxP3+regulatory T cells in psoriasis, spongiotic dermatitis and mycosis fungoides

    T. Hidaka, T. Fujimura, Y. Ito, S. Aiba

    JOURNAL OF INVESTIGATIVE DERMATOLOGY　127　S118-S118　2007/04

    ISSN： 0022-202X

  131. A synthetic Nod2 agonist, muramyl dipeptide (MDP)-Lys (L18), and IFN-beta synergistically stimulate the maturation of dendritic cells with augmented IL-12 production and suppress the growth of established B16F10 melanoma

    T. Fujimura, Y. Ito, S. Aiba

    JOURNAL OF INVESTIGATIVE DERMATOLOGY　127　S118-S118　2007/04

    ISSN： 0022-202X

  132. 悪性黒色腫の皮膚転移巣に対するIFN-β療法の可能性

    藤村卓, 奥山隆平, 橋本彰, 芳賀貴裕, 長谷川聡, 舛貴志, 相場節也

    日本皮膚科学会雑誌　117　(4)　694-694　2007

  133. Establishment of cutaneous eosinophilic inflammation and its regulation by CpG oligodeoxynucleotide

    T Kootiratrakarn, T Fujimura, K Sano, R Okuyama, S Aiba, T Terui

    JOURNAL OF INVESTIGATIVE DERMATOLOGY　122　(3)　A117-A117　2004/03

    ISSN： 0022-202X

  134. 前胸部に生じた悪性青色母斑の1例

    藤村 卓, 舩山 道隆, 田上 八朗, 金生 英雄

    日本皮膚科学会雑誌　111　(9)　1399-1399　2001/08

    Publisher: (公社)日本皮膚科学会

    ISSN： 0021-499X

  135. 前胸部に生じた悪性青色母斑の1例

    藤村 卓, 舩山 道隆, 金生 英雄, 中川 聡

    皮膚科の臨床　43　(7)　863-865　2001/07

    Publisher: 金原出版(株)

    ISSN： 0018-1404

  136. 頭部への外用ステロイド剤により高眼圧をきたした1例

    佐藤 晃子, 安井 朝輝, 田中 友博, 清水 尚子, 角田 雅宏, 舩山 道隆, 藤村 卓

    磐城共立病院医報　21　(1)　54-58　2000/09

    Publisher: いわき市立総合磐城共立病院

    ISSN： 0916-3387

  137. 小児腹壁遠心性脂肪萎縮症の1例

    國方 なぎさ, 加藤 泰三, 藤村 卓, 田畑 伸子, 田上 八朗

    日本皮膚科学会雑誌　110　(1)　69-70　2000/01

    Publisher: (公社)日本皮膚科学会

    ISSN： 0021-499X

Show all ︎Show first 5

Books and Other Publications 2

  1. Immunology of the skin

    Taku Fujimura, Alexander H. Enk

    Springer　2016/02/01

  2. 皮膚科臨床アセット ここまでわかった乾癬の病態と治療

    藤村 卓, 相場節也

    中山書店　2012/06/08

Presentations 36

  1. Generation of B7H1-expressing CD11b+Gr1+ myeloid derived suppressor cells (MDSCs) during immune-modulatory therapy for B16F10 melanoma.

    Taku Fujimura, Yumi Kambayashi, Setsuya Aiba

    第37回日本研究皮膚科学会　2012/12/07

  2. Comparison of immunosuppressive cells and immunomodulatory cells in Angiosarcoma; the possible novel supportive therapies for angiosarcoma.

    Yumi Kambayashi, Taku Fujimura, Sadanori Furudate, Akira Hashimoto, Takahiro Haga, Setsuya Aiba

    第37回日本研究皮膚科学会　2012/12/07

  3. Comparison of Foxp3+ regulatory T-cells and CD163+ macrophages in invasive and non-invasive extramammary Paget’s disease.

    Sadanori Furudate, Taku Fujimura, Yumi Kambayashi, Akira Hashimoto, Takahiro Haga, Setsuya Aiba

    第37回日本研究皮膚科学会　2012/12/07

  4. 生涯、襁褓を着用してきた中年女性の外陰部に生じていた多発性表皮膿腫

    田上八朗, 岩崎鋼, 藤村卓

    第360回日本皮膚科学会宮城地方会　2012/12/01

  5. Imiquimod augments the expression of B7H1 on CD11b+Gr1+ myeloid derived suppressor cells (MDSCs) in B16F10 melanoma International-presentation

    Taku Fujimura, Yumi Kambayashi, Setsuya Aiba

    European Society for Dermatological Research　2012/09/19

  6. Comparison of immunosuppressive cells and immunomodulatory cells in kerartoacanthoma and cutaneous squamous cell carcinoma International-presentation

    Yumi Kambayashi, Taku Fujimura, Setsuya Aiba

    European Society for Dermatological Research　2012/09/19

  7. Cutaneous lymphadenoma: A case report and immunohistochemical study. International-presentation

    Taku Fujimura, Yumi Kambayashi, Takahiro Haga, Setsuya Aiba

    2nd Eastern Asia Dermatology Congress　2012/06/13

  8. T-cell/Histiocyte-Rich B-Cell Lymphoma (THRLBCL) primarily presenting on the skin: A case report and immunohistochemical study. International-presentation

    Yumi Kambayashi, Taku Fujimura, Akira Tsukada, Akira Hashimoto, Setsuya Aiba

    2nd Eastern Asia Dermatology Congress　2012/06/13

  9. HER-2陽性転移性皮膚アポクリン腺癌に対してラパチニブが奏効した1例

    日高 高徳, 藤村 卓, 渡部 晶子, 橋本 彰, 芳賀 貴裕, 大浪 薫, 水芦 政人, 相場 節也

    第111回日本皮膚科学会総会　2012/06/01

  10. 放射線治療後にxanthogranulomaが出現したMerkel 細胞癌の1例

    島田遼子, 藤村卓, 那須めい, 沼田透効, 玉渕恵里佳, 大谷朋之, 神林由美, 芳賀貴裕, 相場節也

    第111回日本皮膚科学会総会　2012/06/01

  11. Tumor infiltrating lymphocytes in squamous cell carcinoma on the lips: the effect of administration of intra-arterial peplomycin on suppressive and cytotoxic T cells.

    Taku Fujimura, Yumi Kanbayashi, Akira Hashimoto, Takahiro Haga, Yumiko Ito, Setsuya Aiba

    第36回日本研究皮膚科学会年次学術大会　2011/12/09

  12. Foxp3+ regulatory T-cells (Tregs) in Keratoacanthoma and squamous cell carcinoma.

    Yumi Kambayashi, Taku Fujimura, Yumiko Ito, Setsuya Aiba

    第36回日本研究皮膚科学会年次学術大会　2011/12/09

  13. Granulomatous pigmented purpuraの一例

    涌澤千尋, 藤村卓, 芳賀貴裕, 相場節也

    宮城地方会第３５６回例会　2011/12/03

  14. 4mmデルマパンチによる皮膚生検で診断できたIntravascular large B cell lymphomaの一例

    柿崎 彩, 藤村 卓, 日高高徳, 島田遼子, 水芦政人, 菊地克子, 相場節也

    宮城地方会第３５６回例会　2011/12/03

  15. The profiles of tumor infiltrating lymphocytes in squamous cell carcinoma on the lips after treated with intra-arterial peplomycin administration. International-presentation

    Taku Fujimura, Yumi Kanbayashi, Akira Hashimoto, Takahiro Haga, Yumiko Ito, Setsuya Aiba

    41th European society for dermatological research annual meeting　2011/09/07

  16. 自然消退傾向を示した鼻尖部Peripheral T cell lymphomaの一例

    柿崎彩, 藤村卓, 沼田郁子, 橋本彰, 相場節也

    三県合同地方会第３５５回例会　2011/09/04

  17. Cutaneous CD4+CD25+Foxp3+ regulatory T cells in sarcoidosis and granuloma annulare International-presentation

    Taku Fujimura, Yumi Kanbayashi, Yumiko Ito, Kenshi Yamasaki, Setsuya Aiba

    22nd World Congress of Dermatology　2011/05/24

  18. 原発性アルドステロン症およびCushing症候群治療後に急速に増大したDFSPの１例

    古舘 禎騎, 藤村 卓, 橋本 彰, 相場 節也

    宮城地方会第352回例会　2010/12/18

  19. Cross-talk of B7H1-positive myeloid derived suppressor cells (MDSC) and regulatory T cells (Tregs) during the melanoma growth

    Taku Fujimura, Karsten Mahnke, Sabine Ring, Viktor Umansky, Setsuya Aiba, Alexander H. Enk

    第35回日本研究皮膚科学会総会　2010/12/03

  20. Cross-talk of novel phenotypes of MDSC and regulatory T cells (Tregs) during the melanoma growth International-presentation

    Taku Fujimura, Karsten Mahnke, Sabine Ring, Viktor Umansky, Setsuya Aiba, Alexander H. Enk

    40 th European Society for Dermatological Research　2010/09/08

  21. Generation of myeloid derived suppressor cells during the progression of murine RET melanoma International-presentation

    Taku Fujimura, Karsten Mahnke, Sabina Ring, Setsuya Aiba, Alexander Enk

    39th European Society for Dermatological Research　2009/09/09

  22. MDP-Lys (L18)併用による悪性黒色腫に対するIFN-βの抗腫瘍効果増強の検討

    藤村卓, 伊藤由美子, 相場節也

    第四回東北大学バイオサイエンスシンポジウム　2007/06/04

  23. 炎症性皮膚疾患における表皮／真皮内Foxp3陽性制御性T細胞の検討

    藤村卓, 日高高徳, 伊藤由美子, 相場節也

    第四回東北大学バイオサイエンスシンポジウム　2007/06/04

  24. Photodynamic therapy (PDT) を用いた難治性菌状息肉症の治療

    菅原正幸, 藤村卓, 奥山隆平, 橋本彰, 渡部晶子, 小泉秀華, 浅野雅之, 長谷川聡, 芳賀貴裕, 相場節也

    第23回日本皮膚悪性腫瘍学会　2007/05/11

  25. 東北大皮膚科における皮膚悪性黒色腫の統計的検討

    橋本彰, 芳賀貴裕, 藤村卓, 渡部晶子, 長谷川聡, 舛貴志, 菅原正幸, 奥山隆平, 相場節也, 渡辺洋

    第23回日本皮膚悪性腫瘍学会　2007/05/11

  26. 鼻翼溝に生じた基底細胞癌の２例

    芳賀貴裕, 長谷川聡, 本蔵賢治, 藤村卓, 浅野雅之, 相場節也

    第23回日本皮膚悪性腫瘍学会　2007/05/11

  27. A synthetic Nod2 agonist, muramyl dipeptide (MDP)-Lys (L18), and IFN-b synergistically stimulate the maturation of dendritic cells with augmented IL-12 production and suppress the growth of established B16F10 melanoma. International-presentation

    Taku Fujimura, Yumiko Ito, Setsuya Aiba

    The 68th Annual Meeting of the Society for Investigative Dermatology　2007/05/09

  28. The immunohistological demonstration of cutaneous CD4+CD25+FoxP3+ regulatory T cells in psoriasis, spongiotic dermatitis and mycosis fungoides International-presentation

    Takanori Hidaka, Taku Fujimura, Yumiko Ito, Setsuya Aiba

    The 68th Annual Meeting of the Society for Investigative Dermatology　2007/05/09

  29. 悪性黒色腫の皮膚転移巣に対するIFN-β療法の可能性

    藤村 卓, 奥山隆平, 橋本 彰, 芳賀貴裕, 長谷川聡, 舛 貴志, 相場節也

    第106回日本皮膚科学会総会　2007/04/20

  30. Intransit metastasis を伴ったatypical fibroxanthomaの１例

    菅原正幸, 藤村卓, 芳賀貴裕, 小泉裕子, 橋本彰, 相場節也

    宮城地方会第336回例会　2006/12/09

  31. Inhibitory effect of the polyinosinic-polycytidylic acid/cationic liposome on the progression of murine B16F10 melanoma International-presentation

    Taku Fujimura, Satoshi Nakagawa, Tomoyuki Ohtani, Yumiko Ito, Setsuya Aiba

    Tohoku University 21st century COE program. The 3rd International Symposium　2006/11/09

  32. 足趾間に生じたverrucous carcinoma：有棘細胞癌との鑑別に苦慮した一例

    藤村卓, 橋本彰, 長谷川聡, 高山晶理子, 渡辺洋, 奥山隆平, 相場節也

    第70回日本皮膚科学会東部支部学術大会　2006/10/14

  33. ,Inhibitory effect of the Polyinosinic-Polycytidylic Acid/Cationic Liposome Complex on the progression of murine B16F10 melanoma International-presentation

    Taku FUJIMURA, Satoshi NAKAGAWA, Yumiko ITO, Setsuya AIBA

    第９回日本中国皮膚科学術会議　2006/09/16

  34. Photodynamic therapy (PDT) を用いた難治性菌状息肉症の治療

    藤村卓, 奥山隆平, 橋本彰, 長谷川聡, 芳賀貴裕, 小泉秀華, 水芦政人, 相場節也

    日本皮膚科学会山形、宮城、福島地方会第335回例会　2006/09/10

  35. テグレトールにより誘起されたＤＩＨＳ（薬剤過敏性症候群）：HHV6抗体価の経時的推移

    小泉秀華, 藤村卓, 橋本彰, 徳永英夫, 渡部昌子, 相場節也

    日本皮膚科学会山形、宮城、福島地方会第335回例会　2006/09/10

  36. ケナコルト筋注が著効したlupus ,iliaris disseminatus faciei (LMDF) の１例

    徳永英夫, 藤村卓, 相場節也

    日本皮膚科学会山形、宮城、福島地方会第335回例会　2006/09/10

Show all Show first 5

Industrial Property Rights 2

  1. 免疫チェックポイント阻害薬使用における免疫関連副作用の予測方法

    藤村 卓

    特許第6910653号

    Property Type: Patent

  2. 血中ケモカインを用いた免疫チェックポイント阻害薬の治療効果判定

    藤村 卓

    Property Type: Patent

Research Projects 18

  1. Development of novel assist tool for the diagnosis of skin cancer by the active measurement of effective thermal conductivity

    Taku Fujimura, Yoshihide Asano, Yumi Kambayashi, Ryo Amagai

    Offer Organization: Japan Agency for Medical Research and Development

    Category: DermatoOncology

    Institution: Tohoku University Graduate School of Medicine

    2023/10 - 2026/03

  2. 線溶系制御因子を標的とした新規複合的がん免疫療法の確立

    八幡 崇, 藤村 卓, アブドゥル アジズ, 安藤 潔

    Offer Organization: 日本学術振興会

    System: 科学研究費助成事業 基盤研究(B)

    Category: 基盤研究(B)

    Institution: 東海大学

    2021/04/01 - 2025/03/31

    More details Close

    プラスミノーゲン活性化阻害因子（PAI-1）は、その線溶系阻害活性からがん細胞の浸潤や転移を抑制するはずであるが、実際はPAI-1を高発現するがんの悪性度は非常に高い。これは『PAI-1パラドックス』と呼ばれ、多くのがんに共通する悪性化の重大要因であるにも関わらず、その機序は不明のままである。申請者らは、PAI-1が免疫チェックポイント分子（PD-L1）の発現を誘導し、がん細胞を免疫監視から逃避させることがPAI-1パラドックスの本態である可能性を見出した。 今年度はPAI-1によるPD-L1発現制御の分子的機序の解明に取り組んだ。細胞外体液中で線溶系阻害因子として機能するPAI-1であるが、細胞が受容体を介して刺激を受ける場合がある。PAI-1は、細胞膜上のLRP1に結合すると同時に、uPAとその受容体（uPAR）との複合体にも結合し、４量体を形成してシグナルを伝達する。そこで、LRP-1やuPARの欠損株を作製、または、LRP1との結合部位やuPA受容体との結合部位に変異のあるPAI-1を用いて検討を行ったところ、PAI-1によるPD-L1発現誘導はキャンセルされたことから、PD-L1発現誘導はPAI-1による直接的な作用であることを明確にした。さらに、シグナル伝達経路についても解析を行い、PAI-1がJAK/STAT経路を活性化し、JAK/STAT阻害剤の添加により発現誘導がキャンセルされることから、PAI-1はLRP-1/uPARに結合し、JAK/STAT経路依存的にPD-L1の発現を誘導していることをあきらかにした。

  3. Investigation for the roles of IL-17/LL37 signaling in melanoma

    Offer Organization: Japan Society for the Promotion of Science

    System: Grants-in-Aid for Scientific Research Grant-in-Aid for Scientific Research (C)

    Category: Grant-in-Aid for Scientific Research (C)

    Institution: Tohoku University

    2021/04/01 - 2024/03/31

  4. Anti-PD-1 plus TM5614 immunotherapy for unresectable malignant melanoma: Protocol for an investigator-initiated, open-label, single-arm, multicentre, phase 2 clinical trial

    Taku Fujimura, Yasuhiro Fujisawa, Koji Yoshino, Atsushi Otsuka, Satoshi Fukushima, Hiroshi Kato, Shigeto Matsushita, Takashi Yahata, Toshio Miyata, Koji Naito

    Offer Organization: Japan Agency for Medical Research and Development

    Category: DermatoOncology

    Institution: Tohoku University Graduate School of Medicine

    2021/04 - 2024/03

  5. 能動的精密表面温度計測を用いた熱パルスレーダ－による癌の生体内診断

    圓山 重直, 野中 崇, 井関 祐也, 細川 靖, 藤村 卓, 山家 智之, 岡部 孝裕, 古川 琢磨, 郭 福会, 横田 実世

    Offer Organization: 日本学術振興会

    System: 科学研究費助成事業 基盤研究(B)

    Category: 基盤研究(B)

    Institution: 八戸工業高等専門学校

    2020/04/01 - 2023/03/31

    More details Close

    本研究の目的は，これまで研究してきたガードヒータ型高精度表面温度計測をさらに発展させ，半導体薄膜サーミスタを用いた皮膚癌や内視鏡手術用カテーテル熱パルスレーダーを開発し，癌の生体内診断を行う新たな診断法を確立することである．さらに動物実験や，模擬生体で皮膚や臓器内部の熱的性質を計測し，手術や診断の精度を格段に向上させる．つまり，（1）薄膜サーミスタと小型ペルチェモジュールを組み合わせた高精度能動温度プローブのプロトタイプを製作し，ダブル熱パルスレーダーの基本動作を模擬生体で実験する．（2）皮膚ガンや臓器ガンが，リンパ血流などの物質移動が大きいことを考慮した新しい生体伝熱モデルの構築を行い，熱パルスレーダーの臨床結果を記述する新理論を展開する．（3）さらに小型のサーミスタ・プローブと小型ペルチェ冷却機構を製作し，内視鏡に組み込んで消化器や腹腔内手術の新しい診断方法としてのカテーテル型熱パルスレーダーを開発し，模擬生体と動物実験でその有用性を実証する． 令和2年度には(1)の高精度能動温度プローブのプロトタイプの製作が完了し，プロトタイプを用いた実験およびコンピュータ・シミュレーションの比較から本手法の有用性について検討を行った．また，当初計画では令和3年度に計画していたペンシル型ホルダーへの組み込み，サーミスタ・プローブの小型化および新しい生体伝熱モデルの構築が完了し，当初計画よりも順調に研究が進んでいる．

  6. Treatment of melanoma with IL-36

    Numasaki Muneo

    Offer Organization: Japan Society for the Promotion of Science

    System: Grants-in-Aid for Scientific Research Grant-in-Aid for Scientific Research (C)

    Category: Grant-in-Aid for Scientific Research (C)

    Institution: Tohoku University

    2018/04/01 - 2021/03/31

    More details Close

    IL-36β is produced by bronchial epithelial cells and dendritic cells. To examine the anti-tumor activity of IL-36 β, we constructed two types of recombinant retroviral vector DFG-PTH-truncated IL-36β-IRES-Neo and DFG-GH-truncated IL-36β-IRES-Neocarrying truncated IL-36β, and transduced into B16-F10 melanoma cells. Established B16-F10-PTH-truncated IL-36β cells and B16-F10-GH-truncated IL-36β cells grew very slowly compared with that of parental B16-F10 cells in vivo. We examined the mechanisms of anti-tumor effects of truncated IL-36β, and found that truncated IL-36β could down-regulate the surface expression levels of programmed cell death (PD)-1 on CD4 and CD8 T cells stimulated by anti-CD3 monoclonal antibody and anti-CD28 monoclonal antibody.

  7. Early diagnosis and low invasive treatment of cancer by micro/nano thermal engineering

    Maruyama Shigenao

    Offer Organization: Japan Society for the Promotion of Science

    System: Grants-in-Aid for Scientific Research Grant-in-Aid for Scientific Research (B)

    Category: Grant-in-Aid for Scientific Research (B)

    2016/04/01 - 2020/03/31

    More details Close

    This study measured the effective thermal conductivity of healthy and lesional skin in 11 cancer patients. Clinical studies have shown that when the tumor invades the dermis, the effective thermal conductivity of the lesion is higher than in the healthy area. Complex in-vivo heat transfer analysis during laser treatment was performed considering multiple heat scattering in vivo, plasmon heating by GNR, and combined heat transfer analysis considering blood flow and metabolic heat in the body. As a result, it was found that the GNR can be locally heated with a short irradiation time. We examined the usefulness of low invasive laser treatment by an experimental method. From the experiment, the usefulness of the surface cooling by the Peltier device could be evaluated.

  8. 免疫チェックポイント阻害薬使用による免疫関連副作用予測システムの開発 Competitive

    藤村 卓

    Offer Organization: 日本医療研究開発機構

    System: 次世代がん創生研究事業領域D

    2018/06 - 2020/03

  9. 非侵襲熱物性計測による皮膚腫瘍浸潤度測定法の開発 Competitive

    藤村 卓

    Offer Organization: 日本医療研究開発機構

    System: 橋渡し研究戦略的推進プログラム

    2018/10 - 2019/03

  10. Development of novel immune therapy for melanoma by targeting tumor associated macrophages Competitive

    Fujimura Taku

    Offer Organization: Japan Society for the Promotion of Science

    System: Grants-in-Aid for Scientific Research Grant-in-Aid for Scientific Research (C)

    Category: Grant-in-Aid for Scientific Research (C)

    Institution: Tohoku University

    2016/04 - 2019/03

    More details Close

    We have developed several novel systems for tumor immunology fields, especially in the areas of tumor associated macrophages. During this period, we have published 15 research studies about tumor associated macrophages. Among them, we have determined safety dose of IFN-beta in combination with anti-PD1 antibodies, which is based on the logics of tumor associated macrophages. Moreover, we also found the release of sCD163 and CXCL5 from tumor associated macrophages, which could be the biomarker for the prediction of the efficacy of anti-PD1 antibodies for the treatment of advanced, unresectable melanoma patients. Furthermore, we found that these biomarkers are also useful for the prediction of immune related adverse events in patients with melanoma who treated with anti-PD1 antibodies. According to these results, today, we have set up a clinical research for the development of optimal immune therapy using anti-PD1 antibody.

  11. Investigation of subpopulation of skin resident macrophages.

    Watabe Akiko, Kakizaki Aya

    Offer Organization: Japan Society for the Promotion of Science

    System: Grants-in-Aid for Scientific Research Grant-in-Aid for Scientific Research (C)

    Category: Grant-in-Aid for Scientific Research (C)

    Institution: Tohoku University

    2014/04/01 - 2017/03/31

    More details Close

    In this study, we investigated the immunomodulatory effects of cancer-specific storma on tumor-associated macrophages, using skin samples from malignant melanoma, extramammary Paget's disease and cutaneous T cell lymphoma patients. Our study suggested that these skin cancer possesses different cancer storma (e.g. IL-4, periostin, RANKL, etc.), and those stromal factors stimulate macrophages to produce several specific chemokine, such as CCL17 and CCL22, to develop immunosuppressive tumor microenvironment in each tumor. Concerning inflammatory skin disease, we evaluated the immunomodulatory function of tissue-reside macrophages in pemphigus vulgaris and bullous pemphigoid, suggesting that the chemokine production from tissue-reside macrophages play important roles in developing autoimmune bullous disease.

  12. Development of novel immunotherapy for malignant melanoma by targeting MDSC. Competitive

    Fujimura Taku, Aiba SETSUYA

    Offer Organization: Japan Society for the Promotion of Science

    System: Grants-in-Aid for Scientific Research Grant-in-Aid for Scientific Research (C)

    Category: Grant-in-Aid for Scientific Research (C)

    Institution: Tohoku University

    2013/04 - 2016/03

    More details Close

    Our present study revealed that, not only the expression of PD-L1, but also the production of chemokine is important to modify the immunosuppressive microenvironment in B16F10 melanoma model. In addition, on human M2 macrophages, the expression of PD-L1 could be decreased by the treatment of several immune therapy for metastatic melanoma. We published these data at Oncoimmunology in 2015. Moreover, we further investigated tumor-associated macrophages in the series of skin tumor, including invasive and non-invasive extramammary Paget's disease and mycosis fungicides. These data was published at Journal of Investigative Dermatology and Experimental Dermatology in 2015 and 2016.

  13. Role of Foxp3-positive regulatory T cells in moyamoya disease

    FUJIMURA Miki, TOMINAGA Teiji, FUJIMURA Taku

    Offer Organization: Japan Society for the Promotion of Science

    System: Grants-in-Aid for Scientific Research Grant-in-Aid for Challenging Exploratory Research

    Category: Grant-in-Aid for Challenging Exploratory Research

    Institution: Tohoku University

    2012/04/01 - 2014/03/31

    More details Close

    Moyamoya disease is characterized by a progressive stenosis at the terminal portion of the internal carotid artery and an abnormal vascular network at the base of the brain. We investigated the role of regulatory T-cell (Treg) in the patho-physiology of moyamoya disease. Result showed that number of Foxp3-positive Treg was significantly lower in patients with moyamoya disease compared to normal control. We also compared the expression of Foxp3-positive Treg between mice lacking RNF213 (susceptibility gene for moyamoya disease) and wild-type mice, but there was no significant difference. These results suggested that autoimmune response mediated by Treg may play a role in the patho-physiology of moyamoya disease.

  14. The effect of myeloid derived suppressor cells on the induction of peripheral tolerance Competitive

    FUJIMURA Taku

    Offer Organization: Japan Society for the Promotion of Science

    System: Grants-in-Aid for Scientific Research Grant-in-Aid for Young Scientists (B)

    Category: Grant-in-Aid for Young Scientists (B)

    Institution: Tohoku University

    2011/04 - 2013/03

    More details Close

    We invstigated mainly mouse immunosuppressive macrophages and myeloid derived suppressor cells, as well as regulatory T cells on the induction of peripheral tolerance in cancer patient and cancer bearing mouse. By this project, we have published 8 English papers concerned about the effect of immunosuppressive macrophages on cancer microenvironment. Another 5 English papers are still under submission. Through this project, wecharacterized the further subtypes of immunosuppressive macrophages, and in future, by targeting these macrophages in cancer patients, further optimal therapy might be established.

  15. 悪性黒色腫に対する新規樹状細胞療法の開発 Competitive

    藤村 卓

    Offer Organization: 文部科学省

    System: 科学研究費助成事業 若手研究（B）

    Category: 若手研究(B)

    Institution: 東北大学

    2005/04 - 2007/03

    More details Close

    悪性黒色腫に対するPoly(I.C)/カチオニックリボゾーム複合体(PIC-L)を用いた新規免疫療法に開発をマウスB16F10モデルにより検討した。PIC-Lはin vitroでは濃度依存性に増殖の抑制効果を示した。また、in vivoでは生着したB16F10を濃度依存性に増殖を抑制した。この腫瘍増殖抑制効果は既存のCpG-ODNs-やIFN-βより強力であり、抗腫瘍薬としての可能性が示された。そのため、次に病理組織学的に腫瘍の抑制効果を検討したところ、縮小した腫瘍の周辺に超密にリンパ球浸潤を認めた。これら浸潤細胞が腫瘍特異的エフェクター細胞か否かをマウスの所属リンパ節においてのテトラマーアッセイで検討したところ、所属リンパ節の細胞ではPIC-L治療群で有為にTRP-2陽性細胞が増殖していた。さらにこれらのエフェクター細胞が誘導されるメカニズムを抗原提示細胞に注目し検討したところ、PIC-L投与により真皮樹状細胞、表皮ランゲルハンス細胞の活性化が生じることが分かった。ヒトでの臨床応用を考え、ヒト樹状細胞に対するPIC-Lの効果を検討したところ、ヒト樹状細胞においても細胞表面マーカーおよびアロの抗原提示能が増加することが証明された。PIC-Lの抗腫瘍効果は単独投与では短期間のみの維持であったため、in vivoモデルに骨髄由来の樹状細胞(BMDC)を加えたところ、腫瘍は完全に治癒するに至った。この樹状細胞を加えることによる、抗腫瘍効果の増強は全身のIFN-γ産生細胞の増加に伴うものであることをマウスの脾臓細胞のサイトカイン産生能を検討することにより証明した。また、この治療に加えたBMDCの所属リンパ節へのmigrationを検討したところ、PIC-L治療はBMDCの所属リンパ節への遊走能を増加することも証明された。 以上の結果よりPIC-Lは単独投与でも抗腫瘍効果を示すが、BMDCと組み合わせることにより、より強力な抗腫瘍免疫を誘導することが証明された。今後、臨床応用を考えるに当たり、BMDCに代わり、より簡便な方法で長期免疫を誘導する方法の開発が必要であると考えられる。

  16. 悪性黒色腫に対する新規免疫療法の開発

    藤村 卓

    Offer Organization: 日本学術振興会

    System: 科学研究費助成事業 若手研究(B)

    Category: 若手研究(B)

    Institution: 東北大学

    2007 - 2007

  17. 感温磁性体素子と平面コイルを用いた3次元温熱療法による皮膚癌治療法の開発

    相場 節也, 中川 聡, 藤村 卓, 佐藤 文博, 出口 雅敏

    Offer Organization: 日本学術振興会

    System: 科学研究費助成事業 萌芽研究

    Category: 萌芽研究

    Institution: 東北大学

    2006 - 2006

    More details Close

    本研究においては、感温磁性体素子を用いた安全かつ有知なhyperthermiaによる癌治療法の確立をめざした。具体的には、マウスB16メラノーマをC57Bl/6 miceの背部皮膚に接種し、約1週間経過し、腫瘍径が5mmになった時点で、工学部佐藤らにより作成された平面渦巻き型コイルとキュウリー温度が50℃,55℃,60℃の感温磁性体素子を組み合わせてhyperthermiaを施行した。その際に、腫瘍内温度、また、全身の体温の上昇の目安として直腸温を蛍光式光ファイバー温度計でモニターした。その結果、 1.キュウリー温度が60℃の感温磁性体素子を用いた際にのみ、有意な直腸温上昇なしに腫瘍内温度を43℃,45℃,50℃に設定することができた。 2,腫瘍内温度を43℃,45℃,50℃に設定し、処理時間を10分とした際には、50℃に設定した時にのみ腫瘍のほぼ完全な消退が確認できた。 3.Hyperthermiaと樹状細胞を用いた免疫療法との併用の可能性を探る目的で、マウス骨髄細胞からの樹状細胞培養の基礎的検討をおこなった。また、その際に、コントロールとして用いる、樹状細胞の活性化に不可欠なシグナル分子であるp38 mitogen activated protein kinaseの欠損マウスからの樹状細胞培養も試み、樹状細胞活性化マーカーの発現を正常マウス由来樹状細胞と比較した。 4.次に、hyperthermia施行後の腫瘍組織を組織学的に観察した。腫瘍組織の病理組織学的変化は、hyperthermia施行後ほぼ48時間後に確認でき、腫瘍内温度50℃、処理時間10分のhyperthermiaで腫瘍全体の凝固壊死を確認できた。それ以外の条件では、部分的に睡瘍の生存が認められ、それが肉眼的な腫瘍の急激な増大に対応するものと思われた。以上の結果より、感温磁性体素子,平面渦巻き型コイルの組合せによるhyperthermiaによる皮膚癌治療における臨床応用の可能性が示された。

  18. Investigation for the methods of enhanced tumor vaccination using apoptosis-resistant dendritic cells manipulated by transfection of small-interfering RNAs responsible for the apoptosis of dendritic cells

    NAKAGAWA Satoshi, FUJIMURA Taku

    Offer Organization: Japan Society for the Promotion of Science

    System: Grants-in-Aid for Scientific Research Grant-in-Aid for Scientific Research (C)

    Category: Grant-in-Aid for Scientific Research (C)

    Institution: TOHOKU UNIVERSITY

    2005 - 2006

    More details Close

    First we analyzed the viability and the expression of caspases 2, 3, 7 and 8 during the natural apoptotic course of human monocyte-derived dendritic cells (MoDC) which were matured by stimulation with IL-1beta, IL-6, TNFalpha, and PGE2. The viability of MoDC was more than 90% after 2 days of stimulation and decreased to 60-70% after 3 and 4 days, and finally fell into 50% after 5 days. The percentage of apoptotic MoDC was sustained less than 10% after 1 to 4 days, but decreased into 70-80% after 6 to 8 days. As for the expression of the costimulatory molecules such as CD86 and HLA-DR antigen, both were upregulated after 2 days but after 6 days and longer, 2 subpopulations of MoDC were found : one keeping high expression of both molecules, the other reducing these molecules. Among the caspases described above, only caspase-2 was found to be upregulated during the course of the apoptotic process of MoDC. Next we performed to transfect small interfering RNA (siRNA) into human MoDC. First we tried to transfect GAPDH siRNA by lipofection methods to search the best transfection reagents. We used TransIT-TKO【○!R】(Mirus), siPortNeoFX【○!R】 and siPortAmine【○!R】 (Ambion), Dharmafect1, 2, 3, 4【○!R】 (Dharmacon), and Lipofectamine2000【○!R】 (Invitrogen). Among these reagents, Lipofectamine2000【○!R】 performed the best results, maximally 44% of the inhibition. We also tried electrophoration methods using Nucleofector^<TM> II (Amaxa) resulting in maximally 70% of inhibition. We are now trying to transfect caspase2-siRNA into MoDC and examining whether caspase2-siRNA can prolong the viability of mature MoDC.

Show all Show first 5

Social Activities 1

  1. NPO法人 皮膚オンコロジー若手教育機関

    2019/11 -

Other 7

  1. 根治切除不能悪性⿊⾊腫に対するニボルマブ、インターフェロンベータ併⽤療法における安全⾄適⽤量 の検討

    More details Close

    根治切除不能悪性⿊⾊腫に対するニボルマブ、インターフェロンベータ併⽤療法における安全⾄適⽤量の検討

  2. Myeloid derived suppressor cells (MDSC)をターゲットとした新規免疫療法の開発

    More details Close

    Myeloid derived suppressor cells (MDSC)をターゲットとした新規免疫療法の開発

  3. MDSCをターゲットとした新規免疫療法の開発

    More details Close

    MDSCをターゲットとした新規免疫療法の開発

  4. ＭＤＳＣをターゲットとした新規免疫療法の開発

    More details Close

    ＭＤＳＣをターゲットとした新規免疫療法の開発

  5. Cross talk of regulatory T cells and myeloid derived suppressor cells plays a crucial role on the progression of established murine melanoma.

    More details Close

    Cross talk of regulatory T cells and myeloid derived suppressor cells plays a crucial role on the progression of established murine melanoma.

  6. 乾癬における補体成分C5aおよびC5a受容体の役割とその制御に関する研究

    More details Close

    1：乾癬組織におけるC5a受容体等の発現を免疫組織化学的に検討する。 2：乾癬患者の皮膚スケール中における好中球遊走因子に対するC5a受容体拮抗薬等の阻害作用を検討する。

  7. マウスメラノーマ細胞株（B16F10）を用いたNS-9の抗腫瘍効果作用の検討

    More details Close

    1） カチオニックリポゾーム/poly IC複合体投与と同時期に樹状細胞を腫瘍周囲に投与することにより長期間の抗腫瘍効果を持続することが可能かマウスのin vivoで検討する。 2） これらの抗腫瘍効果がどのようなエフェクター細胞により、何を認識して行われているのかをテトラマーアッセイ、51Crを用いた細胞障害アッセイを用いて行う。 3） これらの現象がどのようなサイトカインネットワークに基づき抗腫瘍効果が発動しているかを細胞内染色、ELISA法を用いて検討する。

Show all Show first 5